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Aggressive B-cell lymphomas 
 
B-cell lymphomas are derived from mature B-cells at various stages of differentiation.[1] In the 
Netherlands 4,500 patients are diagnosed with a mature B-cell lymphoma annually.[2] Historically 
B-cell lymphomas have been classified as Hodgkin lymphoma (HL) and non-Hodgkin lymphomas 
(NHL). The B-NHL encompass a broad clinical spectrum of lymphomas (Figure 1). The WHO 
2017 classification recognizes over 30 B-NHL subtypes, with diffuse large B-cell lymphoma 
(DLBCL) as the most common type in adults.[1]  The so called indolent lymphomas, including 
amongst others follicular lymphoma (FL), marginal zone lymphoma (MZL), mucosa associated 
lymphoid tissue (MALT) and lymphoplasmacytic lymphoma (LPL), comprise a group of B-NHL that 
are characterized by a indolent disease course, but with a tendency to relapse. Despite the in 
general favorable outcome, patients with an indolent lymphoma who relapse early tend to have a 
poor outcome.[3]   
The so-called aggressive B-cell lymphomas make up about 40% of all B-NHL and are 
characterized by tumor cells with a high proliferation rate. They include DLBCL (37%), primary 
mediastinal B-cell lymphoma (PBMCL) (3%), high-grade B-cell lymphomas (HGBCL) (3%) and 
Burkitt lymphoma (BL) (0.8%). Prognosis and treatment of aggressive B-NHL varies depending on 
type, stage and other biological variables. 
 
Figure 1: Relative frequencies of the most common B-cell lymphoma subtypes. The aggressive 
lymphomas in blue (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, High 
Grade B-cell lymphoma and Burkitt lymphoma) encompass 40% of B-NHL. The indolent 
lymphomas are shown in red. Mantle cell lymphoma (shown in green) tends to relapse early. 












High grade B-cell 2.5%
Primary mediastinal B-cell 3%
Diffuse large B-cell 35%
Mantle cell 7%
Follicular 27%
CLL / SLL 12%
MALT 9%
Nodal marginal zone 2%
Lymphoplasmacytic 1.4%
Splenic marginal zone 0.9%
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In the WHO 2017 classification there are 14 distinct morphological DLBCL variants.[1] These 
entities, like primary diffuse large B-cell lymphoma of the CNS (PCNSL), intravascular large B-cell 
lymphoma and EBV-positive DLBCL have their own unique biological and clinical properties.  
However, these subtypes are uncommon and the majority of DLBCL cannot be categorized. This 
unclassifiable DLBCL are referred to as “not otherwise specified (NOS)”.  
This thesis will focus on DLBCL-NOS (from here on referred to as DLBCL), and the less common 
subtypes PMBCL and HGBCL with a MYC and BCL2 and/or BCL6 rearrangement, often referred 
to as double hit or triple hit lymphomas (HGBCL-DH). The presentation of all three aggressive B-
NHL’s can vary considerably from single lymph node enlargement to life threatening and 
debilitating disease, e.g. with central nervous system involvement. There are, however, several 
major clinicopathological differences between DLBCL, HGBCL-DH and PMBCL (Table 1). 
Especially MYC expression (mostly in relation to rearrangements of the MYC locus), expression of 
the Ki67 proliferative marker and CD30 are very important elements. Clinically, the HGBCL-DH 
cannot be distinguished from DLBCL, although the majority of patients will present with advanced 
stage disease and extranodal localization.[1]  Morphologically,  HGBCL-DH and DLBCL cannot 
reliably be differentiated from each other. Immunophenotyping for the proliferation marker Ki67 
and/or MYC is indicative in some cases, but generally insufficient for classification.[1]  Therefore, 
the diagnostic tool for HGBCL-DH remains fluorescence in situ hybridization (FISH) to detect 
chromosomal breaks in the MYC gene region. Unlike DLBCL, PMBCL’s are most commonly 
observed in adolescent females presenting with a mediastinal mass, often resulting in a vena 
cava superior syndrome.[4]  PMBCL share several biological features with HL including 
expression of CD30.[4] 
Irrespective of the type of aggressive B-NHL, there is only one opportunity to treat these patients 
with curative intent, since at relapse these tumors are highly proliferative and long-term 
remissions can only be achieved in a minority of relapsed patients.[5-9] 
Table 1:  Major clinicopathological differences between diffuse large B-cell lymphoma, high 
grade B-cell lymphoma with double or triple hit and primary mediastinal B-cell lymphoma 
 DLBCL HGBCL-DH PMBCL 
Median Age 65 65 35 
Gender M ≥ F M ≥ F Female 
Presentation Nodal / extranodal Nodal / extranodal Mediastinal 
Stage 1-2 (%) 20 40 90 
IHC CD20+ CD20+ CD20+ / CD30+ 





Morphologically DLBCL tumor cells have medium to large aberrant B cells with nuclei equal in 
size or larger than those of macrophages. The tumor cells show a diffuse growth pattern.  
The cell of origin (COO) from which the malignant B cell is derived matters for the prognosis and 
therapeutic approach. Based on gene expression profiles (GEP) DLBCL-NOS can be subdivided 
into a germinal center B-cell (GCB) and activated B-cell (ABC) subtype (with ~15% of patients 
remaining unclassified).[10,11]  The two subtypes reflect the B-cell developmental stages from 





Figure 2: Schematic representation of the developmental stage of lymphomagenesis and key 
pathways deregulated in diffuse large B-cell lymphoma, High grade B-cell lymphoma with MYC 
rearrangements and BCL2 and/or BCL6 and primary mediastinal B-cell lymphoma. Legend: * 
mutation, # loss, ^ translocation, ~ copy number, + expression. Adapted from Basso et al.[14] 
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Pathway HGBCL GCB-type ABC-type PMBCL
Terminal differentiation BCL6^ BCL6+, EZH2* BCL6^, PRDM1#





Immune escape HLA#, CD58# PDL1/PDL2+, CIITA^
Cell cycle / apoptosis MYC^, BCL2^ BCL2^ BCL2+





JAK-STAT signaling JAK2+, SOCS*, 
STAT6* 
Cell migration GNA13, S1PR2, P2RY8
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Several different transcription factors regulate the transition of B cells through the germinal center 
reaction. B-cell lymphoma 6 protein (BCL-6) is expressed throughout the germinal center stage. 
MYC  is required for maintaining the B cells in the dark zone (blastoid), whereas NF-kB is 
expressed during the initation of the germinal center reaction and class switch recombination and 
PRDM1 is induced in differentiation of plasma cells.[14] Recombination of the Variable, Diversity 
and Joining (VDJ) gene fragments of the immunoglobulin gene (Ig) is regulated by recombinase-
activating genes (RAG1 and RAG2), whereas the somatic hypermutation machinary and class-
switch recombination is regulated by activation-induced cytidine deaminase (AID). Although 
essential for the normal function of the immune system, these processes put B cells at risk of 
acquiring oncogenic mutations. RAG recombinase can promote translocations involving the 
immunoglobulin loci, whereas AID can introduce mutations in the non immunoglobulin 
genes.[15,16] 
Irrespective of the COO subtype, DLBCL has several common hallmarks. The majority of DLBCL 
have an increased expression of the BCL-6 gene, either by chromosomal translocation affecting 
the BCL-6 gene locus at 3q27, activating mutations, loss of IRF-4 repression, gain-of-function 
mutations in its positive regulator MEF2B and loss-of-function of acetyltransferases CREBPP and 
EP300. [17,18] Overexpression of BCL-6 abolishes plasma cell differentiation of B cells at the 
germinal center of maturation by down regulating the master regulator of plasma cell 
differentiation Blimp-6 / PRDM-1.[19] Secondly, the most frequent inactivating mutations are found 
in the chromatin modifiers CREBBP, EP300 and MLL2, resulting in impaired activation of among 
other genes the tumor suppressor TP53. Third, immune escape through loss of HLA molecules, 
loss of the cell adhesion molecule CD58 and loss of the co-stimulatory molecule TNFSF9 is 
observed in > 60% of patients. GEP of DLBCL shows two stromal gene signatures, which are 
related to prognosis, implicating that the interaction between tumor and immune system shapes 
the course of the disease.[20] 
ABC-subtype  
The hallmarks of ABC-type DLBCL are a block in terminal differentiation and activation of the NF-
kB signaling pathway. Bi-allelic inactivation of PRDM1 is observed in 30% of ABC-type DLBCL. 
Activating mutations in CD79A/B, CARD11 and MYD88 are observed in 20%, 10% and 35% of 
cases, respectively. [21-23]  These activating mutations result in aberrant NFkB activation through 
signaling via the B-cell receptor (BCR), CD40 and the toll like receptor (TLR) pathways. 
Inactivation of TNFAIP3 (A20), which encodes for a negative regulator of the NFkB pathway can 
be found in 30% of the cases and further contributes to the dependency on activation of the NFkB 
pathway in ABC-type DLBCL. Activation of the NF-kB pathway prevents apoptosis and causes 





In addition to the generic genetic aberrations in DLBCL, the GCB subtype has several distinctive 
features. [12-14]  Rearrangement of BCL2 occurs in ~40% of GCB-DLBCL. Gain-of-function 
mutations in the histone methyltransferase EZH2 are present in ~20% of GCB cases. Post 
germinal center differentiation is blocked due to the repression of CDKN1A, PRDM1 and IRF4. 
Deletion of PTEN, a tumor suppressor of the PI3K/AKT/mTOR pathway, is present in 10% of 
GCB-type DLBCL, but loss of expression – as measured by immunohistochemistry - can be 
observed in upto 55% of the cases.[12-14] Finally, some 30% of GCB-type DLBCL have recently 
been shown to carry mutations in genes involved in cell migration (S1PR2, P2RY8, GNA13).[14] 
These mutations are thought to enhance B-cell survival outside of the germinal center. 
HGBCL-DH 
In order to be classified as a HGBCL-DH, these tumors need to have a rearrangement of both the 
MYC gene as well as the BCL2 and/or BCL6 genes.[24,25] Given the ~ 40% incidence of BCL2 
rearrangements in the GCB-type, most of the HGBCL-DH have this COO signature. Of note, the 
majority of MYC rearrangements in HGBCL-DH have non-immunoglobulin partners, like BCL6, 
ZCCHC7 and RFTN1.[25] 
Transformed lymphoma   
Follicular lymphoma has an annual risk of aggressive transformation of 1-3%, which is associated 
with an inferior prognosis.[26,27] It includes transformation into various histologies, commonly 
DLBCL and HGBCL-DH. Recent studies have identified, among other mechanisms, mutations 
and deletions in CDKN2A/B and TP53.[28,29] MYC breaks are present in 25–50% of transformed 
follicular lymphoma (tFL) and are usually acquired during the process of transformation.[28,29] 
Hence, tFL harboring a BCL2 and MYC rearrangement can be considered  HGBCL-DH. 
PMBCL 
PMBCL has characteristics of both DLBCL and HL. The tumor cells of PMBCL morphologically 
resemble those of other large B-cell lymphomas, although multinucleated tumor cells resembling 
Hodgkin-Reed-Sternberg cells can be observed. Genetically PMBCL has large resemblance with 
HL, with genetic aberrations of genes involved in immune escape and chromatin modification.[4] 
Unbalanced rearrangements of CIITA (16p13), was observed in 38% of the PMBCL and probably 
leads to reduced HLA class II expression.[30] In nearly half of patients an amplification of 
chromosomal region 9p24 is observed, which results in upregulation of the immune checkpoint 
inhibitors program death ligand 1 and 2 (PDL1-2).[31] Aberrant activation of the JAK-STAT 
pathway is another hallmark of PMBCL, either through gain of JAK2, mutations of the tumor 
suppressor gene SOCS1 or mutations of STAT6.[4] Like in ABC-type DLBCL, there is constitutive 
activation of the NF-kappa-B pathway. Copy number gains of REL can be found in 50% of 
PMBCL, whereas bi-allelic mutations of TNFAIP3 can be detected in 36% of cases. 
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Prognosis and risk stratification 
 
Although the prognosis for patients with low risk DLBCL is excellent, the outcome of patients with 
high risk disease remains unsatisfactory. Apparently, risk stratification is very important. The most 
frequently used scoring system is the clinical International Prognostic Index (IPI) score, ranging 
from a 2 year overall survival (OS) of 91% for patients with low risk disease (IPI score 0-1) to 59% 
for patients with a high risk disease.[32] Besides the IPI score, patients at risk of treatment failure 
can be identified by tumor localization, amongst which the risk of central nervous system (CNS) 
recurrence is one of the most common ones [33]. Other prognostic factors that have been 
reported are interim fludeoxyglucose (
18
F-FDG) positron emission (PET) scans [34,35], cell-of-
origin (COO) [36], MYC translocations [24],  MYC/BLC2 expression [37,38], mutations in a high 
variety of genes  [12,39-49], and dynamics of minimal residual disease (MRD), such as reduction 
of circulating tumor DNA (Figure 3). [42,50,51] 
 
Figure 3: Timeline with diagnostic and prognostic improvements from 1976 until present. 
Abbreviations: IPI, international prognostic index; COO, cell of origin; WHO, world health 
organization; PET, positron emission tomography; NGS, next generation sequencing; ctDNA, 
circulating tumor DNA. 
 
 
As mentioned above, the initial lymphoma localization is very important for prognosis. For 
example, patients with a DLBCL of the skin have an excellent outcome after radiotherapy only, 
whereas patients with CNS involvement (either primary, or secondary) have a poor outcome.[52]  
It is important to realize that in most scoring systems, patients with these unusual localizations 
have been excluded.  
The IPI-score, a simple and robust scoring model, was first published in 1993.[53] Its prognostic 
value for aggressive B-cell lymphoma was shown to be valid in the rituximab era.[54] As 
described before, GEP identified two major DLBCL subgroups, the ABC and GCB type in the year 
2000.[10] The ABC-type was shown to have an inferior outcome compared to the GCB-type.[36] 
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The potential role of 
18
F-FDG PET-scans in the evaluation of DLBCL was first published in 
2005.[55] In 2014 international guidelines were published on the evaluation, staging and response 
assessment of lymphomas using the 5-point Deauville-scale.[56] Studies on the prognostic value 
of interim PET-scans, which show good negative predictive value but low positive predictive value, 
have fuelled various intervention trials using interim 
18
F-FDG PET-scan in HL (succesfull) and 
aggressive B-cell lymphomas (unsuccesfull). [34,57-60] 
From early 2000 onward the prognostic relevance of MYC rearrangements in aggressive B-cell 
lymphoma, other than Burkitt lymphoma, was recognized.[24] The HGBCL-DH tend to have a 
poor response to R-CHOP.[61] Whether the inferior prognosis holds true for the MYC and BCL2 
double expressor by immunohistochemistry remains to be established.[37,38]  
 
In recent years, next generation sequencing (NGS) studies have identified various mutations 
resulting in activation of different pathways (like the NF-kB and mTOR pathway) important for 
proliferation, survival and protection against cell death.[12,39-49] However, the prognostic and 
predictive role of the mutational landscape needs to be studied further. Most recently, mutational 
analysis and assessment of minimal residual disease based on circulating tumor DNA has been 




Until recently the standard treatment for DLBCL, PMBCL and HGBCL-DH patients consisted of 6 
to 8 cycles of rituximab combined with cyclophosphamide, doxorubicin, vincristine and 
prednisolone (R-CHOP). In 1976 cyclophosphamide, doxorubicin, vincristine and prednisolone 
(CHOP) was first introduced for the treatment of aggressive large B-cell lymphomas.[62] Although 
classification has changed over time, CHOP has been the most commonly used treatment for 
decades. In patients with limited stage disease 3 CHOP plus involved field radiotherapy (IFRT) 
was shown to be at least equally effective as 8 cycles of CHOP and subsequently became 
standard of care in those patients.[63] 
 
The addition of rituximab to CHOP in early 2000  has increased long-term survival of DLBCL 
patients with 10-15%.[8,9] Rituximab is a human / murine chimeric immunoglobulin G1 
monoclonal antibody with specific affinity for the pan-B-cell marker CD20, which eliminates B cells 





Despite the improved survival of patients treated with R-CHOP, 20% of patients with high risk 
disease will not achieve a complete remission (CR) after R-CHOP.[9] Patients with a high risk 
DLBCL, defined as an IPI score > 2, who do achieve CR, have a 2-year progression free survival 
(PFS) of only 79%.[65] The majority of relapses occur within the first year. Especially patients with 
these early relapses have a very poor response to current salvage chemotherapy regimens (anti-
CD20 antibodies with DHAP, ICE, PECC) and a dismal outcome.[5,6] Only 10-15% of patients 
with refractory disease or an early relapse (< 12 months after R-CHOP) will achieve a long term 
remission with the abovementioned salvage regimens.[5-7] Patients with stage I disease are 
considered to have an excellent outcome, but even amongst those patients relapses occur in 
about 10-20%.[66] Remarkably, data of the treatment and subsequent outcome of these relapsing 
patients are scarce.  
Central nervous system involvement requires a separate treatment approach. Not only the 
unfavorable prognosis, but also the blood-brain barrier are reasons for using high dose 
chemotherapy. High dose regimens with a backbone of methotrexate and cytarabine for patients 
with primary CNS lymphoma have been studied in several trials and show modest results in 
patients under the age of 60 year [52,67,68]. The efficacy of high dose chemotherapy in patients 
with secondary CNS involvement developing at relapse is limited.[69-71] There are no treatment 
guidelines for patients with the rare occurrence of CNS dissemination at presentation. 
During the last decades major advances based upon understanding the pathobiology of mature B-
cell lymphomas have resulted in the approval of several novel therapies for the treatment of 




Table 2: Drugs approved for the treatment of mature B-cell lymphomas since 2010 
 Line Drug Target Mode ORR (%) CR (%) Ref 
FL R/R Idelalisib PI3K TKI 57 6 [72] 
LPL R/R Ibrutinib BTK TKI 91 73 [73] 
MCL  
R/R 
Lenalidomide Cereblon IMID 28 8 [74] 
Ibrutinib BTK TKI 68 21 [75] 




Brentuximab vedotin CD30 ADC 
72 38 [77] 




69 22 [79] 
Nivolumab 69 16 [80] 
DLBCL 
R/R Axicabtagene ciloleucel CD19 CAR-T 82 54 [81] 
R/R Tisagenlecleucel CD19 CAR-T 52 40 [82] 
Abbreviations: FL, follicular lymphoma; DLBCL, LPL, lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin 
lymphoma; DLBCL, diffuse large B-cell lymphoma; R/R, relapsed or refractory; PI3K, phosphoinositide 3-kinase; BTK, bruton tyrosine 
kinase; CD, cluster of differentiation; PD1, programmed death 1; TKI, tyrosine kinase; TKI, tyrosine kinase inhibitor; PI, proteasome 
inhibitor; ADC, antibody drug conjugate; CI, checkpoint inhibitor; CAR-T, chimeric antigen receptor T-cell; ORR, overall response rate; 
CR, complete remission; OS, overall survival; PFS, progression free survival. Ref, reference. 
 
Strategies to improve (R)-CHOP can roughly be divided into 4 categories: more intensive 
chemotherapy, enhanced anti-CD20 therapy, incorporation of novel compounds, and 
immunotherapy (Figure 4). 
 
 
Figure 4: Timeline with attempst to improve treatment in aggressive B-cell lymphomas. 
Abbreviations: IFRT, involved field radiotherapy; R, rituximab; (X), additional drug; CPI, 





More intensive chemotherapy 
In the early ‘90s more intensive chemotherapy regimens (m-BACOD, ProMACE-CytaBOM and 
MACOP-B) failed to be superior over CHOP.[83] Although the French showed in a randomized 
study that ACVBP was superior to CHOP in limited stage DLBCL, this regimen has not been 
widely adopted.[84] Autologous stem cell transplantation (ASCT) with myeloablative 
chemotherapy has been studied as a consolidation strategy, but is unlikely to increase overall 
survival.[85,86] More recently, the more intensive chemo regimens have received renewed 
interest with the application of dose adjusted EPOCH-R regimen in both PMBCL and 
HGBCL.[87,88] However, in the setting of DLBCL DA-EPOCH-R does not improve PFS, but 
increases toxicity.[89] Even more, in the PETAL study, in which patients were escalated to the R-
CODOX-M regimen in case of a positive interim PET-scan, there was an increase in treatment 
related mortality.[34] 
Enhanced anti-CD20 
Intensifications of rituximab or replacement of rituximab by alternative anti-CD20 monoclonal 
antibodies have not increased response rates in first line or at relapse.[6,90,91] Until now there 
are no data supporting the role of rituximab maintenance in DLBCL. The phase 3 NHL13 trial that 
randomized patients for rituximab maintenance therapy, did not prolong event-free survival (EFS), 
PFS and OS.[92] Results of the second randomization of the HOVON 84 trial have to be 
awaited.[91] 
Incorporation of novel compounds 
Multiple trials have investigated the effect of additional drugs to the R-CHOP regimen, primarily in 
the ABC subtype. The proteasome inhibitor bortezomib failed to improve response rates.[93] In a 
phase 3 trial the bruton kinase inhibitor ibrutinib did not improve PFS when combined with R-
CHOP.[94] Although in phase 2 trials the immune modulatory agent lenalidomide seemed 
encouraging, the outcome of the phase 3 trials have to be awaited.[95] Outcome data of the 
HOVON 130 phase 2 trial which looked at the efficacy of R-CHOP plus lenalidomide in HGBCL-
DH looks promising but long-term outcome data have to be awaited.[96] Compounds like the 
BCL2 inhibitors (NCT02055820) and the antibody drug conjugate polatuzumab-vedotin 
(NCT01992653) are studied in both the GCB and ABC-type DLBCL. Other studies have employed 
novel compounds as a consolidation strategy. The phase 3 PILLAR-2 trial did not show an 
improvement in 2-year DFS for high risk DLBCL (IPI-score > 2) when treated with everolimus 
consolidation.[97]  Lenalidomide maintenance showed encouraging results in relapsed 
DLBCL.[98] Recent data from a phase 3 trial with lenalidomide consolidation showed a significant 





In the past decade immunotherapy has made major advances in treatment of patients by targeting 
a series of cell surface molecules known as immune checkpoints.[100.101] The checkpoint 
molecules can repress the function of pro-inflammatory lymphocytes. Imbalanced activation of 
signaling pathways, for example through induction of the program death 1 (PD1) ligand, results in 
altered differentiation profiles and suppression of T cells.[100,101] The monoclonal antibodies 
against PD1, program death ligand (PDL1) and CTLA-4 have shown substantial therapeutic 
activity in heavily treated HL patients with also encouraging results in PMBCL.[102-104] In 
relapsed DLBCL the anti-PD1 antibody nivolumab and the anti-PDL1 antibody atezolizumab 
showed overall response rates (ORR) of 10% and 27%, respectively.[105,106] A breakthrough for 
relapsed and refractory DLBCL comes from chimeric antigen receptor T-cells, which target CD19-
expressing B cells.[81,82,107] Although these data look very promising with long term remission 
in 50% of patients with relapsed DLBCL, several major obstacles have to be taken, including 
bridging therapy, availability, toxicity and costs. 
 
In conclusion, although aggressive B-cell lymphomas DLBCL, HGBCL-DH and PMBCL share 
morphologic characteristics, there are distinct differences in pathogenesis, clinical presentation, 
prognosis and treatment. Knowledge on the pathobiology has resulted in the development and 
approval of several news drugs for their treatment. The last 10-years, the tools for diagnosis, 
classification and response assessment have greatly improved. However, despite the advances 
being made on the molecular level, there is a need for better prognostic classification and 
innovative treatment strategies [108,109].   
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Scope of this thesis 
 
The aim of this thesis is to investigate what drives aggressive B cell lymphomas (chapter 2-5), to 
study the characteristics of relapses (chapter 6,7), to explore positron emission tomography (PET) 
as a diagnostic utitily (chapter 8, 9) and to describe the effectiveness of novel treatments (chapter 
10 and 11).  In chapter 2, we explored which proteins are deregulated in DLBCL compared to 
Epstein Bar Virus immortalized lymphoblastoid cell lines. In chapter 3, we performed a detailed 
analysis on the role of MYC translocations and MYC expression in relation to transformation of 
FL. In chapter 4, we studied a novel mechanism of immune escape in which loss of human 
leukocyte antigen (HLA) DM expression might result in aberrant membranous invariant chain 
peptide (CLIP) expression in HLA class II cell surface positive lymphoma cells, preventing 
presentation of antigenic peptides. Aberrant HLA expression could have implications for the 
efficacy of checkpoint inhibitors in B-cell lymphomas. In chapter 5, we investigated the relation 
between HLA loss, cell of origin and FoxP1 given the notion that post germinal B-cells 
downregulate HLA class II when they differentiate into plasma cells. In chapter 6, we looked for 
common characteristics in patients with a limited stage DLBCL who relapse after R-CHOP, since 
current prognostic models only partially identify patients at risk for relapse. In chapter 7, we 
performend an exploratory study using whole exome sequencing on paired (primary and relapse) 
DLBCL biopsies to globally assess the mutational evolution and to identify gene mutations specific 
for relapse samples from patients treated with R-CHOP. In chapter 8, we look at the relationship 
between MYC rearrangements and metabolism using fludeoxyglucose (
18
F-FDG) PET scans in 
DLBCL and HGBCL-DH, since MYC is the master regulator of metabolism. In chapter 9, we 
describe the impact of false positive 
18
F-FDG PET scans in PMBCL. In chapter 10, we describe 
the results of the combination of R-CHOP with high dose methotrexate-based chemotherapy in 
patients with DLBCL with concurrent systemic and central nervous system localization at 
diagnosis. In chapter 11, we describe the succesfull combination therapy of the JAK2 inhitibor 
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Follicular lymphoma and diffuse large B cell lymphomas comprise the main entities of adult B cell 
malignancies. Although multiple disease driving gene aberrations have been identified by gene 
expression and genomic studies, only a few studies focused at the protein level. We applied 2-
dimensional gel electrophoresis to compare seven GC B cell non-Hodgkin lymphoma (NHL) cell 
lines with a lymphoblastoid cell line (LCL). An average of 130 spots were at least two folds 
different in intensity between NHL cell lines and the LCL. We selected approximately 38 protein 
spots per NHL cell line and linked them to 145 unique spots based on the location in the gel. 34 
spots that were found altered in at least three NHL cell lines when compared to LCL, were 
submitted for LC-MS/MS. This resulted in 28 unique proteins, a substantial proportion of these 
proteins were involved in cell motility and cell metabolism. Loss of expression of B2M and gain of 
expression of PRDX1 and PPIA was confirmed in the cell lines and primary lymphoma tissue. 
Moreover, inhibition of PPIA with cyclosporine A blocked cell growth of the cell lines, the effect 
size was associated with the PPIA expression levels. In conclusion, we identified multiple 
differentially expressed proteins by 2-D proteomics and showed that some of these proteins might 






Follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) compose 60% of non-
Hodgkin lymphomas (NHLs), both are derived of germinal center or post germinal center B cells 
[1]. FL is usually an indolent lymphoma, while DLBCL is an aggressive lymphoma [2,3]. 
Transformation from FL to DLBCL occurs in 25-30% of the patients [4]. Gene expression profiling 
of DLBCL showed a distinct clustering of cases into two main groups, i.e. germinal center B cell 
like (GCB) and activated B cell like (ABC) DLBCL [5,6]. 
  
To study the transforming mechanisms for germinal B cell derived lymphomas at the protein level 
several proteomics-based studies have been conducted. The follicular lymphoma derived cell line 
SUDHL-4 was used to identify secreted proteins [7]. In this study 209 proteins were found with a 
number of potential candidates for screening, diagnosis and monitoring of treatment efficiency [7]. 
Mixtures of cell lines were used to perform quantitative analyses by 2-D gel electrophoresis and 
SILAC approaches [8–10]. Fujii et al [8,9] compared 42 cell lines including Hodgkin lymphoma, B, 
T and NK cell lymphomas to a reference sample which was a mixture of all cell lines by quantative 
proteomics. The resulting expression profiles of 389 proteins were used to compare between the 
different groups of cell lines. Super SILAC was used to compare cell lysates of 5 GCB and 5 ABC 
DLBCL cell lines using a heavy stable isotype labeled mixture of cell lines as a reference. This 
yielded a proteome consisting of 7,500 proteins and a subset of 55 proteins that could differentiate 
between GCB and ABC DLBCL [10]. Comparison of normal B cells, LPS activated B cells and 
transgenic Eμ-driven murine B cell lymphoma by 2-D gel electrophoresis revealed 48 differentially 
expressed proteins [11]. 
 
In this study we compared the 2-D proteome profiles of NHL cell lines to Epstein Barr virus (EBV) 
transformed lymphoblastoid cell lines (LCL) to identify differentially expressed proteins. 
Expression of a selection of the differentially expressed proteins (B2M, PRDX1 and PPIA) was 
validated in the cell lines and in primary patient material. Inhibition of PPIA with cyclosporine A 
(CsA) showed a clear effect on cell growth in all NHL cell lines with a correlation between PPIA 




Materials and Methods 
Cell lines 
DOHH2, SUDHL4 (FL), SUDHL6, SUDHL10, OCILY3, Karpas 422 and SUDHL5 (DLBCL) were 
obtained from DSMZ (Braunschweig, Germany). DOHH2, SUDHL4, OCILY3, Karpas 422 cells 
were routinely grown at 37°C at 5% CO2 in RPMI 1640 supplemented with 10% fetal calf serum 
(FCS), ultra-glutamine, penicillin and streptomycin (100U/ml). SUDHL5, SUDHL6 and SUDHL10 
cells were cultured with 20% FCS. Five LCLs were generated from peripheral blood mononuclear 
cells by infection with B95.8 virus. One LCL was used to compare in the 2-D experiments, the 
other four were used in the validation and functional studies. LCLs were routinely grown in RPMI 
1640 with 10% FCS. For the production of LCLs from peripheral blood permission was granted by 
the Institutional Review board (medical ethical committee UMCG) and written informed consent 
was obtained.  
Patient material 
Tissue samples of 46 patients were collected from the pathology biobank for validation by 
immunohistochemistry. These 46 cases, consisted of 13 low grade FL, 8 FL transformed to 
DLBCL with evidence of FL in the sample or earlier diagnosis of FL (TFL), and 25 nodal DLBCL. 
The 25 DLBCL cases were stained for CD10, BCL6 and MUM1 and classified according to the 
Hans algorithm [12] in GCB (n = 14) and ABC (non-GCB, n = 11). A second group of 137 DLBCL 
NOS patients, of which 12 patients were also included in the first cohort, was used for the 
validation of B2M expression. The study protocol was consistent with international ethical and 
professional guidelines (the Declaration of Helsinki and the International Conference on 
Harmonization Guidelines for Good Clinical Practice). The use of anonymous rest material is 
regulated under the code for good clinical practice in the Netherlands. Informed consent was 
waived in accordance with Dutch regulations. 
Protein extraction 
Cells (5–10 x 108) were homogenized in 1 ml of the Homogenize Buffer Mix (BioVision, Milpitas, 
CA USA) in an ice-cold Dounce homogenizer. The homogenate was centrifuged at 700g for 10 
minutes at 4°C. The supernatants were transferred to a new tube and centrifuged at 10,000g for 
30 minutes at 4°C. The total cellular membrane protein pellet was lyzed in lysis buffer (8M urea, 
4% CHAPS, 2% Pharmalyte) and kept on ice for 30 minutes. The supernatants were harvested by 
centrifuging at 16,000g for 5 minutes at 4°C. The protein concentrations of the lysates were 
determined by Bradford assay. 
Two-dimensional polyacrylamide gel electrophoresis fractionation of cell extracts  
100 μg protein was admixed with rehydration buffer (8M urea, 2% CHAPS, 0.28% dithiothreitol 
and 0.5% Pharmalyte pH 3–10). Immobilized pH gradient strips (11 cm, pH 3–10) were 
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rehydrated for 12–16 hours after the protein was loaded. Isoelectric focusing (Bio-Rad, Shanghai, 
China) was performed at 20°C by the following program: a linear increase from 0–500V over 30 
minutes, 500–1000V over 1 hour, 1000–5000V over 4 hours, 5000–8000V 4 hour and then held at 
8000V for a total of 64,000Vh. This was followed by a two-step equilibration; first, strips were put 
into 10 ml equilibration buffer (6M urea, 30% glycerol, 2% SDS, and 50mM Tris-HCl, pH 8.8), 
which contained 1% dithiothreitol for 15 minutes; next, strips were put into 10 ml equilibration 
buffer with 2.5% iodoacetamide for 25 minutes, and transferred to 12% SDS polyacrylamide gels. 
All proteins were visualized by silver staining of the gel, according to standard protocols. 
 In each experiment, two gels were run in parallel, one with the LCL sample and the second gel 
with one of the lymphoma cell lines. In order to assure reproducibility, all samples were run at 
least twice. All gels were scanned with a GS-710 calibrated imaging densitometer imager. The 
comparative analysis of gels was performed with PD Quest software (BioRad). The density of 
each spot was evaluated by normalizing volumes of all spots. Spots which were consistently up or 
downregulated (≥ 2-fold) or spots that appeared or disappeared and were showing consistent 
differences between LCL and NHL were carefully cut out. For LC-MS/MS spots with the highest 
density were selected, destained and digested overnight with 5ng/μl trypsin (freshly made in 
20mM ammonium bicarbonate pH 8–8.5). After incubation, formic acid was added and gels were 
incubated 5 minutes on a shaker. They were centrifuged at 5,000rpm for 1 minute and the 
supernatant was collected for LC-MS/MS analysis with the LTQ-Orbitrap XL (Thermo Scientific, 
Bremen, Germany).  
Protein identification 
The peaks and sequences of peptides from selected protein spots were identified by ProteinPilot 
3.0 (Applied Biosystems). Proteins were identified by using the UniprotKB/Swiss-Prot database 
[13]. Proteins with the correct molecular weight and the highest peptide coverage were considered 
as the correct protein.  
Flow cytometry 
Cells were collected by centrifuging at 1200rpm for 5 minutes at 4°C and incubated with an anti-
B2M antibody (1:750, Dako, Glostrup, Denmark) for 30 minutes on ice. Cells were washed with 
1ml 1% PBS/BSA and FITC labeled goat anti rabbit antibody (1:10, Southern Biotech, 
Birmingham, AL USA) was added as the secondary antibody. Acquisition was performed on a 
Calibur flow cytometer (BD Biosciences, San Jose, CA USA) and data were analyzed with Winlist 
software. 
Quantitative RT-PCR 
Total RNA was isolated using QIAzol (Carlsbad, CA USA) and samples were DNAse treated 
(Ambion, Foster City, CA USA) according to the manufacturer’s protocol for cell lines. RNA 
concentration was quantified using the Nanodrop™ 1000 Spectrophotometer (Thermo Fisher 
29 
 
Scientific Inc., Waltham, MA USA) and RNA integrity was evaluated by 1% agarose 
electrophoresis. cDNA was synthesized using 500ng input RNA, Superscript II and random primer 
according to the manufacturer’s protocol (Invitrogen, Bleiswijk, the Netherlands). Primers used 
were for PRDX1 forward 5’-AGCCTGTCTGACTACAAAGGAAAATAT-3’ and reverse  
5’-GGCACACAAAGGTGAAGTCAAG-3’ and for PPIA forward 5’-GCTGTTTGCAGACAAGGTCC-
3’ and reverse 5’-CAGGAACCCTTATAACCAAATCC-3’. The qPCR reaction was performed in 
triplicate in a final volume of 10μl consisting of 5μl SYBR Green mix (Applied Biosystems, Foster 
City, CA USA), 2μl of forward and reverse primer (300mM) and 2,5μl 1ng of cDNA. Amplification 
was performed on a Roche LightCycler1 480 Instrument (Roche, Almere, the Netherlands). TBP 
was used as a housekeeping gene and 2-ΔCp values were calculated. 
Immunohistochemistry 
Immunohistochemistry was performed according to standard protocols with appropriate positive 
and negative controls. Antibodies used were: anti-B2M (1:200, antigen retrieval with TRIS/EDTA 
pH9, Dako), anti-PRDX1 (1:200, antigen retrieval with citrate buffer pH6, Abcam, Cambridge, UK) 
and anti-PPIA (1:800, antigen retrieval with citrate buffer pH6, Abcam). 
Cytotoxicity assay 
Cell lines were cultured in triplicate at 105 cells/ml with different concentrations (0–10μg/ml) of 
Cyclosporine A and Alamar Blue (Abd Serotec, Oxford, UK). Cultures were measured every 24 
hours for 3 days at an emission of 560nm and extinction of 590nm. Experiments were performed 
3 times. 
Statistical analysis 
Statistical analysis was performed with IBM SPSS Statistics 22. The Mann-Whitney U-test was 
used to compare B2M, PRDX1, and PPIA expression levels in NHL groups and LCLs for MFI and 
mRNA levels. Differences of B2M, PRDX1, and PPIA staining were defined by Chi-square test for 
immunohistochemistry. A paired T-test was performed to define the difference in cell viability 
before and after cyclosporine A treatment. The correlation of PPIA expression level and cell 






Proteome profiles of LCL and NHL cell lines and protein identification 
An average of 1,133 (±355) and 1,119 (±330) spots were detected in the 2-D gels of the LCL and 
NHL cell lines, respectively (Figure A in S1 File). The paired match rate of spots on control gels to 
lymphoma cell line gels ranged from 92 to 96% indicating a good consistency. We excluded spots 
that were too weak in both gels or that were incorrectly annotated. This resulted in an average of 
248 (±24) reliable spots per gel that could be used for differential expression analysis. An average 
of 130 (±25) spots were at least 2-fold up or downregulated between the paired NHL and LCL cell 
lines. We picked 38 (±4) protein spots in each pair of gels, based on sufficiently high expression 
levels to analyse and reliable separation on the 2-D gel. Based on the position in the 2-D gels we 
were able to link them to 145 unique protein spots. Of these 34 spots were found in at least three 
NHL cell lines. Spots that were consistently up or downregulated (n = 22) were pooled for protein 
identification, whereas spots that were up in some and downregulated in other NHL cell lines (n = 
12 spots, resulting in 2x 12 protein IDs) were analyzed separately. For the 34 spots differentially 
expressed in 3 or more cell lines a total of 46 analyses were performed. The results are 
summarized in Table 1. Of the 12 spots that were analyzed in duplicate and were upregulated in 
some and downregulated in other cell lines, 7 represented the same protein, while 5 represented 
different proteins with similar molecular weights. Of those 5 spots (10 different proteins) only 4 
were found in at least 3 cell lines, the other 6 were removed from further analysis. Four proteins 
were found twice (PFN1, CFL1, PRDX1 and PPIA) at similar weight but at different iso-electric 
focusing points, probably due to posttranslational modifications such as phosphorylation, and are 
indicated as modified. 
 
Fourteen proteins, i.e. B2M, FAHD1, PRDX4, LYZ, CALM1, ARPC5, CALR, TUBB, PRDX3, 
RPSA, ATIC, RPS12, PFN1, and CFL1, were downregulated in NHL cell lines compared to LCL 
cell lines and 8 proteins, i.e. CFL1 (modified), PPIA (modified), MDH2, PRDX1 (modified), MDH1, 
ENO1, PRDX2 and PCBP1 were upregulated (Fig 1). The remaining 10 proteins, i.e. LGALS1, 
PFN1 (modified), MYL6, SSBP1, CAPZA1, GSTP1, IDH3A, PPIA, PRDX1 and PKM, were 
downregulated in some of the NHL cell lines and upregulated in others. The identified proteins are 
involved in cell motility (n = 6), cell metabolism (n = 5), chromatin modification and transcription (n 
= 5), anti-oxidant (n = 4), immune response (n = 4), signal transduction and membrane transport 
(n = 3) and drug metabolism (n = 1) (Fig 1). 
 
We selected B2M, PRDX1 and PPIA for further validation based on the differential expression 
patterns in the NHL cell lines and availability of suitable antibodies for immunohistochemistry. 
B2M plays a role in the immune response, PRDX1 has an anti-oxidant function, and PPIA is 
involved in signal transduction. 
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Validation of B2M 
Expression of B2M was absent or reduced in all NHL cell lines compared to the LCL cell line in 
the 2-D analysis (Fig 2A). These 2-D results were validated on the cell lines by flow cytometry (Fig 
2D). Four of the NHL cell lines showed lower mean fluorescent intensity (MFI) as compared to the 
4 LCLs, consistent with the 2-D analysis, whereas the other three cell lines showed a similar MFI.  
Immunohistochemistry of 46 primary cases revealed total loss of B2M expression in 21% of 
cases, i.e. 1 out of 13 FL, 2 out of 8 TFL, 5 out of 14 GCB, and 2 out of 11 ABC. In addition, 9% of 
the patients showed cytoplasmic staining for B2M, i.e. 1 TFL, 1 GCB, 3 ABC (Fig 3A–3C), so in 
total 30% of cases showed no membrane expression of B2M. Since B2M loss was most common 
in DLBCL patients, we further checked loss of B2M expression in a larger cohort of 137 DLBCL 
patients. Of the 126 evaluable cases 35 (28%) were completely negative for B2M while 29 
patients (23%) showed cytoplasmic expression of B2M, so a loss of membrane B2M expression 
was observed in a total of 51% of the DLBCL cases. 
Validation of PRDX1 
PRDX1 (modified) was upregulated in 3 NHL cell lines (SUDHL4, SUDHL6 and SUDHL10) 
compared to the LCL cell line. Expression of PRDX1 was upregulated in 2 NHL cell lines 
(SUDHL4 and SUDHL10) and downregulated in 1 NHL cell line (SUDHL5)(Fig 2B). PRDX1 
mRNA expression levels were higher in SUDHL4, SUDHL10 and SUDHL6 (Fig 2E) compared to 
the LCL cell lines, consistent with the 2-D results. In contrast, SUDHL5 had the highest mRNA 
levels, while in the 2-D experiment PRDX1 protein levels were downregulated compared to the 
LCL cell line. Immunohistochemistry of the 46 primary NHL cases showed positive staining in 33 
cases (72%). In FL, 5 of the 13 cases were positive with 4 cases showing weak positive and 1 
case showing strong positive staining. Of the TFL cases, 3 showed weak positive staining and 3 
strong staining. In GCB DLBCL 10 cases were weak positive and 3 cases were strong positive. Of 
the ABC DLBCL cases 5 showed weak positive staining and 4 showed strong staining (Fig 3D–
3F). When comparing the staining pattern of PRDX1 in the NHL subtypes, a significant difference 
(p = 0.0409) was found. Comparison of the staining results between the three lymphoma subtypes 
revealed a significant difference between FL and GCB-DLBCL (p = 0.0112). 
Validation of PPIA 
The expression of PPIA (modified) was upregulated in 4 cell lines (DOHH2, SUDHL4, OCILY3 
and Karpas 422) compared to LCL in the 2-D gels. The unmodified PPIA was upregulated in 2 cell 
lines (DOHH2 and SUDHL4) and downregulated in 1 cell line (SUDHL6) (Fig 2C). 
 PPIA mRNA expression levels were upregulated in all NHL cell lines compared to LCLs (p = 
0.0040, Fig 2F). SUDHL4 mRNA levels were highest, fitting the 2-D pattern, while the other NHL 
cell lines with upregulated protein levels in the 2-D (DOHH2, OCILY3 and Karpas 422) analysis 
were amongst the lowest at the mRNA levels. Immunohistochemistry of primary cases revealed in 
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most of the FL cases (8 of 13) weak positive staining, while all 8 TFL cases showed strong 
positive staining for PPIA. GCB and ABC DLBCL staining results were comparable with 9 and 7 
strong positive cases, for ABC the remaining cases were weak positive, while for GCB they were 
partly weak and partly negative. The results are summarized in Fig 3G–3I. The pattern of PPIA 
expression in primary patient material was significantly different (p = 0.0418) with the significant 
difference between FL and TFL (p = 0.0079). 
 
To further investigate the role of PPIA in NHL, we inhibited PPIA in all cell lines with cyclosporine 
A (CsA). After treating the cells for 72 hours with different concentrations (0, 0.5, 1, 2, 5, 10 μg/ml) 
of CsA the viability of LCL and NHL cell lines was assessed (Fig 4; Figure B in S1 File). The NHL 
cell lines were significantly more sensitive to the effect of CsA than the LCL cell lines at each 
concentration. SUDHL5 and SUDHL10 were most sensitive. To explore whether the expression 
level of PPIA is related to the sensitivity of CsA treatment, we correlated the PPIA mRNA level 
with the relative cell viability of 7 NHL and 4 LCL cell lines upon treatment with CsA. A significant 
negative correlation was observed between PPIA mRNA level and the viability of cells after CsA 
treatment, with the most significant effect in cells treated with 5 μg/ml CsA (p = 0.0064, r2 = 




Our 2-D gel electrophoresis approach revealed 28 differentially expressed proteins in lymphoma 
cell lines compared to LCLs. LCLs were chosen since they are cell lines and have similar 
proliferation patterns, while normal B cells are in a resting stage. For LCLs the transformation 
mechanism is by EBV and the proteins involved should be different from those in the NHL cell 
lines. The identified proteins are involved in various processes relevant to the pathogenesis of B 
cell lymphoma including cell motility and metabolism. 
 
The proteins included in the cell motility gene ontology are ARPC5, TUBB, CFL1, MYL6, CAPZA1 
and PFN1. With the exception of the modified CFL1 and PFN1, these proteins are all 
downregulated in NHL. ARPC5, CFL1, CAPZA1 and PFN1 have been shown to play roles in 
metastasis and invasion of solid tumors. Downregulation of ARPC5 blocks metastasis [14], 
whereas downregulation of CAPZA1 [15] and PFN1 [16] enhances metastasis and invasion or 
motility of cells. The presence of phosphorylated CFL1 [17] is associated with metastasis, and 
phosphorylated PFN1 [18] leads to enhanced angiogenesis via the upregulation of HIF1α. The 
functional consequences of downregulation of this group of proteins in NHL remains unknown. 
The proteins associated with metabolism are involved in the process known as the Warburg effect 
[19], which is a hallmark of cancer. PKM and ENO-1 are part of glycolysis, while IDH3, MDH1 and 
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MDH2 are part of the Krebs cycle. Four of the five metabolism proteins are upregulated in NHL, 
except for IDH3 which was downregulated in 2 cell lines and upregulated in one. The PRDX 
proteins (anti oxidative proteins) are indirectly related to the Warburg effect, since reactive oxygen 
species levels are up as a result of the Warburg effect and the PRDX proteins can neutralize that 
effect. Upregulation of PRDX1 and PRDX2 fits with the upregulation of metabolism proteins, 
however, PRDX3 and PRDX4 were downregulated in NHL compared to LCL cell lines. 
Various proteins identified by us as differentially expressed in NHL compared to LCL have been 
identified in B cell lymphoma previously. In the Eμ-driven mouse model Romesser et al found 
differential expression of ENO1, CALR, CFL1 and PPIA by comparing the proteome of activated B 
cells to B cell lymphoma [11] Consistent with their results we found downregulation of CALR and 
upregulation of the modified CFL1 protein and PPIA in lymphoma compared to LCL cells. The 
unmodified CFL1 protein was downregulated in our experiments, suggesting a shift towards the 
modified form of the CFL1 protein, which could indicate a more active form due to for example 
phosphorylation. PRDX1 expression was reported in a LCL cell line [20] and in DLBCL [21]. We 
found upregulation of PRDX1 in NHL compared to LCL. PRDX4 was shown to be upregulated in 
DLBCL [21], while we found downregulation in NHL compared to LCL. Protein levels of GSTP1 
were reported to be high in 29% of DLBCL cases and low in all FL cases [22] Expression of 
GSTP1 has also been found with 2-D electrophoresis in a LCL cell line [23]. In our study, GSTP1 
was downregulated in 2 cell lines and upregulated in one cell line. Loss of B2M has been 
described previously in DLBCL of testis and the central nervous system as well as in DLBCL NOS 
[24,25].  
 
B2M levels were decreased in all seven NHL cell lines compared to LCL. LGALS1 expression has 
been reported in 7% of DLBCL [26]. In LCLs and EBV+ post-transplant lymphoproliferative 
disorders expression of LGALS1 has been reported upregulated [27]. We found downregulation in 
3 cell lines and upregulation in 1 cell line, comparable to the reported data. Thus 9 of 28 proteins 
identified in this study have been reported in B cell lymphoma before and showed expression 
changes consistent with the literature. B2M, expression is downregulated or absent in all NHL cell 
lines compared to LCL cells. This observation is partially supported by flow cytometry and IHC 
staining. B2M is one of the polypeptide chains of human leukocyte antigen class I (HLA class I), 
and both chains are essential for membrane expression of HLA class I. Loss of HLA class I 
expression provides an immune escape mechanism for tumor cells. A number of studies have 
shown loss of HLA class I in DLBCL patients, especially in DLBCL presenting at immune 
privileged sites [28]. Loss of B2M membrane expression has been published in up to 60% of 






Another differentially expressed protein we identified, CALR, has also been associated with 
antigen presentation [29]. CALR expression is decreased or lost in some NHL cell lines compared 
to LCLs. CALR is a chaperone molecule for HLA class I stability, as well as a chaperone for 
misfolded proteins [29]. Loss of CALR might be part of the immune escape mechanism or 
alternatively be a consequence of the loss of HLA class I expression. 
 
PRDX1 expression is elevated at protein and mRNA level in part of NHL cell lines compared to 
LCL cells. In patient samples, we observed a higher proportion of strong positive and positive 
PRDX1 expression in the more aggressive TFL and DLBCL as compared to the indolent FL, this 
difference is most pronounced in the comparison between GCB-DLBCL and FL. Peroxiredoxins 
are thiol peroxidases, that play a role in maintaining the redox balance and have anti-apoptotic 
ability. PRDX1 is expressed in germinal center B cells and plasma cells and in germinal center 
derived B cell lymphomas and multiple myeloma [21]. The expression of PRDX1 in NHL could 
play a role in protection against apoptosis or be part of the Warburg effect.  
 
PPIA, expression was elevated in the 2-D in 3 cell lines and mRNA levels are consistently higher 
in NHL cell lines compared to LCL cells. In addition, PPIA protein expression is higher in 
aggressive TFL and DLBCL as compared to the indolent FL. PPIA belongs to the immunophilin 
family, which catalyzes cis-trans isomerization during protein folding. Elevation of PPIA 
expression has been observed in some solid cancers, such as non-small cell lung carcinoma [30] 
and gastric cancer [31]. Knockdown of PPIA can inhibit growth of non-small cell lung carcinoma 
cells [32]. PPIA supports neoplastic cell proliferation, cell cycle progression and invasion, while 
protecting them from apoptosis, by activating signaling pathways, such as NF-κB [33], and 
ERK1/2 [34]. PPIA can also be secreted into the circulation to attract monocytes and stimulates 
monocytes to produce IL-6 [35,36], and thereby create a pro-tumor microenvironment.  
 
Cyclosporin A (CsA), a widely used immune suppressive drug, binds to PPIA and inhibits its 
function. In T cells, CsA inhibits transcription factor NF-AT which is important in activation of T 
cells. In our study, there is a correlation between PPIA mRNA level and CsA induced cell death. 
The lymphoma cell lines showed significant more inhibition of cell growth than the LCLs, at all 
tested CsA levels. CsA suppressed tumor progression of squamous cell carcinoma and murine B 
cell lymphoma in a mouse model [37]. In mouse xenograft models for bladder cancer [38] and 
breast cancer. [39] CsA treatment prevented tumor growth. The use of CsA in patients has been 
tested in angioblastic T cell lymphoma, with a response to therapy in 8 out of 12 patients [40]. 
These data support CsA treatment as a novel therapy in PPIA positive DLBCL. However, the 
induction of EBV+ lymphoproliferative disease is a severe and well known side effect of long-term 






In summary, we identified 28 differentially expressed proteins and validated the expression in 
primary tissue samples for three selected proteins. The finding of B2M and PRDX1 confirmed 
validity of our approach as it has been shown previously in NHL. Elevated PPIA expression in 
lymphoma compared with LCL cells is novel and its oncogenic potential is supported by the 






Table 1: Altered expression of proteins identified by LC-MS/MS 
spot number protein name UniProtKB/Swiss-Prot 
Mass 
(kDa) 
Sequence coverage (%) 
1 RPSA P08865 32.854 64 
2 TUBB P07437 49.671 45 
3 PRDX1* Q06830 22.11 76 
4 PRDX3 P30048 27.693 59 
5 CALR P27797 48.142 67 
6 PRDX2 P32119 21.892 79 
7 MDH1 P40925 36.426 57 
8 ARPC5 O15511 16.32 77 
9 PFN1 P07737 15.054 74 
10 CALM1 P62158 16.838 48 
11 LYZ P61626 16.537 18 
12 RPS12 P25398 14.515 76 
13 ATIC P31939 64.616 66 
14 PCBP1 Q15365 37.498 67 
15 ENO1 P06733 47.169 47 
16A PRDX4 Q13162 30.54 10 
16B TPI1 P60174 30.791 60 
17A EEF1B2 P24534 24.764 70 
17B NUDT5 Q9UKK9 24.328 19 
18 CFL1 P23528 18.502 73 
19A LGALS1 P09382 14.716 81 
19B LGALS1 P09382 14.716 73 
20 PPIA* P62937 18.012 75 
21A PFN1* P07737 15.054 69 
21B PFN1* P07737 15.054 84 
22A ECHS1 P30084 31.387 72 
22B ACO2 Q99798 85.425 54 
23A GNB2L1 P63244 35.077 18 
23B MDH2 P40926 35.503 51 
24A FAHD1 Q6P587 24.843 37 
24B HSD17B10 Q99714 26.923 26 
25 CFL1* P23528 18.502 83 
26A PKM P14618 57.937 69 
26B PKM P14618 57.937 4 
27 B2M P61769 13.715 71 
28A MYL6 P60660 16.961 63 
28B MYL6 P60660 16.961 26 
29 SSBP1 Q04837 17.260 27 
30A CAPZA1 P572907 32.923 57 
30B CAPZA1 P572907 32.923 26 
31A GSTP1 P09211 23.356 32 
31B GSTP1 P09211 23.356 68 
32A IDH3A P50213 39.592 27 
32B IDH3A P50213 39.592 29 
33 PRDX1 Q06830 22.110 53 







Figure 1. Heatmap of 2-D spots with different intensities in NHL compared with the LCL cell line. 
Proteins that were differentially expressed in at least 3 cell lines are shown. In total, 28 different 
proteins have been found and 4 proteins were also found in a modified form (*). Blue: protein spot 
is missing in NHL cell lines. Light blue: protein spot is down-regulated in NHL cell lines. Red: 
protein spot is missing in LCLs and thus increased in NHL cell lines. Light red: Protein spot is 
weaker in LCL and thus elevated in NHL cell lines. Gene ontology was checked to classify the 





Figure 2. Expression of B2M, PRDX1 and PPIA. (A-C) Silver stained 2 Dimensional SDS PAGE 
gels. Differential expressed spots have been circled. Continuous circles indicate differential 
expression was more than 2-fold. Dotted circles indicate difference in expression level was less 
than 2-fold. Upper line pictures are LCL and lower lines are NHL cell lines. (A) SUDHL10, Karpas 
422, SUDHL4, OCILY3, DOHH2, SUDHL6 and SUDHL5 are shown. Loss of B2M is observed in 
SUDHL10 and Karpas 422, decreased expression of B2M is seen in SUDHL4, OCILY3 and 
DOHH2, and moderate decreased expression of B2M is seen in SUDHL6 and SUDHL5 compared 
to LCL. (B) SUDHL4, SUDHL6, SUDHL10 and SUDHL5 are shown. Modified proteins are located 
on the left. Elevated expression of PRDX1 is observed in SUDHL4, SUDHL10 and decreased 
expression of PRDX1 in SUDHL5 compared to LCL. Elevated expression of modified PRDX1 is 
observed in SUDHL4, SUDHL10 and SUDHL5 compared to LCL. (C) SUDHL4, DOHH2, Karpas 
422 and OCILY3 are shown. Modified proteins are located on the left. Elevated expression of 
PPIA is observed in SUDHL4, DOHH2 and decreased expression of PPIA in OCILY3 compared to 
LCL. Elevated expression of modified PPIA is observed in SUDHL4, DOHH2, OCILY3 and Karpas 
422 compared to LCL. (D) The mean fluorescent intensity of B2M expression determined by flow 
cytometry. (E) The mRNA expression level of PRDX1. (F) The mRNA expression level of PPIA. 
Mann-Whitney U test was used to compare the differences in B2M, PRDX1, and PPIA expression 





Figure 3. Immunohistochemistry staining of B2M, PRDX1 and PPIA. (A-C) B2M, (D-F) PRDX1, 
(G-I) PPIA. (A, D, G) negative cases, (B, E, H) positive cases. (C, F, I) Percentage of positive 
cases in different types of NHLs. Black bar indicates positive staining; grey bar indicates 
cytoplasmic staining for B2M and weak staining for PRDX1 and PPIA; white bar indicates 
negative staining. Chi-square test were performed to determine the differences in the B2M, 





Figure 4. Sensitivity of NHL and LCL cell lines to inhibition of PPIA by 5 μg/ml CsA. (A) The 
inhibition of cell viability after CsA treatment. After adding 5 μg/ml CsA for 72 hours, the viability of 
NHL and LCL cell lines was evaluated by alamar blue assay. A paired T-test was performed to 
compare the cell viability before and after treatment. Mann-Whitney U test was used to compare 
the cell viability between the NHL cell line group and LCL group. (*: p<0.05; **: p<0.01; ***: 
p<0.001; ****: p<0.0001) (B) The correlation between PPIA expression level and the inhibition of 
cell viability after NHL cell lines treated with 5 μg/ml CsA for 72 hours. Statistical significance was 
determined by Spearman test (p = 0.0064, r2 = 0.6112). There is a negative correlation between 






Supplementary figure 1. Representative 2 dimensional gel of LCL and NHL cell line. Silver 
stained 2 Dimensional SDS PAGE gels with the  LCL cell line on the left and the SUDHL10 cell 
line on the right. PI ranges from 3 to 10 and molecular weight  from 10 to 200 kDa. 1366 spots 
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Aims Low‐grade follicular lymphoma (FL) (grade 1/2, FL1/2) has an annual risk of transformation 
of ≈3%, which is associated with aberrations in CDKN2A/B, TP53, and MYC. As in diffuse large B‐
cell lymphoma, high MYC expression in transformed FL (tFL) might predict a MYC breakpoint. 
Methods and results We quantified MYC expression by immunohistochemistry and digital analysis 
in 41 paired biopsies from 20 patients with FL1/2 with subsequent transformation and in four 
isolated biopsies of tFL. As controls, 28 biopsies of FL1/2 without transformation (median follow‐
up of 105 months) and nine biopsies of FL3A/B were analysed. In the 20 FL1/2–tFL pairs, MYC 
expression was significantly higher in tFL than in the initial FL1/2 biopsies (median 54% versus 
6%; 7% in FL3A, and 35% in FL3B). MYC breaks (MYC‐R) were detected in eight of 21 (38%) 
tFLs analysed by fluorescence in‐situ hybridization (FISH), with a median MYC score of 86%. In 
two of the analysed tFL cases, the translocation was already detected in antecedent FL1/2. MYC 
partners were immunoglobulin (IG) loci in three of eight cases (one IGL, one IGH, and one IGK) 
and non‐IG in five of eight cases (two PAX5, one BCL6, and two unknown). Of the eight MYC‐R+ 
cases, six were BCL2+/MYC+ double‐hit, one was BCL2+/BCL6+/MYC+ triple‐hit, and one was 
MYC+ single‐hit. All three IG‐MYC+ cases showed a MYC expression level of >85%, whereas the 
five cases with a non‐IG MYC partner had a wider range of expression (median 68%, range 13–
86%). Among the 13 MYC‐R− tFLs, two groups with almost dichotomous MYC expression could 
be observed (three cases showed ≥90% MYC expression), suggesting alternative mechanisms of 
MYC activation.  
Conclusions We show an increase in MYC expression from FL1/2 to tFL. MYC breakpoints were 
present in ≈40% of the cases, which is markedly higher than in de novo DLBCL. MYC expression 
was uniformly high in cases with an IG‐MYC translocation but much more heterogeneous and in 





Low‐grade follicular lymphoma (FL) (grade 1/2, FL1/2) is an indolent B‐cell lymphoma 
characterized by an annual risk of high‐grade transformation (HT) of ≈3%, which is associated 
with an inferior prognosis.[1,2] It includes transformation into various histologies, most commonly 
diffuse large B‐cell lymphoma (DLBCL), high‐grade B‐cell lymphoma (HGCBL) with MYC and 
BCL2 and/or BCL6 rearrangements, blastoid lymphomas [terminal deoxynucleotidyl transferase 
(TdT)‐negative], and, very rarely, histiocytic sarcoma and TdT+ precursor B‐cell lymphoma.[3-9] 
Recent studies have identified, among other mechanisms, mutations and deletions in CDKN2A/B 
and TP53 as being involved.[5,10] MYC breaks have been detected in 25–50% of transformed 
FLs (tFLs), [4,5,10,11] and are usually acquired during the process of transformation. However, in 
rare cases, MYC breaks can be detected (already) in morphological FL1/2 lymphomas.[12-14] 
Several RNA expression studies have identified MYC up‐regulation as an important pathway in 
transformation of FL1/2.[15-18] However, the dynamics of transformation in terms of MYC 
expression and how this correlates with the presence of MYC breaks and MYC translocation 
partners are unknown. We investigated and quantified MYC expression in a series of FL1/2 with 
and without subsequent transformation. In cases of transformation, both the FL1/2 and tFL 
samples were studied. Using a broad set of fluorescence in‐situ hybridization (FISH) assays, we 
subsequently analysed the same samples for the presence of MYC breaks and tried to identify the 
MYC translocation partner. 
 
Material and methods 
Case Selection 
All patients were selected from the files of the departments of Haematology and Pathology of the 
University Medical Centre Groningen, The Netherlands, and were diagnosed between 1986 and 
2012. These included both patients admitted directly to the centre and patients with tFL 
secondarily referred from affiliated hospitals. For the present study, five different cohorts were 
defined: FL1/2 without subsequent transformation, FL1/2 with subsequent transformation, tFL, 
and, for comparison of the spectrum of MYC expression in FL, a separate series of de‐novo FL3A 
and FL3B. The initial database search was conducted by application of the following selection 
criteria. For the FL1/2 group without subsequent transformation, a minimal follow‐up of 50 months 
was required. For patients with tFL, a previously histologically confirmed (and centrally revised) 
FL1/2 was required (see below). By the use of a hospital‐based haematology database and the 
nationwide histopathology and cytopathology data network and archive, tissue biopsies were 
traced and requested.[19] Case selection, revision and classification were performed according to 
the 2008 and 2016 World Health Organization classification by an expert haematopathologist 
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(P.M.K.).[20] For low‐grade FL, only FL1/2 cases were accepted, and all cases with a distinct 
component of FL3A/B or transformation were excluded. Transformation was morphologically 
defined by a change into DLBCL, HGBCL, or TdT+ lymphoblastic lymphoma. FL3A/B was 
excluded. In cases of composite morphology in tFL samples, the high‐grade component needed 
to be dominant and amenable to dissection/separate analysis. If multiple FL1/2 and/or tFL 
samples were available, the first biopsies were selected. If an initial sample was unavailable, the 
next biopsy in line with the same morphology was analysed. Only excision or core biopsies were 
used, and bone marrow and skin biopsies were excluded. The use of rest material is regulated 
under the code for good clinical practice in The Netherlands. Informed consent was not required, 
in accordance with Dutch regulations.  
Immunohistochemistry 
Freshly cut 3‐μm‐thick whole tissue sections were stained with an anti‐cMYC rabbit monoclonal 
antibody (clone Y69; Ventana‐Roche, Basel, Switzerland) on an automated immunostainer 
(Ventana‐Roche), according to a routine protocol. Antigen retrieval was performed at 95°C for 64 
min in a Tris‐based CC1 buffer, pH 8.5 (Ventana‐Roche) in a ready‐to use‐dilution. 
Assessment of MYC Expression 
MYC IHC‐stained slides were scanned on a digital slide scanner (NanoZoomer 2.0; Hamamatsu, 
Hamamatsu city, Japan) and subsequently analysed with NDP VIEW software (Hamamatsu). First, 
the neoplastic follicles (in cases of FL) or diffuse areas with the highest MYC expression were 
selected by two investigators (R.v.P. and P.K.). These areas were further used for quantitative 
evaluation of MYC expression. Within these selected areas, five squares (0.16 mm
2
 per square, 
five squares equivalent to 3.3 high‐power fields when viewed directly by use of a standard 
microscope) were selected, and a virtual grid containing 154 intersections was projected over 
these squares. Each intersection was analysed for the presence of a MYC+ or a MYC− nucleus 
(Figure S1). The intensity of staining was not taken into account. The average percentage of 
MYC+ cells was calculated, and a standard error (SE) of the weighted proportion was calculated 
on the basis of the five selected squares. If the SE exceeded 2%, more squares were included in 
the counting until an SE of 2% had been reached. For validation of MYC IHC, staining of four 
benign paediatric hyperplastic tonsils and of three immunoglobulin (IG)–MYC+ Burkitt lymphomas 
was performed. To enable a more quantitative analysis and comparison between groups, MYC 
expression was analysed primarily as a continuous variable (in percentages). In addition, an 
arbitrary cut‐off of ≥40% for MYC positivity was used, as is commonly used for DLBCL.[21] 
FISH and Conventional Cytogenetics 
Interphase FISH was performed on 3‐μm‐thick whole tissue paraffin sections as described in 
Supporting information Figure S2. All tFLs and the corresponding FL1/2 biopsies as well as the 
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separate FL3A/B biopsies were hybridized with both MYC break‐apart (BAP) and IGH–MYC 
probes (Abbott‐Vysis, Downers Grove, IL, USA), as hybridization with the BAP probe alone could 
miss rare IGH–MYC+ cases, e.g. insertions.[22, 23] All cases with a MYC break [referred to as 
MYC rearranged (MYC‐R)+] and the corresponding FL1/2 biopsies (if available) were also 
analysed for BCL2 and BCL6 breaks with break‐apart probe assays (Abbott‐Vysis). To further 
determine the MYC translocation partner, all MYC‐R+ but IGH–MYC– cases were analysed with 
the following homebrew dual‐colour dual‐fusion probe sets: IGK–MYC, IGL–MYC, 9p13/PAX5–
MYC, and BCL6/MYC (Supporting information Figure S2). For the applied MYC FISH algorithm, 
see Figure S2. Conventional cytogenetic analysis was performed as previously described.[11] 
Statistical Analysis 
For comparison of MYC expression in paired and unpaired samples, the Wilcoxon signed rank 
test (matched pairs) and Mann–Whitney test, respectively, were used. Statistical analyses were 
conducted with GRAPHPAD PRISM, version 7.0 (GraphPad Software, La Jolla, CA, USA) and SPSS 




In total, 82 biopsies were analysed, including 28 cases of FL1/2 without later histological 
transformation (median follow‐up of 105 months, range 57–329 months), 20 pairs of FL1/2 with a 
later tFL (corresponding to 41 biopsies, as two transformed biopsies from one patient were 
analysed), four cases of tFL without initial FL1/2 biopsies available for further IHC and FISH 
analyses (for all cases, median time to transformation of 36 months, range 1–318 months), six 
cases of FL3A, and three cases of FL3B. The clinical characteristics at presentation of FL1/2 and 
treatment regimens are shown in Table 1.  
MYC Expression in Different Grades of FL 
As in the control tissues, an exclusively nuclear staining pattern was observed in all cases 
(representative images are shown in Figure 1A–D). In 67 of 82 biopsies evaluated (82%), 
counting of MYC+ nuclei in five areas was sufficient to reach an SE of ≤2%; in the other 15 cases 
(18%), up to 10 areas were necessary to reach this SE. The results for control tissues were 
according to the literature,[24] with MYC positivity rates of 11% in the germinal centres of four 
hyperplastic tonsils and of 98% in three Burkitt lymphomas (Figure 1A,B).  
The median MYC IHC scores were comparable and not significantly different for FL1/2 without 
and with later transformation, i.e. 4% and 6%, respectively (Table 2), and were 7% for FL3A, 35% 
for FL3B, and 54% for tFL (Figure 2A). The MYC score was significantly higher in tFLs than in the 
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corresponding FL1/2 samples (P < 0.001; Figure 2B). With a cut‐off of ≥40%, none of 28 FL1/2 
cases without HT, one of 20 FL1/2 cases with HT, none of six FL3A cases, one of three FL3B 
cases and 15 of 24 tFL cases were MYC+ by IHC. 
FISH 
Seventeen of the 20 tFL biopsies of the FL1/2–tFL pairs, all four isolated tFL cases and all nine 
FL3A/B cases with material available for FISH analyses were successfully hybridized with both 
MYC BAP and IGH–MYC probes. In three tFL cases, no material for FISH was available. In the 
FL3A and FL3B samples, no MYC breaks were detected (0/6 and 0/3, respectively). Eight of the 
21 analysed tFL cases (38%) showed a MYC break (MYC‐R+; Table 3). In one case, the first tFL 
sample did not show a MYC break, but a biopsy taken 30 months later was MYC‐R+ (both DLBCL 
morphology; case no. 1 in Figure 3). In one other case, we identified an unusual low‐distance 
(maximal one to two signal diameters) separation between the centromeric and telomeric MYC 
signals in the MYC BAP assay, probably indicative of an insertion or inversion affecting the MYC 
locus, but we could identify neither any IG (IGH, IGK, or IGL) nor any non‐IG (BCL6, 9p13/PAX5) 
insertion with the applied FISH assays. Although we cannot fully rule out another change affecting 
the MYC locus in this case, it was conservatively scored as MYC FISH‐negative (Figure 2C). In 
six of eight cases, the involved MYC translocation partners could be identified with the applied 
FISH assays, and these included an IG partner in three cases (Table 3; Figures 3 and 4): the IG 
partners were IGL, IGK and IGH in one case each. Among the five cases without an IG partner 
(non‐IG–MYC), the involved non‐IG partners were 9p13/PAX5 and BCL6 in two cases and one 
case respectively. In the two remaining non‐IG–MYC cases, the translocation partner could not be 
identified (negative with all applied FISH assays); these cases were assigned as ‘non‐IG‐other’. 
Of the eight MYC‐R+ tFL cases, six represented a BCL2+/MYC+ double‐hit lymphoma, one was a 
BCL2+/BCL6+/MYC+ triple‐hit lymphoma, and one was a MYC+ single‐hit lymphoma; in the last 
of these, the corresponding FL1/2 also lacked a BCL2 or BCL6 translocation (case 1 in Figure 3 
and Table 2; Figure S3). Of the six corresponding FL1/2 cases that could be investigated by FISH, 
one showed the MYC break (PAX5–MYC) already in a relapse FL1/2 sample taken 18 months 
after the initial FL1/2 diagnosis and 27 months before transformation (Table 2; Figure 3; Figure 
S4). In one other case that also had a 9p13/PAX5–MYC translocation in the tFL sample, 
t(8;9)(q24;p13)/9p13/PAX5–MYC was identified by conventional cytogenetics and FISH in a 
relapse FL1/2 sample taken 15 months after diagnosis and 7 months before transformation (Table 
3; Figure 3; Figure S4). It is of note that, in both cases, the very first FL1/2 biopsy could not be 
analysed by FISH, so it remains unclear whether the MYC break was already present there. 
Correlation Between MYC Expression and MYC Break in tFL  
Seven of the eight MYC‐R+ tFL cases showed MYC expression of ≥40%, whereas this level was 
attained in only six of 14 MYC‐R–tFL cases (Table 2; Figures 2C, D, 3 and 4). Median MYC 
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expression values for the groups according to MYC break status (IG, non‐IG, and MYC‐R–) were 
90%, 68%, and 29%, respectively, all three cases with an IG–MYC break having expression levels 
of >85%. Median MYC expression was higher but not statistically significant different between 
cases with and without a MYC break, but cases with an IG–MYC translocation had significantly 
higher MYC expression than those with a non‐IG–MYC translocation (P < 0.05; Figure 2D). 
Interestingly, among the MYC‐R–cases, two groups could be observed: one with high MYC 
expression of ≥40%, comparable to cases with a MYC break, and including three cases with 
expression levels of ≥90% (one with a possible insertion in the MYC locus with MYC expression of 
95%); and a second with lower MYC expression (Figure 2C).  
Clinical Correlates 
The time line in Figure 3 summarizes data on MYC expression, MYC break status and clinical 
course in 24 individual tFL patients, in 20 of whom the (initial) FL1/2 biopsies were also 
investigated by FISH. The clinical course was very variable, with a median overall survival (OS) of 
65 months (range 2–359 months), a median time‐to‐transformation (TTT) of 36 months (range 1–
318 months), and a median OS after transformation of 20 months (range 0–108 months). No 
significant differences in outcome parameters were seen with respect to MYC status and MYC 
expression level (cut‐off of ≥40%) at the time of transformation (data not shown). Table S1 
summarizes the clinical characteristics of lymphomas at the time of transformation according to 
MYC status. The small number of patients and the retrospective nature of this cohort, patients 
with early transformation probably being selectively referred to our hospital, precludes the drawing 
of any conclusion about MYC expression in initial biopsies and clinical behaviour.  
 
Discussion 
In this study on the role of MYC expression and MYC breakpoints in FL and its transformation, we 
found higher MYC expression in FL3B than in FL3A and FL1/2, and even higher expression in 
tFL. Paired cases of FL1/2 and tFL showed a significant increase in expression with 
transformation. It is of note that two cases showed (slightly) lower MYC expression in the tFL 
sample, suggesting that other, MYC‐independent, mechanisms are involved in transformation. 
The incidence of MYC breaks in the present study (38%) in tFL is markedly higher than the 5–
15% reported in DLBCL.[25] This supports previous observations that, in spite of many similarities 






Similarly to what has been found in DLBCL [21,27] MYC expression levels were (although not 
statistically significantly) higher in tFL cases with a MYC break, and, as in many studies on 
DLBCL, a threshold of 40% staining cells could be used to select cases that should be analysed 
by FISH for a MYC break: only one of the eight cases with a MYC break had a MYC score of 
<40%.[28] Also, all MYC‐R– FL3A/B cases had a MYC score of <40%. An unexpected finding was 
that high MYC expression levels were also found in cases without a MYC break. In particular, 
three tFL cases without a detectable MYC break (one of them with a potential small insertion or 
inversion within the MYC locus) had MYC expression levels of ≥90%, which is the level to be 
expected in Burkitt lymphoma. Therefore, other (not identifiable by FISH) structural or non‐
structural mechanisms, such as activating or stabilizing MYC mutations or overexpression related 
to differentially expressed microRNAs, could be responsible for the high MYC expression in these 
cases. Importantly, and in line with previous RNA expression studies that showed a role for 
alternative pathways in the transformation of FL, a significant proportion (9/24) of tFL cases 
showed low MYC expression of <40%.[15-17] 
 
Using a broad panel of FISH assays, we were able to identify the MYC translocation partner in six 
of eight cases. The three IG–MYC– cases showed uniformly high (>85%) expression, and this 
level was significantly higher than that in non‐IG–MYC cases. This relationship between the 
nature of the MYC partner and the level of MYC expression is also supported by a fourth tFL case 
with an IGL–MYC fusion and a MYC expression level of 97% that had to be excluded from the 
present series because it already showed focal transformation in the initial FL1/2 sample (Figure 
S5; Table S2). In non‐IG–MYC‐R cases, the expression levels were much more diverse. These 
data are in line with studies on DLBCL, and suggest that IG enhancers are more powerful in up‐
regulation of MYC than those of other genes.[22,29,30] 
 
An interesting observation in our series is the frequent involvement of non‐IGH partners and, in 
the case of an IG–MYC break, the frequent involvement of a light chain locus. Although the small 
number of cases precludes any statistical analysis, our findings are in line with observations in 
other BCL2+/MYC+ double‐hit lymphomas, whereby non‐IG locus involvement was found in ≈15–
40% of cases, and light chain instead of heavy chain involvement was detected in 40–100% of 
cases.[31-35] This is in contrast to Burkitt lymphoma, which, by definition, has an IG–MYC single‐
hit configuration, and which shows variant IG light chain involvement in only 10–20% of cases.[36] 
One explanation may be that, in contrast to the translocation in Burkitt lymphoma and single‐hit 
MYC‐R+ cases of DLBCL, one IGH allele is already affected by t(14;18)(q32;21); in consequence, 
involvement of the other allele by another translocation may be deleterious for cases in which 
proper B‐cell receptor signalling is necessary for tumour cell survival.[3] Indeed, these 
observations support the idea that these MYC breaks represent late(r) events, secondary to the 
initial t(14;18) translocation.[36,37]  
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We investigated whether the presence of a MYC breakpoint and/or overexpression of MYC might 
be associated with the behaviour of the tumour and patient outcome. No obvious association was 
found, the timing of a MYC break being randomly distributed, in some patients occurring >7 years 
after FL1/2 presentation. It is of note that rare patients with FL1/2 may show a MYC 
breakpoint,[12-14] as was observed in two of seven MYC+ tFL cases in which a (relapsed) 
antecedent FL1/2 biopsy could be analysed by FISH. In view of the small size of the series, its 
retrospective nature, with a possible referral bias, and the heterogeneity of the applied treatment 
regimens (including limited administration of anti‐CD20‐containing therapies), we are not able to 
draw any conclusions on the possible impact of MYC expression on clinical behaviour.  
 
Conclusion 
In conclusion, we showed an increase in MYC expression from FL1/2 to tFL. MYC breakpoints 
were present in ≈40% of the cases, which is a markedly higher proportion than in de‐novo DLBCL. 
MYC expression was uniformly high in cases with an IG–MYC translocation, but much more 
heterogeneous and, in part, independent of the presence of a MYC break in non‐IG–MYC and 





Table 1. Clinical characteristics and treatment regimens in 52 follicular lymphoma patients, speciﬁed 
according to the pre-transformation and post-transformation periods (if applicable) 
 Without transformation  
(n = 28) 
With subsequent transformation  
(n = 24) 
Characteristics   
Male (%) 15 (53) 11 (46) 
Median age (range) 55 (30-88) 51 (26-72) 
Age   
    < 60 year (%) 20 (71) 18 (75) 
    ≥ 60 year (%) 8 (29) 6 (25) 
Ann Arbor stage*   
    I/II (%) 10 (36) 6 (25) 
    III/IV (%) 18 (64) 16 (67) 
    Unknown 0 (0) 2 (8) 
Therapy pre-transformation period 
Rituximab 
     Yes (%) 18 (64) 7 (29) 
Chemotherapy   
     Anthracyclines (%) 6 (21) 7 (29) 
     Purine analoge (%) 4 (14) 1 (4) 
     Alkylating agents (%) 19 (68) 15 (63) 
     AutoSCT (%) 1  (4) 1 (4) 
Radiotherapy (%) 10 (36) 10 (42) 
Therapy post-transformation period 
Rituximab 
     Yes (%) N.A. 15 (63%) 
Chemotherapy 
     Anthracyclines (%) N.A. 19 (79%) 
     Purine analoge (%) N.A. 0 
     Alkylating agents (%) N.A. 23 (96) 
     AutoSCT (%) N.A. 8 (33) 
     Allo-SCT N.A. 2 (8) 
Radiotherapy (%) N.A. 7 (29) 








(n = 28) 
FL with subsequent 
transformation 







Median  % (range) 4 (1-27) 6 (1-42) 27 (1-95) 86 (13-94) 
< 40% (%) 28 (100) 19 (95) 8 (57) 1 (13) 
> 40% (%) 0 (0) 1 (5) 6 (43) 7 (87) 
Of the 52 follicular lymphoma patients samples at diagnosis four were not available for this analysis. Of the 24 patients with subsequent 
transformation MYC-FISH status was available for 22 samples of 21 patients. *Note that case Nr. 4 from Table 3 and Figure 5 is 
included twice in the analysis: both in the MYC-R negative group (first tFL sample MYC-R negative) and in MYC-R+ group (2
nd
 tFL 





Table 3: Histopathologic and genetic characteristics of MYC-R-positive tFL samples and their 




















1-FL1/2 50 56 M FL1/2 Pos Pos 36 Neg Neg  2 Pos Neg  
1-tFL
‡
 57   DLBCL Pos Pos NA Pos Neg 
Non-IG 
unknown 
86 Pos Neg  
2-FL1/2 45 318 F FL1/2 Pos NA Low Neg Neg  5 Neg Neg  
2-tFL 72   
HGBCL, 
NOS 








3-FL1/2 55 32 M FL1/2 Pos NA NA Neg Neg  7 Pos Neg  
3-tFL 57   
B-LBL 
(TdT+) 
Pos Pos 89 Pos Neg IGL 90 Pos Neg  
4-FL1/2 71 19 M FL1/2 Pos Neg 46 Neg Neg  11 Pos Neg  
4-tFL 72   DLBCL Pos 
Pos/ 
Neg 
52 Pos Neg BCL6 54 Pos Pos  
5-FL1/2 54 8 F FL1/2 Pos Pos 37 Neg Neg  17 Pos Neg  
5-tFL 55   
MYC+ 
HGBCL 
Pos Pos 81 Pos Neg 
Non-IG 
unknown 
68 Pos Neg  
6-FL1/2* 68 45 M FL1/2 Pos Pos 21 Pos NA 
9p13/ 
PAX5 




6-tFL 70   DLBCL/FL Pos Pos 51 Pos Neg 
9p13/ 
PAX5 










 52 22 M DLBCL NA NA 61 Pos Neg 
9p13/ 
PAX5 
86 Pos Neg  
8-tFL 61 131 M DLBCL Neg Pos 26 Pos Neg IGK 94 Pos Neg  
Case numbers in Table also refer to individual cases in Fig. 4.  
HGBCL: high grade B-cell lymphoma; NOS, not otherwise specified ; LBL, lymphoblastic lymphoma ; NA, not available ; NOS, not otherwise 
specified ; TTT, time-to-transformation    
# except for case 1 FL1/2 Ki67 was counted in at least 200 cells. 
*represent FL1/2 relapse, original FL1/2 biopsy (age 66) not available for analysis. 
†previous FL1/2 biopsy not available for analysis by IHC but conventional cytogenetics showed t(8;9)(q24;p13) as subclonal aberration. 




‡sample is second transformed lymphoma biopsy. First transformed biopsy was MYC break negative. 







Figure 1. Representative images of MYC immunohistochemical staining (% of positive staining 
refers to the individual area shown in the ﬁgure, and not necessarily to the average value over 
multiple areas). A,B, Benign tonsil (7% positive) (A) and IGH–MYC+ Burkitt lymphoma (98% 
positive) (B). C,D, Follicular lymphoma (FL)1/2–transformed FL (tFL) diagnosis transformation pair 








Figure 2: A, Overview of MYC immunohistochemistry (IHC) scores in different follicular lymphoma 
(FL) cohorts. B, Dynamics of MYC expression in individual cases of FL1/2 and HT FL patient pairs 
with MYC IHC for both time points available. MYC in transformed FL (tFL) versus FL1/2 (P < 
0.001). C, Assessment of MYC IHC scores in HT FL according to MYC break status (cases with 
both IHC and MYC fluorescence in‐situ hybridization available only). □, case with possible MYC 
insertion. D, Assessment of MYC IHC scores in HT FL according to MYC translocation partner. ○, 
IGK–MYC; , IGL–MYC; •, IGH–MYC; ■, unknown–MYC; , PAX5–MYC; □, BCL6/MYC. *P < 






Figure 3. Timeline showing MYC expression, MYC break status and clinical course in all 24 
individual patients. Case numbers of MYC‐R+ cases in this figure also refer to individual cases in 
Table 3; cases without a number represent MYC‐R− cases. Numbers in circles and squares 
indicate percentages of MYC positivity (MYC immunohistochemistry score). ○, FL1/2, MYC−; , 
follicular lymphoma (FL)1/2, non‐IG–MYC+; , FL1/2, MYC status not available; , transformed 
FL (tFL), MYC−; , tFL, non‐IG–MYC+; , tFL, IG–MYC+; , tFL, MYC status not available; 
, tFL, extensive disease at autopsy; 
†
diseased; *cytology sample; 
#
MYC− by conventional 
cytogenetics; , length of follow‐up. For readability, metachronous/synchronous bone marrow 
staging and follow‐up biopsies are not displayed in the figure. Time‐to‐transformation was 
calculated from the first histological samples. Cytological punctures are not displayed in the figure 
(unless stated otherwise, e.g. when no metachronous/synchronous histological biopsy was 
available). Cytogenetics from other haematological malignancies, e.g. secondary acute myeloid 
leukaemia after stem cell transplantation, are also omitted from the figure. Cases are ordered 





Figure 4. Heatmap of MYC-R+ transformed follicular lymphoma (tFL) cases and corresponding 
follicular lymphoma (FL)1/2 counterparts analysed by immunohistochemistry (IHC) and 
ﬂuorescence in-situ hybridization (if available). Grey indicates the presence of bcl-2 or bcl-6 
breaks, and empty boxes indicate the absence of these. Light blue indicates non-IG–MYC 
translocation, and dark blue indicates IG–MYC. The colour key (top) refers to the MYC IHC score 
(in quartiles). Numbers in headers refer to individual cases in Table 3 and Figure 4, with FL 







Supplemental table 1: Clinical characteristics of 21 transformed follicular lymphoma patients 










Male 5 (36%) 5 (71%) 
Median age (range) 54 (37-72) 61 (51-72) 
Median Time to transformation 
in months (range) 
35 (1-156) 39 (9-318) 
Stage *   
    I/II (%) 2 (14%) 3 (43%) 
    III/IV (%) 11 (79%) 4 (57%) 
    Unknown 1 (7%) 0 (0%) 
IPI-score   
    Low risk (0-1) 3 (21%) 3 (43%) 
    Intermediate (2-3) 5 (36%) 2 (29%) 
    High risk (4-5) 6 (43%) 2 (29%) 
* 1 missing 
ʃ
Note that number of  MYC-R negative and MYC-R positive is 14 and 7 respectively as clinical characteristics refer to MYC-
status in first analyzed tFL biopsy and this case (nr. 1) being MYC-R negative in first but MYC-R positive in second analyzed 
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Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally 
considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated 
cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry 
(IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin 
lymphomas (NLPHL), 137 diffuse large B-cell lymphomas (DLBCL), 39 primary central nervous 
system lymphomas (PCNSL) and 19 testicular lymphomas. We describe a novel mechanism of 
immune escape in which loss of HLA-DM expression results in aberrant membranous invariant 
chain peptide (CLIP) expression in HLA class II cell surface positive lymphoma cells, preventing 
presentation of antigenic peptides. In HLA class II positive cases, HLA-DM expression was lost in 
49% of cHL, 0% of NLPHL, 14% of DLBCL, 3% of PCNSL and 0% of testicular lymphomas. 
Considering HLA class I, HLA class II and HLA-DM together, 88% of cHL, 10% of NLPHL, 62% of 
DLBCL, 77% of PCNSL and 87% of testicular lymphoma cases had abnormal HLA expression 
patterns. In conclusion, an HLA expression pattern incompatible with normal antigen presentation 
is common in cHL, DLBCL, PCNSL and testicular lymphoma. Retention of CLIP in HLA class II 
caused by loss of HLA-DM is a novel immune escape mechanism, especially prevalent in cHL. 
Aberrant HLA expression should be taken into account when evaluating efficacy of checkpoint 






In the past decade, cancer immunotherapy has made major advances by targeting a series of cell 
surface molecules known as immune checkpoints. The checkpoint molecules can repress the 
function of killer and pro-inflammatory lymphocytes. Checkpoint inhibitors are monoclonal 
antibodies (mAbs) that block these inhibitory receptors, thereby stimulating T-cells and generating 
an antitumor response.[1-3] B-cell lymphoma comprise a heterogeneous group of malignancies, 
which arise from malignant transformation of B-cells.  
The mAbs against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
have shown substantial therapeutic activity in heavily treated classical Hodgkin lymphoma (cHL) 
and encouraging results in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with overall 
response rates (ORR) of 87% and 36% respectively.[4-8] Despite these encouraging results, 
complete remissions are rare and it remains to be established which patients benefit most from 
checkpoint inhibition. 
Antigen presentation depends on the proper processing of proteins and presentation of peptides 
through the human leukocyte antigens (HLA).[9] Normal B-cells present antigens through HLA 
class I, like any other nucleated cell, and as professional antigen-processing cells also in the 
context of HLA class II.[10,11] In cancer cells, so called neo-antigens can arise from proteins that 
are altered, e.g. by gene mutations. Presentation of these neo-antigens by HLA should induce 
antitumor immune responses. However, lymphoma cells can prevent these responses by various 
immune evasive mechanisms, including expression of immune checkpoint molecules.[12,13] 
Another mechanism to prevent antitumor immune responses involves loss or aberrant expression 
of HLA, which precludes presentation of tumor cell specific antigens. Thus, loss or aberrant HLA 
expression may very well have an impact on the efficacy of checkpoint inhibitors. 
 
Loss of membranous HLA class I and/or HLA class II expression has frequently been described in 
B-cell lymphomas, including cHL, DLBCL, primary mediastinal B-cell lymphoma (PMBCL) and the 
immune privileged aggressive B-cell lymphomas of brain and testis.[14-27] Observations in 
several B-cell non-Hodgkin lymphomas (NHL) indicate cytoplasmic retention of HLA-molecules in 
a proportion of patients.[17,20,25,27,28] In three cHL lymph node cell suspensions, it has been 
described that disruption of antigen presentation is caused by retention of the class II-associated 
invariant chain peptide (CLIP) in the membranous HLA class II molecules.[16] HLA-DM is 
essential in the intracellular assembly of HLA class II-antigenic peptide complexes. It displaces 
CLIP from the antigen binding groove of HLA class II molecules, to make this groove accessible 
for loading of antigens. Lack of HLA-DM results in an apparently normal cell surface expression of 
HLA class II, but without presentation of antigens and neo-antigens.[9] 
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In this study, we examined the combined protein expression patterns of HLA class I and HLA 
class II in a large set of cHL, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 
DLBCL, primary central nervous system lymphoma (PCNSL) and primary testicular lymphoma. 
We expanded this with HLA-DM as well as CLIP in a subset of patients to determine whether the 
lymphoma cells apply this alternative mechanism of inducing functional loss of HLA class II 
antigen presentation. 
 
Material and methods 
Patients and tumor samples 
Primary diagnostic FFPE tissue blocks of 389 cHL, 22 NLPHL, 137 DLBCL not otherwise 
specified 39 PCNSL and 19 primary testicular lymphoma patients were retrieved from the tissue 
banks of the pathology department of the University Medical Center Groningen and affiliated 
hospitals between 1987 and 2011. Part of the HLA expression data in cHL (n = 292) was 
described previously in relation to clinical outcome.[15] In addition, frozen tissue sections from 20 
cHL patients included in the cohort of 389 patients, were included. All cases were reviewed by two 
experienced hematopathologists. To determine the prognostic value of aberrant HLA expression 
in DLBCL clinical data on the patients was retrieved from the electronic hospital database of the 
University Medical Center Groningen. The primary clinical end point was PFS, defined as the time 
from treatment until relapse or death. Follow-up was completed until December 2015. Patients 
were treated according to best practice. IHC was performed on anonymized tissue sections in 
compliance with national ethical guidelines (“Code for Proper Secondary Use of Human Tissue,” 
Dutch Federation of Medical Scientific Societies) and the declaration of Helsinki. 
Immunohistochemistry and scoring 
Tissue sections of 3 μm were cut from formalin fixed and paraffin embedded tissue samples. 
Immunohistochemical staining was performed according to standard procedures. Briefly, sections 
were dewaxed with xylene and endogenous peroxidase was blocked. Antigen retrieval was 
performed in 10 mM Tris (tris-hydroxymethyl-aminomethane)/1 mM EDTA (ethylene diamine 
tetracetic acid) at pH 9.0. Staining was visualized with mouse mAbs HC10 (HLA class I heavy 
chains, 1:500, kindly provided by Prof. Dr J. Neefjes, the Netherlands Cancer Institute, 
Amsterdam), B2M (1:200, DAKO, Glostrup, Denmark), HLA DR/DQ/DP (HLA class II, 1:500, 
DAKO) and HLA-DM (1:200, BD Biosciences, Breda, the Netherlands). Primary antibodies were 
detected by secondary and tertiary conjugate antibodies. All cases were stained for B2M, HLA 
class I and HLA class II. HLA-DM staining was performed in all DLBCL and PCNSL cases and in 
the cHL cases with membranous HLA class II expression. CLIP staining was performed on fresh 
frozen material of 20 cHL patients with anti-CLIP (CerCLIP 1:200 BD) and HLA-DM staining with 
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anti HLA-DM (1:200 BD). For all stainings, normal tonsil tissue was used as a positive control. In 
the cHL cases, EBV status was determined by in situ hybridization using a probe specific for EBV 
encoded RNAs (EBERs). Scoring was performed by two experienced hematopathologists. 
Discrepant cases were subsequently discussed until consensus was reached. For HLA class I 
and HLA class II, membranous staining in the majority of tumor cells was considered normal. Per 
case, HC10 and B2M were scored consecutively and membranous staining was concordant for all 
cases. For HLA-DM cytoplasmic staining was considered as normal and for CLIP membranous 
staining was scored as abnormal. 
Statistical analysis  
All categorical variables were expressed as percentages. Where applicable, differences between 
groups were evaluated by chi-square (for binary variables). A two-tailed p value of less than 0.05 
indicated statistical significance. PFS curves were estimated according to the Kaplan–Meier 
method. Between-group differences in PFS were evaluated using the log-rank test. All analyses 
were performed using IBM SPSS Statistics version 22. 
 
Results 
HLA expression in cHL 
Of the 389 cHL samples, 28 were not evaluable for HLA class I and/or HLA class II and were 
excluded from further analysis. Normal HLA class I cell surface expression was observed in tumor 
cells in 132 out of 361 cases (36.6%), significantly more often in EBV+cHL (72.6%) than in EBV-
cHL (16.8%) (p < 0.001). Various aberrant staining patterns were observed, including complete 
lack of both B2M and HC10 in 52.8% of negative cases (Fig. 1). Of the HLA class I negative 
cases 38.1% had only cytoplasmic B2M staining and in 8.3% only cytoplasmic HC10 staining. Cell 
surface expression of HLA class II was present in 214 out of 361 cHL cases (59.3%), significantly 
more often in EBV+cHL (70.3%) than in EBV-cHL (53.2%) (p < 0.001) (Table 1). In 40.1% of the 
HLA class II cell surface negative cases cytoplasmic staining was observed.  
CLIP and HLA-DM expression in cHL 
Twenty HLA class II membrane positive cases, for which frozen material was available, were 
stained for CLIP and HLA-DM. CLIP staining was clearly membranous in eight cases, indicating 
diminishment or lack of presentation of immunogenic peptides in the context of HLA class II. In all 
of these eight cases HLA-DM staining was completely negative, both in frozen and corresponding 
formalin-fixed paraffin-embedded (FFPE) tissue. In the 12 cases with normal CLIP staining (weak 
cytoplasmic), HLA-DM was expressed (Fig. 2). HLA-DM staining was then performed on an 
additional 69 HLA class II positive FFPE cases. In total, HLA-DM expression was lacking in 44 out 
of 89 cases of cHL (49.4%).  
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HLA expression in NLPHL 
Of the 22 NLPHL cases, 1 was not evaluable for HLA class II and was excluded from further 
analysis. The majority of cases (90.5%) had normal HLA class I and HLA class II expression. Loss 
of HLA class II was observed in one case and combined loss of HLA class I and class II in another 
case. None of the HLA class II positive cases had HLA-DM loss. 
HLA expression patterns in DLBCL 
Of the 137 DLBCL samples, 20 were not evaluable for either HLA class I, HLA class II or HLA-DM 
and were excluded from further analysis. HLA class I surface expression was observed in 53 out 
of 117 cases (45.3%) (Table 2). Of the HLA class I membrane negative cases, two showed 
cytoplasmic HC10 staining. Cytoplasmic B2M was detected in 31 of the 64 (48.4%) HLA class I 
negative cases, these did not include the two HC10 cytoplasmic staining cases. Cell surface HLA 
class II expression was observed in 78 out of 117 DLBCL cases (66.7%). Of the negative 
membrane cases, cytoplasmic HLA class II expression was seen in 10 out of 39 (25.6%). We 
found that in the 78 HLA class II cell surface expressing tumor cells, HLA-DM expression was 
lacking in 11 cases (14.1%). Representative examples of the various staining patterns observed 
for HC10, B2M and HLA class II are shown in Fig. 2.  
HLA-expression patterns in PCNSL and testicular lymphoma 
Of the 39 PNCSL samples, 5 were not evaluable for either HLA class I, HLA class II or HLA-DM 
and were excluded from further analysis. HLA class I and HLA class II cell surface expression was 
observed in 29.4% of cases, whereas there was a loss of HLA class I and HLA class II in 24 out of 
34 (70.6%) and 19 out of 34 (55.9%) cases, respectively (Table 2). HLA-DM loss was observed in 
1 case (2.9%). Of the 19 primary testicular lymphoma, 4 were excluded because of missing 
staining data. Two samples (13.3%) showed normal HLA expression, while 12 samples (80%) 
lacked both HLA class I and HLA class II (Table 2) 
Combined expression patterns in cHL, NLPHL, DLBCL, PCNSL and testicular lymphoma 
Combined results of functional cell surface HLA class I and II expression are presented in Table 3. 
These combined analyses show that only 12.4% of cHL, 37.6% of DLBCL, 23.5% of PCNSL and 
13.3% of testicular lymphoma show an HLA expression pattern that is compatible with normal 
antigen presentation. In contrast, 90.5% of NLPHL cases show normal HLA class I and HLA class 
II expression.  In EBV-cHL the most prevalent pattern is the combined loss of HLA class I and 
HLA class II, whereas in EBV+cHL there is more often disruption of HLA class II signaling, either 
through HLA class II or HLA-DM loss (Table 1). In DLBCL the most frequent aberrant HLA 
expression is the loss of both HLA class I and HLA class II (35%). Isolated HLA class I loss 
(19.7%) is more common than isolated loss of HLA class II and HLA-DM (7.7% and 4.3%) 
(Tables 2 and 3). The HLA expression patterns were not related to gender, age or stage of the 
disease (Table S1). In the cohort of patients treated with R-CHOP, we observed no significant 
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difference in progression free survival (PFS) between patients with a normal HLA pattern or 
aberrant HLA pattern (Log Rank p value 0.25) (Fig. S1). PCNSL and testicular lymphoma have 
the highest frequency of combined HLA class I and HLA class II loss (52.9% and 80%), with 
isolated loss of HLA class I or HLA II only being observed incidentally. HLA-DM loss does not 




As proper antigen presentation in the context of HLA is expected to be a prerequisite for the 
action of immune checkpoint inhibitors, we studied HLA expression in retrospective cohorts of B-
cell lymphoma. We showed that only a minority of cHL, DLBCL, PNCSL and testicular lymphoma 
cases show HLA expression that is compatible with normal antigen presentation for both HLA 
class I and II. Combined loss of HLA class I and HLA class II was the most prevalent aberrant 
pattern in all these lymphoma. In cHL and DLBCL, we identified loss of HLA-DM as a novel 
mechanism causing disruption of normal antigen presentation in the context of HLA class II. 
The minimal requirement for B-cell lymphoma tumor cells to act like professional antigen 
presenting cells is cell surface expression of the HLA class I heavy chain-B2M complex and the 
HLA class II heavy chain dimer. Immunohistochemistry (IHC) for these components in normal 
germinal center B-cells shows strong membranous staining and weak cytoplasmic staining. In 
EBV-cHL, HLA class I expression has previously been reported to be lacking in 55% (n = 38), 
81% (n = 21) and 71% (n = 14) of cases [29-31] while, we found 83.2% (n = 233). In EBV+cHL 
these percentages are much lower: 8% (n = 25), 24% (n = 17), 25% (n = 24) and in our series loss 
of HLA class I was observed in 27.4% (n = 128). 
 
In previous publications on DLBCL a wide range of HLA class I loss has been reported, ranging 
from 34% to 75%,[19-22] compared with 54.7% in our study. The lower values in this range 
correspond to studies that made no distinction between membranous and cytoplasmic staining in 
IHC. Loss of HLA class II expression is consistently less frequently reported than HLA class I 
loss.[24-27] Importantly, in the majority of these studies no aberrant cytoplasmic HLA class II 
staining was described and probably included as positive. In a recent study, specifically looking at 
cytoplasmic HLA class II expression, aberrant expression patterns were observed in 41%. 
Interestingly, aberrant HLA class II expression was more often observed in the non-germinal 
center B-cell type.[28] Taking this into account, as well as differences in methodology and 
antibodies used, the results of these studies are compatible with our observed loss of 




Our IHC results indicate that there is a variety of mechanisms involved in the lack of cell surface 
HLA expression, judging from different staining patterns in the cytoplasm (absent, diffuse, 
granular or with Golgi-like localization). In PCNSL and primary testicular lymphoma, loss of HLA-I 
and HLA-II is frequently due to homozygous or heterozygous deletions of the HLA loci on 
chromosome 6p21.[18,19] Both in cHL and DLBCL recent studies indicate that mutations of B2M 
are a common mechanism for HLA class I loss.[20,32,33] as B2M is required for the stabilization 
of the HLA class I heavy chain. Decreased HLA class II expression in DLBCL is believed to arise 
through repression of the HLA locus by decreased expression of CIITA.[27,34-38] The 
mechanism behind this repression is unclear. Although CIITA alterations are common in primary 
mediastinal B-cell lymphoma and result in loss of CIITA.[39] mutations of CIITA in DLBCL are 
infrequent (0–9%) and can only partially explain the loss of HLA class II.[32,40-43] In cHL, 15% of 
cases harbor a translocation of CIITA, resulting in an incomplete downregulation of HLA class 
II.[44] In addition, we previously found mutations in 2 out of 6 cHL cell lines.[45] Whatever the 
mechanism is, downregulation of HLA is probably a response to continuous antitumor immune 
responses that increase over time with emergence of antigenic peptides that are related to 
malignant transformation or disease progression. 
 
Another immune evasive mechanism that we found to be frequent in cHL cases is retained 
localization of CLIP in the antigen binding groove of HLA class II. In a previous publication it was 
shown that in three fresh cHL affected lymph node cell suspensions cell surface HLA class II was 
not occupied by antigenic peptides, but by the non-immunogenic CLIP.[16] We have now shown 
that this is caused by lack of expression of HLA-DM. HLA-DO is another HLA accessory molecule 
that counteracts HLA-DM, but we found no increased expression of HLA-DO (results not shown). 
Interestingly, presentation of CLIP by dendritic cells antagonizes Th1 polarization. Thus, 
presentation of CLIP by Hodgkin tumor cells may contribute to the predominant Th2/Treg T-cell 
populations that are known to directly surround these tumor cells.[46]
 
 
Loss of HLA in B-cell lymphoma has been shown to be related to a decrease in number of tumor 
infiltrating lymphocytes and diminished interferon-gamma responses.[18,21] Both in cHL and 
DLBCL lack of membranous HLA class II expression on tumor cells has been shown to be an 
independent adverse prognostic factor.[15,25,26] However, with the introduction of rituximab the 
prognostic value of HLA class II in DLBCL has become less clear.[47] It was recently suggested 
that cytoplasmic HLA class II conveys a worse prognosis when compared with HLA class II 
membrane or HLA class II negative staining.[28] In our current cohort of DLBCL patients treated 
with R-CHOP, there was no significant difference in PFS between patients with normal HLA 




Disrupted antigen presentation is expected to have important implications for the efficacy of 
checkpoint inhibitors. Despite a high ORR in relapsed cHL treated with a checkpoint inhibitor only 
17% of patients achieve a complete remission.[5] In relapsed DLBCL, checkpoint inhibition as 
monotherapy shows modest efficacy (ORR of 36%).[6] However, checkpoint inhibition appears 
more effective when applied as a consolidation strategy (ORR 51%).[8] Lack of HLA class I 
results in loss of presentation of tumor derived neo-antigenic peptides and makes the tumor cells 
unrecognizable to CD8
+
 cytotoxic T-cells. This implies that the rationale for using immune 
checkpoint inhibitors might be restricted to HLA class I positive cases. Loss of cell surface 
expression of HLA class II on the tumor cells may not be a problem, as priming of antitumor 
immune responses can also occur through professional antigen presenting cells present in the 
micro-environment. However, in melanoma response to a PD-1 inhibitor does depend on 
presence of HLA class II on the tumor cells.[48] Since, aberrant HLA expression is the most 
prevalent finding that potentially can hamper the efficacy of checkpoint inhibitors, future clinical 




In conclusion, the majority of cHL, DLBCL, PCNSL and primary testicular lymphoma show HLA 
expression that is incompatible with normal antigen presentation. The combined losses of HLA 
class I and HLA class II represent the most frequent mechanism of immune escape. Loss of HLA-
DM resulting in the loss of antigen presentation through HLA class II presents a novel mechanism 
of immune escape in cHL and DLBCL. Our data implicate the importance of taking HLA 






Table 1. HLA class I, HLA class II and HLA-DM staining patterns in tumor cells of 361 classical 






I II DM 
Total % 
(n = 361) 
EBV+ %  
 (n = 128) 
EBV- % 
(n = 233) 
+ + + 12.4 27.7 4.1 < 0.01 
+ - ND 11.1 15.6 8.6 0.11 
+ + - 13.0 29.3 4.1 < 0.01 
- + + 17.6 3.8 25.4 < 0.01 
- - ND 29.7 14.1 38.2 < 0.01 
- + - 16.2 9.5 19.6 0.03 
 
Table 2: HLA class I, HLA class II and HLA-DM tumor cell staining patterns in 117 diffuse large 
B-cell lymphoma, 34 primary central nervous system lymphoma and 15 primary testicular 
lymphoma patients 
HLA DLBCL % 
 (n = 117) 
PCNSL % 
(n = 34) 
Testicular % 
(n = 15) I II DM 
+ + + 37.6 23.5 13.3 
+ - n.a. 3.4 5.9 6.7 
+ + - 4.3 0 0 
- + + 19.7 17.7 0 
- - n.a. 29.9 50 80 




   
Table 3. Functional deficits in antigen presentation in tumor cells of classical Hodgkin 
lymphoma, diffuse large B-cell lymphoma and primary central nervous system lymphoma 
patients 
Antigen presentation capability cHL % NLPHL % DLBCL % PCNSL % Testis % 
‘Normal’ 12.4 90.4 37.6 23.5 13.3 
HLA class I dysfunction 17.6 4.8 19.7 17.7 0 
HLA class II dysfunction 24.1 0 7.7 5.9 6.7 
HLA class I and II dysfunction 45.9 4.8 35.0 52.9 80 
Notes: Membraneous expression of HLA class I and class II with cytoplasmic HLA-DM. HLA class I dysfunction indicates loss of 
membraneous HLA class I staining with preserved membraneous HLA class II and cytoplasmic HLA-DM. HLA class II dysfunction 
refers to loss of HLA class II or loss of HLA-DM with preserved membraneous HLA class I. HLA class I and II dysfunction indicates 






Figure 1. Immunohistochemical staining patterns in formalin fixed embedded classical Hodgkin  
lymphoma tissue for HLA class I, B2M and HLA class II. (A and B) negative and positive 
membranous staining for HLA class I heavy chains. (C and D) negative and positive membranous 




Figure 2. CLIP and HLA-DM immunohistochemistry in frozen classical Hodgkin lymphoma tissue 
from two representative patients. (A) aberrant membranous CLIP staining in (B) the absence of 
HLA-DM. (C) normal absence of membranous CLIP staining in (D) presence of cytoplasmic HLA-




Figure 3: Immunohistochemical staining patterns in formalin fixed paraffin embedded diffuse large 
B-cell lymphoma tissue for HLA class I, B2M, HLA class II and HLA-DM. (A and B) negative and 
positive membranous staining for HLA class I heavy chains. (C and D) negative and positive 
membranous staining for B2M. (E and F) negative and positive membranous staining for HLA 





Supplementary figure 1: Progression free survival Kaplan-Meier plot of diffuse large B-cell 
lymphoma patients treated with R-CHOP, comparing aberrant to normal tumor cell HLA 
expression.  
Supplementary table 1. Clinical characteristics of the 117 patients with diffuse large B-cell 
lymphoma stained for HLA class I, HLA class II and HLA-DM 
 Total 
(n = 117) 
Normal HLA  
(n = 44) 
Aberrant HLA  
(n = 73) 
p-value 
Gender     
     Male % (n) 60.0 (70) 56.8 (25) 61.6 (45) 
0.70 
     Female % (n) 40.0 (47) 43.2 (19) 36.4 (28) 
Median age (range) 65 (15-92) 63 (15-92) 66 (19-92) 0.90 
Ann Arbor 
#
     
     Stage I/II % (n) 51.8 (57) 55.8 (24) 49.3 (33) 
0.74 
     Stage III/IV % (n) 48.2 (53) 44.2 (19) 50.7 (34) 
Localisation     
     Nodal % (n) 62.4 (73) 66.0 (29) 57.1 (44) 
0.61 
     Extranodal % (n) 37.6 (44) 34.0 (15) 42.9 (33) 
IPI-score *     
     Low (0-1) % (n) 46.1 (53) 45.4 (20) 46.5 (33) 
0.41      Intermediate (2-3) % (n) 47.8 (55) 52.3 (23) 43.9 (32) 
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As an immune escape mechanism, tumour cells may down‐regulate expression of human 
leucocyte antigens (HLA). Loss of HLA classes I and II has been described in various subtypes of 
diffuse large B cell lymphoma (DLBCL), including the not otherwise specified (NOS) 
subgroup.[1,2] We analysed HLA classes I and II expression in DLBCL‐NOS to investigate 
whether there is an association between HLA expression, cell of origin (COO) and the recently 
reported FoxP1 expression in non‐GCB DLBCL.[3] 
 
Material and methods 
Case selection 
We selected 77 cases of primary DLBCL-NOS diagnosed between 1992 and 2012 in the 
University Medical Centre Groningen. The cases were reviewed, based on the 2008 WHO 
Classification. Cases with a presentation at extranodal sites in the skin, bone, CNS, testis and GI 
tract were excluded. In addition, patients history was checked for an indolent lymphoma.  
Immunohistochemistry 
Formalin fixed, paraffin embedded tissues were stained for HLA class I (clone HC10, reacting with 
HLA-B, HLA-C and HLA-A (gift of J. Neefjes, NKI Amsterdam), HLA class II (clone CR3/43, 
reacting with HLA DP, DQ, DR, Dako (Agilent Technologies, Santa Clara, CA USA)), FOXP1 
(Abcam, Cambridge, UK), CD10 (clone SP67 (Ventana, Roche, Basel, Switzerland)), BCL6 (clone 
CI191E/A8 (Ventana)) and MUM1 (clone MUM-1p (Abcam)). All cases were independently scored 
by two investigators (LEM and PMK). For evaluation of HLA class I and class II expression, other 
cells than tumor cells were used as internal negative and positive controls. Tumor cells were 
scored as homogeneously positive or negative or partially negative when distinct areas showed 
lack of expression. Hans criteria were used to classify cases as GCB or ABC. Accordingly, for 
CD10, BCL6 and MUM1 a threshold of >30% positive tumor cells was used. FOXP1 was scored 
in ten-parts of 0-100% positive tumor cells and considered positive when ≥80% of the tumor cells 
stained positive (S1 and S3). Sixteen cases could not be scored for FOXP1 due to technical 
problems. 
Statistics 






Seventy‐seven cases of DLBCL‐NOS with an almost exclusively nodal presentation were 
classified for COO by immunohistochemistry (IHC) according to the Hans algorithm as germinal 
centre B (GCB) cell‐type (n = 42) or non‐GCB‐type (n = 35) (Table 1). Clinical data available from 
67 cases indicated a histologically confirmed pre‐existent or concurrent indolent lymphoma in 16 
patients, i.e. 13 follicular lymphoma, two marginal zone lymphoma and one chronic lymphocytic 
leukaemia. Expression of HLA and FoxP1 was assessed by IHC; methods are described in the 
Supporting Information. 
Significant differences (P < 0.01) in HLA loss were observed between the COO categories in the 
total group: loss of HLA class I in 51% of non‐GCB versus 21% of GCB, of HLA class II in 37% of 
non‐GCB versus 10% of GCB and combined loss in 34% of non‐GCB versus 5% of GCB (Figure 
1A). 
In the total group, 35% of the cases showed loss of HLA class I expression, 22% showed loss of 
HLA class II and 18% showed loss of both, whereas 25% retained expression of both HLA 
classes I and II. Two lymphomas with partial loss of HLA class I and two other lymphomas with 
partial loss of HLA class II were considered HLA‐negative. 
In 51 de‐novo cases loss of HLA class I was observed in 21 (41%) and loss of HLA class II in 16 
(31%) cases. In 16 transformed cases, expression of HLA class I was lost in 5 (31%; Figure S2), 
two cases of which showed additional loss of class II (13%). As transformation from follicular 
lymphoma is associated with the GCB‐type, we studied GCB‐type DLBCL separately, and found 
loss of HLA class I in five of 14 transformed cases (36%) versus four of 28 de‐novo GCB cases 
(14%) (P = 0.13). In consequence, the differences for HLA class I between the COO subtypes 
were even more pronounced after exclusion of transformed cases: 55% of non‐GCB versus 14% 
of GCB cases showed loss of expression (P ≤ 0.01). Thus, these results were not influenced by 
the inclusion of 16 cases with a history of follicular lymphoma or other types of indolent lymphoma 






Brown et al. suggested that FoxP1, a protein associated with non‐GCB‐type DLBCL, is related 
inversely with HLA class II expression.[4] A high expression of FoxP1 with a low expression of 
HLA class II expression was observed in normal pre‐plasma cells and non‐GCB‐type DLBCL 
maturing to plasmablasts.[5] This is in line with data from the group of Rimsza et al., suggesting 
that loss of HLA class II is seen in DLBCL cases maturing into plasmablastic lymphoma.[2,6] We 
studied the correlation between FoxP1 expression and HLA class II expression in 61 DLBCL 
cases (Figures S1 and S3). FoxP1 expression was not associated significantly with non‐GCB‐type 
DLBCL (Table 1; P = 0.08). We did not find an association between FoxP1 and HLA class II 
expression: loss of HLA class II was associated very weakly with FoxP1 expression in both non‐
GCB‐ and GCB‐type DLBCL. However, the majority of cases retained HLA class II expression 
while expressing high FoxP1 levels in both categories and vice versa; not all cases with low HLA 
class II showed high FoxP1 expression (Figure 1B,C). Of note, high expression of FoxP1 and HLA 
class II expression were excluded from analysis in the original study.[4] Furthermore, while most 
FoxP1‐positive cases showed homogeneous staining of the tumour cells and only a few cases 
showed partial loss of HLA class II expression, a qualitative (intensity of staining) analysis of both 




In conclusion, we show that loss of HLA class I and/or HLA class II, in particular the double‐
negative signature, is much more common in non‐GCB‐type DLBCL than in GCB‐type DLBCL. 
Our data support previous reports, focusing on class II expression.[6] The preferential loss of HLA 







Table 1. Features of DLBCL‐NOS cases 
Characteristic 
Non-GCB  
(n = 35) 
GCB  
(n = 42) 
P-value 
Male (%) 23 (66) 24 (57) 
 
Median age (years; range) 66 (9–85) 56 (14–77) 
 
Ann Arbor stage 
   I/II (%) 6 (17) 18 (43) 
 
   III/IV (%) 26 (74) 18 (43) 
 
   Unknown (%) 3 (9) 6 (14) 
 
IPI 
   0–1 (%) 5 (14) 13 (31) 
 
   2–3 (%) 19 (55) 18 (43) 
 
   4–5 (%) 7 (20) 1 (2) 
 




(%) 2 (6) 14 (33) <0.01 
HLA    
   HLA class I
+
 (%) 17 (49) 33 (79) <0.01 
   HLA class I
−
 (%) 17 (49) 8 (19) 
 
   Partial loss HLA class I (%) 1 (2) 1 (2) 
 
   HLA class II
+
 (%) 22 (63) 38 (91) <0.01 
   HLA class II
−
 (%) 12 (34) 3 (7) 
 
   Partial loss HLA class II (%) 1 (3) 1 (2) 
 
   Double‐negative (%) 12 (34) 2 (5) <0.01 
FoxP1 ≥ 80%
+
/evaluable cases (%) 18/26 (69) 16/35 (46) 0.08 
IPI, International Prognostic Index; HLA, Human leucocyte antigen; FoxP1, Forkhead box protein 1; GCB, Germinal centre B cell; 
DLBCL‐NOS, Diffuse large B cell lymphoma, not otherwise specified. a Transformation from a pre‐existent or concurrent indolent 








Figure 1: Difference in loss of human leucocyte antigen (HLA) class I and HLA class II between 
non‐germinal centre B cell (GCB) and GCB diffuse large B cell lymphoma (DLBCL). A, 
Percentage of HLA class I and II negative cases in non‐GCB and GCB DLBCL and double‐
negative cases; B, percentage of FoxP1 positive and negative cases in HLA class II negative and 
positive non‐GCB DLBCL cases; C, percentage of FoxP1 positive and negative cases in HLA 






Supplementary figure S1. Percentage of FOXP1 positive cells. A cut‐off of ≥80% was used as in 
the literature,
4





Supplementary figure 2. HLA class I expression in a single case with DLBCL and co‐existent 
follicular lymphoma (FL). The DLBCL shows loss of expression while the FL shows retained 
expression.  
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Despite a general favourable outcome in limited stage diffuse large B‐cell lymphoma (DLBCL), 
relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients 
at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar 
to the outcome after relapse in advanced stages. From January 2004 through December 2012, all 
newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical 
databases to investigate the relapse pattern and outcome in relation to initial treatment and 
clinical characteristics. In 126 patients (median age 64 years), histologically confirmed stage I(E) 
DLBCL was diagnosed. With a median follow‐up of 53 months (range 5‐132 months), 1 
progressive disease and 18 relapses occurred. The 5‐year time to tumour progression and 
disease‐specific survival were 85% (95% CI 79‐91%) and 92% (95% CI 87%‐97%), respectively. 
We observed no significant difference in relapse localization, time to tumour progression, and 
disease‐specific survival between patients treated with abbreviated R‐CHOP plus involved field 
radiotherapy or with 6 to 8 cycles of R‐CHOP. Analysis of relapses showed relapse >5 years after 
initial treatment (late relapse) in 5 of 19 patients (26%). Six of 19 patients (32%) had central 
nervous system relapse. Three of 11 relapsed cases available for analysis (28%) showed an MYC 
translocation, suggesting an overrepresentation in the relapse group. Outcome of patients with a 
relapse was poor with a median survival after relapse of 8 months. Only 1 patient (5%) underwent 
successful autologous stem cell transplantation. To improve outcome in these patients, early 
identification of new biological factors such as a MYC translocation or a high risk for CNS 
dissemination might be helpful. Moreover, treatment of any relapse after stage I disease should 






Diffuse large B‐cell lymphoma (DLBCL) accounts for 25 to 30% of adult non‐Hodgkin 
lymphomas.[1] Twenty‐five to 40% of patients present with limited stage disease, defined as 
stages I and II according to the Ann Arbor classification. 
 
Until the beginning of this century, optimal treatment for limited stage DLBCL used to consist of 3 
cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus 
involved field radiotherapy (IFRT). This combined modality approach resulted in a significantly 
better overall survival (OS) than treatment with 8 cycles of CHOP alone.[2] The addition of 
rituximab to CHOP has increased OS with 10‐15% in both limited stage and advanced stage 
DLBCL.[3-5] Apparently, this became for many haematologists a reason to refrain from 
consolidation IFRT for patients with stage I and II.[6] Although randomized controlled trials are 
lacking, a very large registry study covering >59,000 patients strongly suggested that combined 
modalitytherapy was associated with better OS, even in the rituximab era.[6] Despite the generally 
favourable outcome, relapses still occur in 10 to 20% of patients with limited stage DLBCL and 5‐
year OS ranges between 75% and 94%, which suggests that salvage of relapses is frequently 
unsuccessful.[6-10] Clinical prognostic models only partially identify patients at risk for 
relapse.[2,11] Biological tumour characteristics such as cell of origin and especially presence of 
MYC translocation have prognostic significance in DLBCL.[12,13]  
 
We decided to analyse in an observational cohort study the relapses of patients with stage I(E) 
DLBCL focusing on (1) initial therapy (only R‐CHOP vs. combined modality treatment), (2) clinical 
characteristics and risk profile of the patient, (3) patterns of relapse, (4) if available the presence 
of MYC breaks, and (5) the final outcome after treatment. To this end, we used 2 large databases 
in the northern part of the Netherlands, thereby avoiding trial‐based selection and better 
approaching real life observation. 
 
Material and methods 
Study design and patient identification 
Clinical data on all consecutive patients with histologically confirmed stage I(E) DLBCL diagnosed 
during an 8‐year period from January 1, 2004 through December 31, 2012 were retrieved from 2 
clinical databases from 5 medical centres and 1 academic medical centre. The combined 
databases are representative of the incidence, characteristics, and treatments of patients in the 
northern part of the Netherlands. Patients should have received at least 1 cycle of R‐CHOP. 
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Primary coetaneous, central nervous system (CNS) large B‐cell lymphoma, primary mediastinal 
B‐cell lymphoma, and immunodeficiency lymphomas were excluded. At diagnosis, patients were 
staged by fludeoxyglucose positron emission tomography (18FDG PET) and/or computed 
tomography (CT) scans. The stage‐adjusted IPI and CNS IPI were used to stratify patients.[2,14] 
Pathological review was performed by experienced haematopathologists (RK and AD). Approval 
for this observational study was obtained from the Medical Ethics Review Committee from Medical 
Centre Leeuwarden. Informed consent was waived in accordance with Dutch regulations. after 5 
years were designated as late relapses.[16,17] Follow‐up was completed until December 2015. 
MYC fluorescence in situ hybridization analysis 
For evaluation of a MYC translocation, formalin‐fixed paraffinembedded tissue blocks were 
collected of the relapsed DLBCL cases. Interphase fluorescence in situ hybridization (FISH) was 
performed on 3‐μm‐thick whole tissue sections of the primary tumour as previously described by 
using Vysis break apart probes (Abbot Technologies).[18] 
Statistical analysis 
Duration of follow‐up was calculated for all patients alive. The primary endpoints were OS, 
disease‐specific survival (DSS), time to tumour progression (TTP), and survival after relapse. 
Overall survival was defined as time from diagnosis until death (from any cause), DSS as the time 
from diagnosis until death as a consequence of DLBCL, TTP as the time from diagnosis until 
relapse or progression, and survival after relapse as the time from relapse until death (from any 
cause).[15] Survival curves were estimated according to the Kaplan‐Meier method. Between‐
group differences in DSS and TTP were evaluated by using the log‐rank test. All categorical 
variables were expressed as counts and percentages. Where applicable, differences between 
groups were evaluated by chi‐square for binary variables and independent t tests for continuous 
variables. Cox regression was used for univariate analysis. Given the low incidence of events no 
multivariate analysis was performed. A 2‐tailed P value of less than.05 indicated statistical 







A total of 126 patients with a median age of 64 years were eligible for analysis. At presentation, 
41% (n = 50) of patients had a nodal localization; extranodal sites consisted of gastrointestinal 
(20%, n = 25), bone (10%, n = 13), and nasopharyngeal localization (11%, n = 14). Other sites 
encompassed the remaining 18%, i.e., testis (n = 7), thyroid (n = 5), breast (n = 5), and salivary 
glands (n = 2) (Figure SS1). High stage‐adjusted IPI was observed in 19% (n = 23) of patients. 
Central nervous system‐IPI 0‐1 (low risk), 2 to 3 (intermediate risk), and >3 (high risk) were 
observed in 52% (n = 66), 47% (n = 59), and 1% (n = 1), respectively. 
Treatment 
Of the 126 patients 97% (n = 122) completed, at least 3 cycles of R‐CHOP were evaluable for 
comparison between treatment arms, e.g., combined modality (68%, n = 83) or R‐CHOP alone 
(32%, n = 39); see Figure 1 and Table 1. In patients receiving R‐CHOP, the number of cycles was 
reduced in 8% of patients (n = 3) because of previous tumour resection and treatment‐related 
toxicity. The cumulative dosage of IFRT was 30 to 40 Gray. All patients with testicular 
localization received CNS prophylaxis with intrathecal methotrexate. 
Clinical and biological characteristics of relapse 
One patient had PD during the first 3 cycles of R‐CHOP, and 18 patients experienced a relapse. 
Of these 18 patients, 28% of patients (n = 5) had a relapse more than 5 years after diagnosis: 3 of 
14 patients treated with abbreviated R‐CHOP plus IFRT and 2 of 4 patients treated with R‐CHOP 
(p 0.52) (Figure 1). In 79% of cases (n = 15), the relapse/progression occurred at a site distant 
from the initial tumour localization. In 32% of cases (n = 6), this involved the CNS, with either 
meningeal and/or parenchymal localization. Two of the CNS relapses occurred in patients with a 
testicular lymphoma, despite CNS prophylaxis. In the remaining cases, the primary tumour had 
nodal (n = 2) and nasopharyngeal localizations (n = 2) (Figure 2). The initial calculatedCNS‐
IPIwas low (n = 3) and intermediate (n = 3). In addition, 1 patient with initial nodal localization had 
a testicular relapse, another sanctuary site. Of the 19 relapsed/progressive DLBCL, 58% of cases 
(n = 11) had tissue blocks with sufficient tumour material for MYC‐FISH analysis. In 28% of cases 
(n = 3), an MYC translocation could be demonstrated. All these MYC positive DLBCL were 
observed in patients with an early relapse. None of the evaluable CNS relapses had a MYC 
translocation (Figure 2). 
Patient outcome 
The median duration of follow‐up of the 126 patients was 53 months (range 5‐132). Twenty‐seven 
patients died (11 of relapse; 16 unrelated). The 5‐year TTP, DSS, and OS for the entire cohort 
were 85% (95% CI 79‐91%), 92% (95% CI 87%‐97%), and 80% (95% CI 73‐86%), 
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respectively (Figure 3A and B). In univariate analysis of 122 patients completing therapy, age had 
the strongest association with shorter TTP (Table 2). Age > 60 years and elevated LDH, both 
composites of stage adjusted IPI, were associated with a shorter DSS (Table 2). Localization 
and treatment regimen were not found to be prognostic factors (Figure S2A). Univariate analysis 
showed that age > 60 years (HR 9.1,95% CI 2.1‐38, P < .01), but not localization, LDH, or 
treatment regimen was associated with a shorter OS (Figure S2B). 
 
Treatment after relapse 
The median age of relapsing patients was 77 years (range 41‐83). The median survival after 
relapse was 8 months (Figure 3C). Treatment of patients who relapsed consisted of rituximab, 
dexamethasone, cytarabine, and cisplatin salvage chemotherapy (16%, n = 3), retreatment with 
R‐CHOP (10%, n = 2), palliative chemotherapy (16%, n = 3), radiotherapy (32%, n = 6), and 
palliative care (26%, n = 5). Only 1 patient (5%) underwent high dose chemotherapy followed by 
autologous stem cell transplantation as part of the salvage regimen. A second remission was 
achieved in 3 of 5 (60%) patients receiving curative chemotherapy, in 1 patient (33%) treated with 
“intended” palliative chemotherapy, and in 2 patients (33%) treated with radiotherapy. 
One‐year survival after relapse for patients receiving salvage radiotherapy or chemotherapy was 




In this population‐based cohort study with a long median follow‐up, we followed all consecutive 
patients with newly diagnosed DLBCL stage I(E) during an 8‐year period. We observed no 
differences in relapse localization, TTP, and DSS between patients treated with abbreviated R‐
CHOP plus IFRT and R‐CHOP only. Obviously, this was not a randomized comparison but a 
reflection of real‐life approaches. Patients with extranodal disease more frequently received R‐
CHOP, reflecting physicians' choice to avoid radiotherapy‐induced toxicity. By looking into the 
characteristics of relapsed patients, we made several observations that offer a reason for the 
occurrence of relapses in these good risk patients. 
 
Regardless of initial therapy, one‐third of relapses (26%) occurred more than 5 years after 
therapy. Although late relapses have been observed in the pre‐rituximab era,[17] we and others 
observed these late relapses in patients with limited stage DLBCL treated with rituximab as 
well.[16] Although clonal relationship in late relapses is established, the biology underlying the 
long interval remains unclear.[19] Most relapses (73%, n = 15) arose at distant sites, indicative of 
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good local tumour control with either abbreviated R‐CHOP plus radiotherapy or R‐CHOP. In 
nearly one‐third of relapses, there was CNS involvement. Because rituximab and CHOP have 
only limited activity in the CNS, it is unlikely that either of the treatment regimens will prevent the 
CNS relapses.[20] Even when initial CNS prophylaxis with intrathecal MTX is provided, CNS 
relapses can occur as illustrated by 2 patients with lymphoma of the testes in our study.[21] 
Recently, the CNS‐IPI as risk model for CNS relapse in patients with DLBCL was established to 
identify patients at highest risk for CNS relapse.[14] In patients with a low‐risk CNS‐IPI, less than 
1% showed a CNS relapse. 
 
However, as shown in our study, with stage I(E) DLBCL, 5% of 126 patients with initial low‐risk 
CNS‐IPI had a CNS relapse. It was recently reported that in contrast to advanced stage DLBCL, 
the cell‐of‐origin is not prognostic in limited stage disease.[9,13] To impact prognosis of these 
good risk patients, a biomarker, such as MYC breaks, might be helpful.[12] We found an MYC 
translocation in 3 of 11 evaluable relapsed cases. It is plausible that in the relapsed setting, 15 to 
20% of DLBCL harbour an MYC translocation.[22] Although the number of analysed patients is 
low, we found no MYC positive DLBCL in late relapses. Despite an increased risk of CNS 
dissemination in MYC positive DLBCL, no translocation was detected in the 2 evaluable CNS 
relapses.[23] Combined analysis showed that two‐third of relapses could be assigned to either a 
late relapse, CNS relapse, or MYC positive DLBCL.  
 
In general, outcome of patients with relapsed or refractory DLBCL is very poor, with the exception 
of more favourable outcome in relapses more than 1 year after treatment.[24] We observed a 
similar poor outcome in patients with relapsed stage I(E) DLBCL. This can partially be explained 
by the old age of the relapsed patients, limiting therapeutic options. Because the median age of 
patients with a DLBCL in the general population is 68 years, this is an observation in line with 
general practice. Furthermore, treatment options for relapsed DLBCL in the CNS are limited and 
patients with an MYC translocation tend to have a poor response to salvage 
chemotherapy.]25,26] Salvage therapy for a relapse after stage I(E) disease is not trivial and 






Despite a general favourable outcome in stage I(E) DLBCL, 15% of patients relapsed despite 
previous R‐CHOP therapy and survival after relapse was short. Analysis of relapses showed that 
more than half of cases could be assigned to either a late relapse or CNS relapse. Interestingly, 
there is a suggestion that MYC positive DLBCL was overrepresented in the relapse group. 
Although numbers are small, our results emphasize the necessity to improve first line treatment in 
these patients as well. Any relapse after stage I disease should be taken seriously, and patients 






Table 1. Clinical characteristics of 122 patients with stage I (E) diffuse large B-cell lymphoma 
who completed therapy according to treatment regimen. 
 
Total  
(n = 122) 
R-CHOP 
(n = 39) 
Abb. R-CHOP + 
IFRT (n = 83) 
p-value 
Gender    
 
0.04 
   Male (%) 68 (56) 27 (69) 41 (49) 
   Female (%) 54 (44) 12 (31) 42 (51) 
Median age (range) 64 (15-87) 63 (15-83) 66 (28-87) 0.43 
   Age < 60y (%) 48 (39) 16 (41) 32 (39) 
0.79 




   Nodal (%) 50 (41) 8 (21) 42 (51) 




   WHO < 2 (%) 118 (97) 39 (100) 79 (95) 




   Normal (%) 99 (81) 26 (67) 73 (88) 




   0-1 (%) 64 (52) 15 (39) 49 (59) 
   2-3 (%) 58 (48) 24 (62) 34 (41) 
Stage-adjusted IPI  
 
0.19 
   0-1 (%) 99 (81) 29 (74) 70 (84) 





Table 2. Univariate analysis of factors in time to tumor progression (TTP) and disease specific 




95% CI p-value 
Hazard 
ratio DSS 
95% CI p-value 
Gender        
Male 56 Reference Reference 
Female 44 0.97 0.4 - 2.5 0.94 0.94 0.3 - 3.1 0.92 
Age        
   < 60 years 39 Reference Reference 
   > 60 years 61 4.1 1.2 - 14 0.03 3.6 0.8 - 17 0.06 
Localization        
   Nodal 41 Reference Reference 
   Extranodal 59 1.2 0.5 - 3.0 0.72 1.2 0.3 – 4.4 0.80 
LDH        
   Normal 81 Reference Reference 
   Elevated 19 2.0 0.7 – 5.8 0.19 4.4 1.3 - 15 0.02 
IPI        
   0-1 52 Reference Reference 
   2-3 48 2.7 1.0 – 7.2 0.05 3.8 1.0 - 15 0.05 
Stage adjusted IPI        
   0-1 81 Reference Reference 
   2-3 19 2.7 1.0 – 7.5 0.05 4.5 1.3 - 15 0.02 
Treatment regimen        
   R-CHOP + IFRT 68 Reference Reference 







Figure 1. Schematic representation of the 126 patients with a stage I(E) diffuse large B‐cell 
lymphoma according to treatment regimen. One hundred twenty‐two patients completed therapy. 
Four patients died before completing 3 cycles of (R)CHOP. Abbreviations: TRM, treatment‐related 








N = 39 N = 83
Stage I (E) DLBCL ≥ 1 R-CHOP





Figure 2. (A) Kaplan Meier curves for overall survival (OS) and disease‐specific survival (DSS) of 
the 126 patients with a stage I(E) diffuse large B cell lymphoma (DLBCL). The 5-year OS and 
DSS are 80 ± 6 and 92 ± 5%, respectively. (B) Kaplan Meier curve for time to treatment failure 
(TTF) of the 126 patients with a stage I (E) DLBCL. At 5 years, the TTF was 85 ± 6%. (C) Kaplan 
Meier curve for survival after relapse of 19 patients with a relapsed stage I(E) DLBCL. Median OS 












Figure 3. Schematic overview of clinical and biological characteristics of the 19 patients with a 
stage I(E) diffuse large B‐cell lymphoma who progressed during or relapsed after treatment. 








 R-CHOP only  R-CHOP plus involved field radiotherapy 
Supplementary figure 1. Type of treatment of the 122 patients with a stage I(E) diffuse large B‐
cell lymphoma (DLBCL) who completed therapy according to tumour localization. In nodal DLBCL, 
abbreviated R‐CHOP plus involved field radiotherapy is favoured over R‐CHOP. In extranodal 
DLBCL, nearly half of patients received R‐CHOP. 
 
 
Supplementary figure 2. (A) Overall survival (OS) of the 122 patients with a stage I(E) diffuse 
large B‐cell lymphoma (DLBCL) who completed therapy according to treatment regimen. The 5‐
year OS of patients treated with abbreviated R‐CHOP plus involved field radiotherapy and R‐
CHOP was 85% and 83%, respectively (p 0.47). (B) Disease‐specific survival (DSS) for the 122 
patients with a stage I(E) DLBCL who completed therapy according to treatment regimen. The 5‐
year DSS of patients treated with abbreviated R‐CHOP plus involved field radiotherapy and R‐
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Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor 
biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains 
unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) 
formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally 
assess the mutational evolution and to identify gene mutations specific for relapse samples from 
patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A 
minority of the mutations detected in the primary sample (median 7.6%, range 4.8–66.2%) could 
not be detected in the matching relapse sample. Relapsed DLBCL samples showed a mild 
increase of mutations (median 12.5%, range 9.4–87.6%) as compared to primary tumor biopsies. 
We identified 264 genes possibly related to therapy resistance, including tyrosine kinases (n = 
18), (transmembrane) glycoproteins (n = 73), and genes involved in the JAK-STAT pathway (n = 
7). Among the potentially resistance related genes were PIM1, SOCS1, and MYC, which have 
been reported to convey a risk for treatment failure. In conclusion, we show modest temporal 
heterogeneity between paired tumor samples with the acquisition of new mutations and 
identification of genes possibly related to therapy resistance. The mutational evolution could have 






Diffuse large B-cell lymphoma (DLBCL) accounts for 25–35% of all non-Hodgkin lymphomas 
(NHL) [1]. For more than 15 years, immune-chemotherapy with rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisolone (R-CHOP) has been the standard of care [2]. Although 
the prognosis for patients with low-risk disease is excellent, the 3-years overall survival (OS) for 
high-risk patients is less than 65% [3]. Patients with primary refractory disease or those who 
relapse within a year after treatment have an especially poor response to salvage chemotherapy 
[4,5]. 
 
DLBCL is a genetically heterogeneous disease. Based on gene expression profiling (GEP), 
DLBCL can be subdivided into activated B-cell (ABC-type), germinal center B-cell (GCB-type), 
and unclassified-type. The first two subtypes reflect the B-cell developmental stages from which 
DLBCL arises [6]. The prognostic impact of this so-called cell-of-origin (COO) classification based 
on gene expression profiles (GEP) has been established in multiple studies [6,7]. Several trials 
are currently investigating the efficacy of adding compounds targeting the putative mutations or 
deregulated molecular pathways associated with a specific COO class; for example, adding 
ibrutinib or lenalidomide to R-CHOP therapy in patients with ABC subtype DLBCL [6–8]. 
Over the last decade, a large number of studies have been published on the mutational landscape 
of DLBCL, including over 2000 DLBCL cases [9–21]. These studies identified non-synonymous 
mutations in 30 to 100 genes per case (median 3.3 to 6.6 mutations per megabase) [21]. In total, 
over 1000 individual mutated genes have been described. The mutational landscape differs 
between ABC-type and GCB-type, with mutations in MYD88 and CD79B being more common in 
the ABC-type, and mutations in EZH2 and GNA13 being more common in GCB-type [9–21]. 
Based on the mutational landscapes, DLBCL can be divided into subgroups characterized by 
genetic alterations in the proximal B-cell receptor, NF-kB signaling, PI3-kinase signaling, anti-
apoptotic proteins, DNA damage repair, and immune evasion [20,21]. 
 
One of the main challenges for most genomic profiles is to implement them into clinical practice. 
Due to the high inter-patient heterogeneity of mutations, it has been estimated that for the 
development of a prognostic model, the mutational landscape of 900 patients would have to be 
correlated with clinical outcomes [22]. Earlier trials had been underpowered to properly address 
this question [16,18]. More recently, larger studies have reported on the prognostic impact of 
genomic risk models [19–21]. Apart from being prognostic, these genomic models can form the 
basis for biomarker driven treatment strategies [23]. 
 
Most of the currently published papers do not take into account genomic evolution of tumors with 
presence of subclones at different anatomical sites (spatial), evolution over time (temporal), and 
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dynamics caused by treatment [24]. At this point, data on the clonal evolution of DLBCL is largely 
absent. Data on sequential biopsies in DLBCL is available for less than 20 patients [15,18]. 
Thus, despite the large number of DLBCL samples analyzed, the impact of clonal and mutational 
evolution remains largely unknown. To broaden this knowledge, we performed an exploratory 
study on paired biopsies (primary versus relapse) to globally assess the mutational evolution, and 
to identify gene mutations enriched or exclusively present in relapsing patients. 
 
Materials and Methods 
Patient Selection 
All patients diagnosed with a relapsed or refractory (R/R) DLBCL between 2004 and 2014 at the 
University Medical Center Groningen (UMCG) or affiliated hospitals were retrieved from the 
electronic database of the UMCG. Only patients that received 6 to 8 cycles of R-CHOP as first line 
therapy were included. Patients with post-transplant lymphoproliferative disease, human 
immunodeficiency virus (HIV) related lymphoma, primary central nervous system lymphoma 
(CNS), primary testicular lymphoma, primary mediastinal large B-cell lymphoma, or transformed 
indolent lymphoma were excluded. Of the 61 patients with R/R DLBCL, a histological confirmation 
of relapse was available for 31 patients. CNS relapse was confirmed by flow cytometry on spinal 
fluid samples in 7 patients. In the remaining 23 patients, progression was established through 
imaging modalities. Of the 31 patients with a histological proven relapse, 16 had an excision 
biopsy sufficient for further analyses (Figure S1). The remainder of the patients had core or bone 
marrow biopsies insufficient for analysis. Where applicable, archival samples of non-tumor tissue 
were retrieved for isolation of germ line DNA. Approval for this non interventional study was 
obtained from the Medical Ethics Review Committee from the University Medical Center 
Groningen (October 2014). Informed consent was waived in accordance with Dutch regulations 
The study utilized rest material from patients, the use of which is regulated under the code for 
good clinical practice in the Netherlands and does not require informed consent in accordance 
with Dutch regulations. 
Pathology Review 
Pathology review was performed according to the 2017 “WHO classification of tumors of 
haematopoietic and lymphoid tissues” on formalin fixed paraffin embedded (FFPE) biopsies by an 
experienced hemato-pathologist (AD) [1]. For COO classification, raw counts obtained by 
nanostring gene expression analysis were uploaded at the Lymphoma/Leukemia Molecular 





Fluorescence in Situ Hybridization 
MYC rearrangements were assessed on interphase nuclei on 3 µm thick whole tissue sections of 
the primary tumor as previously described, with Vysis break apart probes (Abbot technologies, 
Santa Clara, CA, USA) using fluorescence in situ hybridization (FISH) [25]. All cases with a MYC 
break were also analyzed for BCL2 and BCL6 breaks using Vysis break apart probe assays 
(Abbot technologies, Santa Clara, CA, USA).  
DNA Isolation 
In total, 67 FFPE tissue blocks were obtained from 16 DLBCL patients. For whole exome 
sequencing (WES) we selected tumor samples with at least 50% tumor cells. To yield at least 500 
µg DNA, a minimum area of 0.5 cm
2
 of tumor cells was obtained from 10 µm thick slides. DNA 
from FFPE tumor and non-tumor biopsies was isolated using the QIAamp DNA FFPE tissue kit 
(Qiagen, Hilden, Germany), following the protocol of the manufacturer. A standard salt-chloroform 
protocol was used to isolate DNA from stem cells collected for hematopoietic stem cell 
transplantation (CD34+ purified cells) from one patient. DNA concentrations were measured by 
NanoDrop (Thermo Fisher Scientific Inc., Waltham, MA, USA), and DNA quality was evaluated on 
a 1% agarose gel. After quality control, 59 samples from 15 patients were sent for WES (Figure 
S1). 
Whole Exome Sequencing  
Library preparation and whole exome sequencing was carried out by Novogene (Novogene 
Bioinformatics Technology Co., Ltd, Beijing, China). Library preparation was done using the 
Agilent SureSelect All Exon V6 kit (Agilent technologies, Santa Clara, CA, USA), starting from 
0.5–1.5 μg genomic DNA of tumor and non-tumor samples. Paired-end sequencing with a read 
length of 2 × 100 nucleotide was performed on Illumina HiSeq2000 (Illumina, Inc., San Diego, CA, 
USA). 
Bioinformatics Approach 
The bioinformatics pipeline of the UMCG genome facility was used for data analysis, as described 
previously [26,27]. Briefly, reads were aligned to the human 1000 genomes reference based on 
the GRCh37 build using BWA 5.9rc. [28]. Picard tools were used for format conversion and 
marking duplicate reads. The Genome Analysis Toolkit (GATK1) was used for realignment of 
insertions and deletions (Indels), and Molgenis Compute 4 for base score quality recalibration 
(BSQR) [29,30]. Custom scripts in the VCF tools library were used to generate VCF files, variant 
calling was performed using the GATK unified genotype, and variant annotation using 
snpeff/snpsift 3.5 with the ensemble release 74 gene annotations 
(http://www.ensembl.org/index.html), dbNSFP2.3, and GATK with annotations from the Database 
of Single Nucleotide Polymorphisms (dbSNP) Bethesda (MD), National Center for Biotechnology 
Information, National Library of Medicine (dbSNP Build ID: 137), and CosmicCodingMuts_v62. 
113 
 
[31–34]. To identify reliable somatic mutations, variants with total reads <20× in either the normal, 
primary, or resistant samples were excluded. In addition, we excluded all variants with ≥2 mutant 
reads in the normal sample, as these might represent personal variants. The remaining variants 
were aligned against the Exome Aggregation Consortium (ExAC) database (Broad Institute, 
Cambridge, MA; URL: http://exac.broadinstitute.org) to screen for any remaining known single 
nucleotide polymorphisms. In addition, we removed variants that (1) were present in the 
Caucasian based 1000-Genome with an allele frequency larger than 0.2%, (2) map in noncoding 
regions, (3) were synonymous, (4) have a quality score <20, or (5) have a mapping quality <20. 
Only variants with ≥2 mutant reads were taken into account. 
Genes Possibly Related to Therapy Resistance 
Variants specific for the R/R, and variants with mutant read frequencies (MAFs) in the resistant 
samples ≥20% and with a MAF at least two times higher compared to the MAF in the paired 
primary sample, were indicated as “possibly related to therapy resistance”, provided the tumor cell 
percentage in primary and relapse samples was similar.  
 
Results 
Patient Characteristics  
Of the 59 samples originating from 15 patients sent for WES, library preparation failed in all 6 
samples of a single patient. The average sequencing coverage of the remaining patients was 
insufficient (<20×) in either the primary sample (6 patients), the relapse sample (1 patient), or both 
samples (1 patient) (Figure S1). In total, WES data of sufficient quality from sequential biopsies 
was obtained for six patients. For two of the six patients with relapse biopsies from different 
anatomical sites, both biopsies were taken at the same time for one patient and at different time 
points for the other patient. Patient and clinicopathological characteristics are summarized in 
Table 1. A MYC and a BCL6 rearrangement were observed in the primary tumor sample of patient 
5. In 5 patients, relapses occurred within 24 months from diagnosis, and one patient had a relapse 
at 55 months. The five patients that died were all due to lymphoma progression 
Quality Control 
The median read depth of the WES data of the 14 tumor samples was 85× (range 29–203×) 
(Figure S2). The median number of non-synonymous coding single nucleotide variants (SNVs) 
and Indels per genome was 568 (range 77–949), affecting 1896 genes in total. An estimation of 
the admixture of normal cells based on the mean mutant allele frequency (MAF) of all somatic 
mutations in the 25–75% interquartile range, as previously described [26], revealed tumor cell 
percentages ranging from 78 to 92% (median 90%), and is in concordance with the pathologist’s 
(AD) estimation (data not shown). No significant differences were observed between tumor cell 
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percentages in the primary and relapse samples (Figure S3). The mean read depth of genes 
frequently mutated in DLBCL was 285× (range 59–1010×) (Table S1). For a few exons, the depth 
was insufficient to reliably assess the presence of mutations. In particular, this was the case for 
exon 3 of FOXO1, with no reads in any of the samples. 
Commonly Mutated Genes 
Fourteen of the 20 genes most frequently mutated in DLBCL according to the Cosmic database 
(version 86) were mutated in one or more of the cases in our study (Figure 1). We identified 28 
genes with mutations in at least 3 patients (Table S2). Functional annotation of these genes 
showed enrichment for genes involved in antigen presentation, including the human leukocyte 
antigen (HLA) molecules and immunoglobulin light chains. Mutations in Suppressor of Cytokine 
Signaling 1 (SOCS1) and Pim-1 Proto-Oncogene (PIM1) were observed in 5 out of 6 patients 
(Figure S4). The patient with a MYC rearrangement had 3 missense mutations in exon 2 of the 
MYC gene. Furthermore, four additional MYC mutations were found in two patients without a MYC 
rearrangement (Figure S4).  
Mutational Evolution 
With the exception of one patient, the vast majority of the mutations were shared between the 
primary and R/R samples. The median percentage of mutations detected in the primary and not in 
the matching relapse sample was 7.6% (range 4.8–66.2%) (Figure 2, Table S3). The loss of 
mutations was particularly high in the patient with a late relapse, where 66% of mutations detected 
in the primary sample could not be detected in the relapse sample. The mean MAF of the 
mutations only detected in primary samples was 0.15, which is in the lower quartile of the 
distribution, indicating genomic heterogeneity in the tumor cells. 
Relapsed DLBCL samples showed a median increase of non-synonymous mutations of 12.5% 
(range 9.4–87.6%) as compared to primary tumor biopsies (Figure 2, Table S3). In the two 
patients with multiple biopsies at relapse, there was a 45.3% and 89.2% concordance for 
mutations detected only in the relapse samples (Figure 2). There was no significant correlation 
between the loss or increase in mutations and time until relapse (ρ 0.32; p, 0.71) (Figure S5). 
Mutations were randomly distributed across the genome (Figure S6). 
Of the 354 relapse specific mutations (in 303 genes), 195 (55%) had a MAF <0.2 and were 
probably subclonal. The remaining 159 (45%) mutations had MAF ≥0.2 and are probably major 
clone mutations, and thus possibly related to therapy resistance (Supplementary Table 3). In 
addition, we identified 215 mutations that showed at least a two-fold increase in MAF in the 
relapse biopsy compared to the primary sample, indicating a possible relation with therapy. The 
combined set of 374 mutations possibly related to therapy resistance encompassed 264 genes 
(Figure S7). Functional annotation of these genes revealed 18 tyrosine kinases, 73 
(transmembrane) glycoproteins, and 7 genes that are related to the JAK-STAT pathway (Table 
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S4). Several of the genes with relapse specific mutations are known to be targets for somatic 
hypermutation, including BCL2, BIRC3, BTG2, IRF4, MYC, PIM1, SGK1, and SOCS1 [21,35]. The 
most frequently observed base substitution among the relapse specific mutations (C:G > T:A) is a 
known cyclophosphamide-induced base substitution, and to a lesser extent a canonical 
Activation-Induced Deaminase (AID) activity dependent substitution (Figure S8) [35,36]. The 
evolution of the resistance-associated and other mutations in SOCS1, PIM1, and MYC showed 
different patterns (Figure 3). The MAF of mutations in SOCS1 showed moderate increases in 
relapse samples. Mutations in PIM1 showed at least two-fold increased MAF in two out of five 
patients. In the patients with two relapse biopsies, the MAF of SOCS1 and PIM1 were similar 
across the relapse samples (Figure 3A, B). Even in this small cohort, the dynamics of MYC 
mutations showed clear heterogeneity with loss of mutations (n = 3), increase of MAF (n = 1), and 
gain of mutations (n = 3) in relapse samples (Figure 3C). The MAF of SOCS1 mutations remains 
relatively stable. The MAF of mutations in PIM1 and MYC had at least a two-fold increase in 2 of 5 




Mutational analysis has expanded the knowledge on the pathogenesis of DLBCL with genomic 
risk models that can aid future biomarker driven treatment strategies [19–21]. However, 
mutational analysis from single tumor biopsies will underestimate the true genomic landscape of 
tumors due to the presence of inter- and intra-tumor heterogeneity, natural clonal evolution, and 
therapy related changes [24,37]. Through targeted sequencing of the variable, diversity and 
joining (VDJ)-segments of the immunoglobulin heavy chain, two DLBCL relapse models have 
been observed: A late (linear) model and early (divergent) model [15]. Data on mutational 
evolution in DLBCL remains largely unknown due to the lack of tumor biopsies [18]. In the current 
study, mutation profiles in relapsed DLBCL were analyzed by pair-wise comparison of primary 
tumor and relapse samples. Despite the limited number of patients with informative WES data, 
several compelling observations were made. 
 
First, a median of 12.5% of mutations detected in relapse samples was not detected in the 
primary samples. Our findings are in line with a previous study showing >80% concordance of 
mutations in 6 out 7 paired R/R samples [38]. However, in 2 of 6 cases we observed a gain >20% 
in mutations in the relapse sample. These might be truly relapse specific, or failed detections in 
the primary sample due to heterogeneity. Based on phylogenetic trees by somatic hypermutation 
and mutational analysis, an increased number of mutations was proposed to be the result of an 
early divergent relapse clone [15]. The change in mutational load of relapses might be bigger in 
the presence of spatial heterogeneity, as exemplified by the divergence in acquired mutations 
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between multiple relapse samples in the two cases from the current study. Nevertheless, the 
observed temporal heterogeneity in DLBCL is relatively low compared to other lymphoproliferative 
diseases (LPD). In chronic lymphocytic leukemia (CLL) [39,40], follicular lymphoma (FL) [41,42], 
and mantle cell lymphoma (MCL) [43], relatively large temporal and spatial heterogeneity was 
observed. In contrast, mutational analysis of circulating cell free tumor DNA in classical Hodgkin 
lymphoma (HL) indicates a relatively constant mutation profile [44].  
 
Secondly, mutations in several known targets of somatic hypermutation were detected as private 
mutations in relapse samples [35]. Although the most frequent base pair substitution (C:G > T:A) 
can arise as a consequence of canonical AID activity, it is also the most frequently observed base 
pair change caused by cyclophosphamide [21,36]. The type and impact of clonal evolution varies 
depending on the LPD, type of therapy, and involved genes and pathways. For example, CLL 
patients who relapse after ibrutinib acquire mutations in Bruton Tyrosine Kinase (BTK) or 
phospholipase C-γ2 (PLCγ2) [45], whereas ibrutinib refractory MCL patients acquire mutations 
within several pathways, including genes of the NF-kB pathway, the mTOR pathway, and 
epigenetic modifiers [46]. 
 
Third, a minority of mutations detected in the primary samples could not be detected in the 
relapse samples. The low MAF of these mutations is suggestive of sub clonal passenger 
mutations, a phenomenon that has also been observed in CLL [39]. This data is in line with the 
study by Morin et al, in which loss of mutations was observed infrequently in cases with VAF <0.2 
[18]. Retention of the vast majority of mutations identified in the primary tumor samples is 
important for reliable assessment of minimal residual disease (MRD) in free circulating tumor DNA 
(ctDNA) using targeted approaches [38,47,48]. Focusing on sub clonal passenger mutations 
might lead to false negative MRD results. Using broad panel-based strategies reduces this 
potential risk and has revealed a success rate of 80–85%. Another main advantage of a broad-
panel based ctDNA analysis is that it also allows detection of mutations not observed in the 
primary biopsy, thus at least partially overcoming the spatial heterogeneity of the tumor sample 
[38]. Interestingly, ctDNA based analysis of BTK revealed emerging mutations in two of three 
DLBCL patients receiving ibrutinib [38]. 
 
Fourth, through pathway analysis we observed enrichment for mutations in genes related to 
antigen presentation (HLA class I and II molecules (HLA locus), B2M, CALR) in relapse samples. 
Although the HLA locus is a highly polymorphic region and somatic mutation calling is prone to 
errors, the high frequency of mutations in antigen-presentation related genes observed is 
consistent with previous studies [49]. Approximately 75% of DLBCL exhibit a genetic basis for 
immune escape [21]. Recently, this type of immune editing has been linked with mutations in 
MYD88 and CD79B [20]. In DLBCL, mutations in genes involved in immune escape (e.g., B2M 
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and CD58) were associated with increased risk of relapse by selective pressure analysis [12]. 
Analysis of paired DLBCL samples showed somatic mutations, Indels, or chromosomal deletions 
targeting CD58 and B2M in five out of seven cases [18]. Mutations in these genes have been 
postulated as relapse-associated events [15]. Loss of HLA-molecules is frequently observed in 
DLBCL, and this might have implications for immunotherapy [50].  
Fifth, we observed mutations in SOCS1 (5/6), PIM1 (5/6), and MYC (3/6) in multiple patients, with 
part of the mutations being relapse specific or enriched. Compared to the reported mutation 
frequencies in these genes in newly diagnosed DLBCL [51], the frequency seems to be enriched 
in R/R DLBCL in this study. Based on a mathematical approach, SOCS1 and PIM1 mutations 
were amongst the genes with the highest selective pressure estimates [12]. PIM1 mutations have 
been reported in 38% of R/R DLBCL ABC-type cases, and MYC mutations in 11% of R/R DLBCL 
cases [18]. In addition, an enrichment for SOCS1 and PIM1 mutations in matched tumor samples 
was not only observed in R/R DLBCL (4 out of 7 patients), but also in transformed FL (4 out of 7 
patients), as well as in relapsed FL (2 out of 7 patients), further supporting the role of mutations in 
these genes in relation to relapse [38]. In the genomic model of Reddy et al., PIM1 and MYC 
mutations, but not SOCS1, were significantly correlated with decreased survival [19]. This is in 
line with our observation, which shows a relatively constant MAF for SOCS1 and an increased 
MAF for PIM1 mutations in two of five patients. The dynamics of PIM1 mutations should be taken 
into account when treating patients with BTK inhibition, since PIM1-stabilizing mutations affect 
upstream regulators and downstream targets of the NF-kB pathway, decreasing sensitivity of 
ABC-type DLBCL to BTK inhibition [52].  
 
Finally, through pathway analysis we observed enrichment for possible therapy related genes 
related to trans membrane receptor tyrosine kinases (RTK) and genes involved in the JAK/STAT 
pathway. Gains of mutations in RTKs was previously observed in matched R/R DLBCL samples 
[15]. Both SOCS1 and PIM1 converge at the JAK/STAT signaling pathway. While SOCS1 inhibits 
JAK/STAT signaling, PIM1 expression is correlated with activation of STAT [51,53]. In addition to 
our observations, loss of the Interleukin 9 receptor (IL9R) locus was previously observed in three 
out of seven relapsed DLBCL cases [15], and STAT6 mutations were reported in 36% of R/R 
GCB-type DLBCL [18], both further implicating a role for the JAK-STAT pathway in relapse. 
This study has several limitations. It clearly shows the challenge of obtaining relapse biopsies and 
good quality genomic DNA from FFPE tissues for WES. Of the 61 initially identified patients, we 
obtained reliable WES data of representative sequential tumor biopsies for only 6 patients (10%). 
In half of the relapse cases in our series a biopsy was omitted, and when available, again in half 
of the cases the biopsy was not sufficient for this type of analysis. Although histological 
confirmation of R/R DLBCL is advocated, it is often omitted for various reasons. In primary R-
CHOP refractory patients hardly any re-biopsies are performed. This is reflected in the current 
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study, in which only half of the patients had histological confirmation. In an attempt to maximize 
the number of patients in this study, WES was performed on all but one excision biopsy, despite 
suboptimal DNA quantity and quality. Unfortunately, either primary or R/R samples of 8 out of 14 
eligible cases failed library preparation, resulting in sufficient quality data for only 6 patients. 
Degradation of DNA during fixation and storage might lead to sequencing artifacts, including false 
positive C:G > T:A substitutions [54]. More than 90% of mutations detected by our pipeline in the 
primary samples could also be detected in the relapse sample, indicating that our filtering criteria 
successfully eliminated sequencing artifacts. To avoid such artifacts, it would be better to use 
fresh frozen samples. However, FFPE is the main mode of storing tissue samples [15,18]. We 
cannot completely rule out the presence of mutations in genes with low coverage in WES, as 
exemplified by FOXO1 [18].  
 
An alternative approach to avoid fixation artifacts applied in more recent studies is the analysis of 
ctDNA. Initial studies showed the potential of using ctDNA to evaluate clonal evolution in LPDs 
[42,46,47]. Larger studies using ctDNA analysis could provide a comprehensive view on the 
mutational evolution of R/R DLBCL. Nonetheless, current ctDNA analysis encompasses 
preselected lists of target genes, while WES offers the best chance of discovering novel 
resistance-promoting mutations, especially when moving to more targeted therapy. 
Implementation of ctDNA analysis in clinical practice requires further standardization for 
purification and detection of mutations to achieve high sensitivity, especially for detection of MRD. 
Finally, our study is not powered to address the impact of individual mutations. Nevertheless, 
recurrent mutations with variable MAF were observed in three genes that all have been implicated 




We show modest temporal heterogeneity between paired tumor samples with the acquisition of 
new mutations and enrichment of possible therapy resistant related genes. These mutational 







Table 1: Patient- and clinicopathological characteristics of the 6 patients evaluable for mutational 
analysis 
Patient characteristics Clinicopathological characteristics Outcome 
ID M/F Age Stage IPI 
Morpholog
y 







EoT PFS OS 
1 F 53 4 3 DLBCL GCB n.a. Incon. Jejunum 
Lymph 
node 
- CR 7 101 





- CR 17 56 
†
 





- PR 7 14 
†
 





- PD 5 8 
†
 
















n.a. 14 36 
†
 




site A ** 
Skin  
site B ** 
CR 55 55 
†
 
Abbreviations: ABC, activated B-cell; COO, cell-of-origin as determined by the nCounter Lymph2Cx assay; CR, complete 
remission; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; GCB, germinal center B-cell; IHC, 
immunohistochemistry; IPI, international prognostic index; n.a., not applicable; OS, overall survival; PFS, progression free survival; 
PR, partial remission; EoT, end-of-treatment. 
#
 According to the WHO 2017 classification the case is classified as a High grade B-
cell lymphoma with MYC and BCL6 rearrangement; * biopsies taken at the different time points; ** biopsies taken at the same time 
points; 
†











Figure 1. Frequency of mutations in the top-20 most commonly mutated genes in diffuse large B-
cell lymphoma according to the Cosmic database version 86, and as observed in the 14 tumor 
samples analyzed in this study. Fourteen of the 20 genes were mutated in at least one of the 14 







































 Primary   Common   Relapse  
Figure 2. Venn diagrams showing for each individual patient (P1–6) the overlap in mutations 
between primary and paired relapse tumor samples. Left panels are Venn diagrams for all 
mutations (all), and right panels are Venn diagrams for mutations with a mutant allele frequency 
(MAF) ≥0.2. The total numbers of mutations per patient are depicted below each diagram. The 
size of the relapse diagram is proportional to the primary sample. In the patients with two biopsies 
at relapse (P5 and P6), the concordance between the novel mutations in the relapse samples was 
45.3% and 89.2%, indicative of spatial heterogeneity.  
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Figure 3. Graphical representation of mutant allele frequency (MAF) of (A) SOCS1, (B) PIM1, and 
(C) MYC in paired biopsies. Mutations above the dashed line are considered as possibly related 





















Supplementary figure 4: Schematic representation of location and type of mutations in SOCS1, 




Supplementary figure 5: Loss and increase in mutational load as a variable over time did not 
show a significant correlation (r, 0.32; p, 0.71). 
 
 
Supplementary figure 6: Distribution of mutations detected only in the relapse samples across 
the genome showed a random pattern 
  




Supplementary figure 7: Global view of mutant allele frequency (MAF) in primary and 





1. Gascoyne, R.D.; Campo, E.; Jaffe, E.S.; et al. Diffuse large B-cell lymphoma, NOS. In Swerdlow, S.H.;, Campo, E.;, Harris, 
N.L.; et al, editors. WHO classification of tumours of haematopoeitic and lymphoid tissues. Revised 4
th
 edition. International 
Agency for Research on Cancer: Lyon, France. 2017; pp. 291–297. 
2. Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, 
P.; et al. CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell 
Lymphoma. N. Engl. J. Med. 2002, 346, 235–242. 
3. Ziepert, M.; Hasenclever, D.; Kuhnt, E.; Glass, B.; Schmitz, N.; Pfreundschuh, M.; Loeffler, M. Standard International 
Prognostic Index Remains a Valid Predictor of Outcome for Patients with Aggressive CD20+ B-Cell Lymphoma in the 
Rituximab Era. J. Clin. Oncol. 2010, 28, 2373–2380. 
4. Gisselbrecht, C.; Glass, B.; Mounier, N.; Singh Gill, D.; Linch, D.C.; Trneny, M.; Bosly, A.; Ketterer, N.; Shpilberg, O.; 
Hagberg, H.; et al. Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the 
Rituximab Era. J. Clin. Oncol. 2010, 28, 4184–4190. 
5. Van Imhoff, G.W.; McMillan, A.; Matasar, M.J.; Radford, J.; Ardeshna, K.M.; Kuliczkowski, K.; Kim, W.; Hong, X.; Goerloev, 
J.S.; Davies, A.; et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed Or Refractory Diffuse 
Large B-Cell Lymphoma: The ORCHARRD Study. J. Clin. Oncol. 2017, 35, 544–551. 
6. Alizadeh, A.A.; Eisen, M.B.; Davis, R.E.; Ma, C.; Lossos, I.S.; Rosenwald, A.; Boldrick, J.C.; Sabet, H.; Tran, T.; Yu, X.; et al. 
Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature 2000, 403, 503–511. 
7. Scott, D.W.; Wright, G.W.; Williams, P.M.; Lih, C.J.; Walsh, W.; Jaffe, E.S.; Rosenwald, A.; Campo, E.; Chan, W.C.; Connors, 
J.M.; et al. Determining Cell-of-Origin Subtypes of Diffuse Large B-Cell Lymphoma using Gene Expression in Formalin-Fixed 
Paraffin-Embedded Tissue. Blood 2014, 123, 1214–1217. 
8. Offner, F.; Samoilova, O.; Osmanov, E.; Eom, H.S.; Topp, M.S.; Raposo, J.; Pavlov, V.; Ricci, D.; Chaturvedi, S.; Zhu, E.; et 
al. Frontline Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone with Bortezomib (VR-CAP) Or Vincristine (R-
CHOP) for Non-GCB DLBCL. Blood 2015, 126, 1893–1901. 
9. Morin, R.D.; Mendez-Lago, M.; Mungall, A.J.; Goya, R.; Mungall, K.L.; Corbett, R.D.; Johnson, N.A.; Severson, T.M.; Chiu, 
R.; Field, M.; et al. Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma. Nature 2011, 476, 298–303. 
10. Pasqualucci, L.; Trifonov, V.; Fabbri, G.; Ma, J.; Rossi, D.; Chiarenza, A.; Wells, V.A.; Grunn, A.; Messina, M.; Elliot, O.; et al. 
Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma. Nat. Genet. 2011, 43, 830–837. 
11. Lohr, J.G.; Stojanov, P.; Lawrence, M.S.; Auclair, D.; Chapuy, B.; Sougnez, C.; Cruz-Gordillo, P.; Knoechel, B.; Asmann, 
Y.W.; Slager, S.L.; et al. Discovery and Prioritization of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) by 
Whole-Exome Sequencing. Proc. Natl. Acad. Sci.U.S.A. 2012, 109, 3879–3884. 
12. Morin, R.D.; Mungall, K.; Pleasance, E.; Mungall, A.J.; Goya, R.; Huff, R.D.; Scott, D.W.; Ding, J.; Roth, A.; Chiu, R.; et al. 
Mutational and Structural Analysis of Diffuse Large B-Cell Lymphoma using Whole-Genome Sequencing. Blood 2013, 122, 
1256–1265. 
13. Zhang, J.; Grubor, V.; Love, C.L.; Banerjee, A.; Richards, K.L.; Mieczkowski, P.A.; Dunphy, C.; Choi, W.; Au, W.Y.; 
Srivastava, G.; et al. Genetic Heterogeneity of Diffuse Large B-Cell Lymphoma. Proc. Natl. Acad. Sci.U.S.A. 2013, 110, 
1398–1403. 
14. De Miranda, N.F.; Georgiou, K.; Chen, L.; Wu, C.; Gao, Z.; Zaravinos, A.; Lisboa, S.; Enblad, G.; Teixeira, M.R.; Zeng, Y.; et 
al. Exome Sequencing Reveals Novel Mutation Targets in Diffuse Large B-Cell Lymphomas Derived from Chinese Patients. 
Blood 2014, 124, 2544–2553. 
15. Jiang, Y.; Redmond, D.; Nie, K.; Eng, K.W.; Clozel, T.; Martin, P.; Tan, L.H.; Melnick, A.M.; Tam, W.; Elemento, O. Deep 
Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated with Relapse in B-Cell Lymphomas. Genome 
Biol. 2014, 15, 432. 
16. Novak, A.J.; Asmann, Y.W.; Maurer, M.J.; Wang, C.; Slager, S.L.; Hodge, L.S.; Manske, M.; Price-Troska, T.; Yang, Z.Z.; 
Zimmermann, M.T.; et al. Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Outcome in 
Immunochemotherapy-Treated Diffuse Large B-Cell Lymphoma. Blood Cancer. J. 2015, 5, e346. 
17. Wise, J.F.; Nakken, S.; Vodak, D.; Troen, G.; Lingjaerde, O.C.; Meza-Zepeda, L.A.; Myklebost, O.; Beiske, K.; Myklebust, 
J.H.; Hovig, E.; et al. Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-
Cell Lymphoma. Blood 2015, 26, 110. 
128 
 
18. Morin, R.D.; Assouline, S.; Alcaide, M.; Mohajeri, A.; Johnston, R.L.; Chong, L.; Grewal, J.; Yu, S.; Fornika, D.; Bushell, K.; et 
al. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin. Cancer Res. 2016, 22, 2290–
2300. 
19. Reddy, A.; Zhang, J.; Davis, N.S.; Moffitt, A.B.; Love, C.L.; Waldrop, A.; Leppa, S.; Pasanen, A.; Meriranta, L.; Karjalainen-
Lindsberg, M.L.; et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 2017, 171, 481–494. 
20. Schmitz, R.; Wright, G.W.; Huang, D.W.; Johnson, C.A.; Phelan, J.D.; Wang, J.Q.; Roulland, S.; Kasbekar, M.; Young, R.M.; 
Shaffer, A.L.; et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2018, 378, 1396–1407. 
21. Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Kamburov, A.; Redd, R.A.; Lawrence, M.S.; Roemer, M.G.M.; Li, A.J.; Ziepert, 
M.; et al. Molecular Subtypes of Diffuse Large B Cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and 
Outcomes. Nat. Med. 2018, 24, 679–690. 
22. Moffitt, A.B.; Dave, S.S. Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma. J. Clin. 
Oncol. 2017, 35, 955–962. 
23. Younes, A.; Berry, D.A. From Drug Discovery to Biomarker-Driven Clinical Trials in Lymphoma. Nat. Rev. Clin. Oncol. 2012, 
9, 643–653. 
24. Aparicio, S.; Caldas, C. The Implications of Clonal Genome Evolution for Cancer Medicine. N. Engl. J. Med. 2013, 368, 842–
851. 
25. Ventura, R.A.; Martin-Subero, J.I.; Jones, M.; McParland, J.; Gesk, S.; Mason, D.Y.; Siebert, R. FISH Analysis for the 
Detection of Lymphoma-Associated Chromosomal Abnormalities in Routine Paraffin-Embedded Tissue. J. Mol. Diagn. 2006, 
8, 141–151. 
26. Saber, A.; Hiltermann, T.J.N.; Kok, K.; Terpstra, M.M.; De Lange, K.; Timens, W.; Groen, H.J.M.; Van den Berg, A. Mutation 
Patterns in Small Cell and Non-Small Cell Lung Cancer Patients Suggest a Different Level of Heterogeneity between Primary 
and Metastatic Tumors. Carcinogenesis 2017, 38, 144–151. 
27. Van der Wekken, A.J.; Kuiper, J.L.; Saber, A.; Terpstra, M.M.; Wei, J.; Hiltermann, T.J.N.; Thunnissen, E.; Heideman, D.A.M.; 
Timens, W.; Schuuring, E.; et al. Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients Treated with 
Afatinib After EGFR TKI and Resistant Mechanisms upon Disease Progression. PLoS One 2017, 12, e0182885. 
28. Li, H.; Durbin, R. Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform. Bioinformatics 2010, 26, 589–
595. 
29. Boomsma, D.I.; Wijmenga, C.; Slagboom, E.P.; Swertz, M.A.; Karssen, L.C.; Abdellaoui, A.; Ye, K.; Guryev, V.; Vermaat, M.; 
van Dijk, F.; et al. The Genome of the Netherlands: Design, and Project Goals. Eur. J. Hum. Genet. 2014, 22, 221–227. 
30. McKenna, A.; Hanna, M.; Banks, E.; Sivachenko, A.; Cibulskis, K.; Kernytsky, A.; Garimella, K.; Altshuler, D.; Gabriel, S.; 
Daly, M.; et al. The Genome Analysis Toolkit: A MapReduce Framework for Analyzing Next-Generation DNA Sequencing 
Data. Genome Res. 2010, 20, 1297–1303. 
31. Danecek, P.; Auton, A.; Abecasis, G.; Albers, C.A.; Banks, E.; DePristo, M.A.; Handsaker, R.E.; Lunter, G.; Marth, G.T.; 
Sherry, S.T.; et al. The Variant Call Format and VCFtools. Bioinformatics 2011, 27, 2156–2158. 
32. Cingolani, P.; Platts, A.; Wang le, L.; Coon, M.; Nguyen, T.; Wang, L.; Land, S.J.; Lu, X.; Ruden, D.M. A Program for 
Annotating and Predicting the Effects of Single Nucleotide Polymorphisms, SnpEff: SNPs in the Genome of Drosophila 
Melanogaster Strain w1118; Iso-2; Iso-3. Fly (Austin) 2012, 6, 80–92. 
33. Liu, X.; Jian, X.; Boerwinkle, E. dbNSFP V2.0: A Database of Human Non-Synonymous SNVs and their Functional 
Predictions and Annotations. Hum. Mutat. 2013, 34, E2393–E2402. 
34. Forbes, S.A.; Beare, D.; Gunasekaran, P.; Leung, K.; Bindal, N.; Boutselakis, H.; Ding, M.; Bamford, S.; Cole, C.; Ward, S.; et 
al. COSMIC: Exploring the World's Knowledge of Somatic Mutations in Human Cancer. Nucleic Acids Res. 2015, 43, D805–
D811. 
35. Khodabakhshi, A.H.; Morin, R.D.; Fejes, A.P.; Mungall, A.J.; Mungall, K.L.; Bolger-Munro, M.; Johnson, N.A.; Connors, J.M.; 
Gascoyne, R.D.; Marra, M.A.; et al. Recurrent Targets of Aberrant Somatic Hypermutation in Lymphoma. Oncotarget 2012, 3, 
1308–1319. 
36. Szikriszt, B.; Poti, A.; Pipek, O.; Krzystanek, M.; Kanu, N.; Molnar, J.; Ribli, D.; Szeltner, Z.; Tusnady, G.E.; Csabai, I.; et al. A 
Comprehensive Survey of the Mutagenic Impact of Common Cancer Cytotoxics. Genome Biol. 2016, 17, 99. 
37. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; 
Stewart, A.; et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl. J. Med. 
2012, 366, 883–892. 
129 
 
38. Scherer, F.; Kurtz, D.M.; Newman, A.M.; Stehr, H.; Craig, A.F.; Esfahani, M.S.; Lovejoy, A.F.; Chabon, J.J.; Klass, D.M.; Liu, 
C.L.; et al. Distinct Biological Subtypes and Patterns of Genome Evolution in Lymphoma Revealed by Circulating Tumor 
DNA. Sci. Transl. Med. 2016, 8, 364ra155. 
39. Landau, D.A.; Tausch, E.; Taylor-Weiner, A.N.; Stewart, C.; Reiter, J.G.; Bahlo, J.; Kluth, S.; Bozic, I.; Lawrence, M.; 
Bottcher, S.; et al. Mutations Driving CLL and their Evolution in Progression and Relapse. Nature 2015, 526, 525–530. 
40. Fabbri, G.; Rasi, S.; Rossi, D.; Trifonov, V.; Khiabanian, H.; Ma, J.; Grunn, A.; Fangazio, M.; Capello, D.; Monti, S.; et al. 
Analysis of the Chronic Lymphocytic Leukemia Coding Genome: Role of NOTCH1 Mutational Activation. J. Exp. Med. 2011, 
208, 1389–1401. 
41. Green, M.R.; Kihira, S.; Liu, C.L.; Nair, R.V.; Salari, R.; Gentles, A.J.; Irish, J.; Stehr, H.; Vicente-Duenas, C.; Romero-
Camarero, I.; et al. Mutations in Early Follicular Lymphoma Progenitors are Associated with Suppressed Antigen 
Presentation. Proc. Natl. Acad. Sci. U.S.A. 2015, 112, E1116–E1125. 
42. Green, M.R.; Gentles, A.J.; Nair, R.V.; Irish, J.M.; Kihira, S.; Liu, C.L.; Kela, I.; Hopmans, E.S.; Myklebust, J.H.; Ji, H.; et al. 
Hierarchy in Somatic Mutations Arising during Genomic Evolution and Progression of Follicular Lymphoma. Blood 2013, 121, 
1604–1611. 
43. Bea, S.; Valdes-Mas, R.; Navarro, A.; Salaverria, I.; Martin-Garcia, D.; Jares, P.; Gine, E.; Pinyol, M.; Royo, C.; Nadeu, F.; et 
al. Landscape of Somatic Mutations and Clonal Evolution in Mantle Cell Lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 
18250–18255. 
44. Spina, V.; Bruscaggin, A.; Cuccaro, A.; Martini, M.; Di Trani, M.; Forestieri, G.; Manzoni, M.; Condoluci, A.; Arribas, A.; Terzi-
Di-Bergamo, L.; et al. Circulating Tumor DNA Reveals Genetics, Clonal Evolution, and Residual Disease in Classical Hodgkin 
Lymphoma. Blood 2018, 131, 2413–2425. 
45. Furman, R.R.; Cheng, S.; Lu, P.; Setty, M.; Perez, A.R.; Guo, A.; Racchumi, J.; Xu, G.; Wu, H.; Ma, J.; et al. Ibrutinib 
Resistance in Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2014, 370, 2352–2354. 
46. Balasubramanian, S.; Schaffer, M.; Deraedt, W.; Deraedt, W.; Davic, C.; Stepanchick, E.; Aquino, R.; Yuan, Z.; Kranenburg, 
B.; Avivi, I.; et al. Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed Or Refractory 
Mantle Cell Lymphoma (MCL). Blood. 2014, 124, 78 
47. Rossi, D.; Diop, F.; Spaccarotella, E.; Monti, S.; Zanni, M.; Rasi, S.; Deambrogi, C.; Spina, V.; Bruscaggin, A.; Favini, C.; et 
al. Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy. Blood 2017, 129, 1947–1957. 
48. Kurtz, D.M.; Scherer, F.; Jin, M.C.; Soo, J.; Craig, A.F.M.; Esfahani, M.S.; Chabon, J.J.; Stehr, H.; Liu, C.L.; Tibshirani, R. et 
al. Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 
2018, 36, 2845–2853. 
49. Shukla, S.A.; Rooney, M.S.; Rajasagi, M.; Tiao, G.; Dixon, P.M.; Lawrence, M.S.; Stevens, J.; Lane, W.J.; Dellagatta, J.L.; 
Steelman, S.; et al. Comprehensive Analysis of Cancer-Associated Somatic Mutations in Class I HLA Genes. Nat. Biotechnol. 
2015, 33, 1152–1158. 
50. Nijland, M.; Veenstra, R.N.; Visser, L.; Xu, C.; Kushekhar, K.; van Imhoff, G.W.; Kluin, P.M.; van den Berg, A.; Diepstra, A. 
HLA Dependent Immune Escape Mechanisms in B-Cell Lymphomas: Implications for Immune Checkpoint Inhibitor Therapy? 
Oncoimmunology 2017, 6, e1295202. 
51. Schif, B.; Lennerz, J.K.; Kohler, C.W.; Bentink, S.; Kreuz, M.; Melzner, I.; Ritz, O.; Trumper, L.; Loeffler, M.; Spang, R.; et al. 
SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Oncotarget 
2013, 4, 35–47. 
52. Kuo, H.P.; Ezell, S.A.; Hsieh, S.; Schweighofer, K.J.; Cheung, L.W.; Wu, S.; Apatira, M.; Sirisawad, M.; Eckert, K.; Liang, Y.; 
et al.; The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Am. J. Cancer. Res. 
2016, 6, 2489–2501. 
53. Brault, L.; Menter, T.; Obermann, E.C.; Knapp, S.; Thommen, S.; Schwaller, J.; Tzankov, A. PIM Kinases are Progression 
Markers and Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Br. J. Cancer 2012, 107, 491–500. 
54. Do, H.; Dobrovic, A. Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization. Clin. 







Tumour necrosis as assessed with 18F-FDG PET is a 
potential prognostic marker in diffuse large B-cell lymphoma 
independent of MYC rearrangements 
 
Xaver U. Kahle 
1
, Menno Hovingh 
1
, Walter Noordzij 
2







, Anke van den Berg 
3





, Ronald Boellaard 
2
, Thomas C. Kwee 
4






 Nuclear Medicine and Molecular Imaging, 
3 
Pathology and Medical Biology and 
4
 Radiology, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands 
 








Objectives: MYC gene rearrangements in diffuse large B-cell lymphomas (DLBCLs) result in high 
proliferation rates and are associated with a poor prognosis. Strong proliferation is associated with 
high metabolic demand and tumour necrosis. The aim of this study was to investigate differences 
in presence of necrosis and semiquantitative 
18
F-FDG PET metrics between DLBCL cases with or 
without a MYC rearrangement. The prognostic impact of necrosis and semiquantitative 
18
F-FDG 
PET parameters was investigated in an explorative survival analysis.
 
Methods: Fluorescence in situ hybridization analysis for MYC rearrangements, visual assesment, 
semi-quantitative analysis of 
18
F-FDG PET scans and patient survival analysis were performed in 
61 DLBCL patients, treated at a single referral hospital between 2008 and 2015.  
Results: Of 61 tumours, 21 (34%) had a MYC rearrangement (MYC
+
). MYC status was neither 
associated with the presence of necrosis on 
18
F-FDG PET scans (necrosisPET; P = 1.0), nor with 
the investigated semiquantitative parameters maximum standard uptake value (SUVmax; P = 0.43), 
single highest SUVmax (P = 0.49), metabolic active tumour volume (MATV; P = 0.68) or total 
lesions glycolysis (TLG; P = 0.62). Multivariate patient survival analysis of the entire cohort 
showed necrosisPET as an independent prognostic marker for disease specific survival (DSS) 
(HR = 13.9; 95% CI: 3.0–65; P = 0.001). 
Conclusions: MYC rearrangements in DLBCL have no influence on the visual parameter 
necrosisPET or the semi-quantiative parameters SUVmax, MATV and TLG. Irrespective of MYC 






Diffuse large B-cell lymphoma (DLBCL) accounts for 35% of all B-cell non-Hodgkin lymphomas 
(B-NHL) [1]. Approximately 10-15% of DLBCL cases harbour a MYC gene rearrangement 
(MYC+), as assessed by fluorescence in situ hybridization (FISH) [2]. These lymphomas are 
characterized by a very high proliferation rate. Patients bearing a MYC+ lymphoma experience an 
aggressive clinical course and have a poor prognosis when treated with the standard regimen of 
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) [3]. In 2017 the 
World Health Organization (WHO) established a new entity for MYC rearranged DLBCL, called 
‘high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements’ [1, 4].  
MYC is an oncogenic transcription factor regulating a vast array of cellular processes and 
pathways [5, 6]. Tumour cells overexpressing MYC, meet their high energy demands by increased 
glucose uptake, glycolysis, lactate production and amino acid consumption [7, 8]. However, unlike 
physiological tissues, cancer cells frequently have acquired resistance to apoptosis and cannot 
regulate their energy expenditure during metabolic stress, resulting in cell death via necrosis when 
nutrient supply is compromised [9–11]. 
 
In B-NHL patients 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scans 
are used for staging and response assessment [12]. Tumour necrosis can be assessed by visual 
inspection of 18F-FDG PET scans (necrosisPET) [13]. Necrosis can be observed in 14-20% of 
DLBCL cases and has been associated with an adverse prognosis [14, 15]. Semiquantitative 
assessment of 18F-FDG PET allows for relative comparison of parameters based on the spatial 
distribution and degree of 18F-FDG uptake and is currently being investigated as a tool for 
therapy monitoring and assessing prognosis in B-NHL [16–18]. Still, data on the prognostic value 
of the semiquantitative parameters maximum standardized uptake value (SUVmax) and 
metabolically active tumour volume (MATV) in DLBCL are conflicting [19–21]. MYC 
rearrangement, tumour necrosis (necrosisPET) and parameters derived from semiquantitative 
analysis of 18F-FDG PET are fundamentally linked to metabolism, yet the relationship between 
these factors remains unknown. We hypothesize, that the higher metabolic activity mediated by 
MYC rearrangements might result in a higher incidence of necrosisPET and increased 
semiquantitative parameters. The previously suggested prognostic impact of necrosisPET [15] 
and semiquantitative parameters [16–18] in DLBCL might be accredited to their potential 
association with MYC rearrangements. 
 
Therefore, the aim of this study was to investigate differences in the presence of necrosisPET and 
semiquantitative 18F-FDG PET metrics between DLBCL cases with or without a MYC 




Material and methods 
 
Study design 
For this retrospective single centre study consecutive patients with newly diagnosed, histologically 
confirmed DLBCL between 2008 and 2015, were identified in the electronic healthcare database 
of the University Medical Center Groningen (UMCG), a reference centre for aggressive B-cell 
lymphomas. Cases of primary cutaneous DLBCL, primary central nervous system lymphoma, 
primary mediastinal B-cell lymphoma and immunodeficiency-associated lymphomas were 
excluded. The selection of cases for this study is summarized in Figure 1. Patients were stratified 
according to the National Comprehensive Cancer Network international prognostic index (NCCN-
IPI) [22]. End of treatment response was assessed by 18F-FDG PET/CT scan. Tumour responses 
were classified according to Lugano criteria [12]. Follow-up was registered until early October 
2017. According to Dutch regulations, no medical ethical committee approval was required for this 
retrospective, non-interventional study.  A waiver was obtained from the medical ethics committee 
of the UMCG on November 13th 2018. The study utilized rest material from patients, the use of 
which is regulated under the code for good clinical practice in the Netherlands and does not 
require informed consent in accordance with Dutch regulations. 
 
Pathology review 
Pathology review was done using the 2008 WHO classification of haematopoietic and lymphoid 
tissues (AD) [23]. Histological scoring for necrosis (necrosisHist) was done by microscopic 
assessment of haematoxylin & eosin stained slides. Only microscopic areas with definite 
histopathological signs of necrosis (i.e. karyolysis) were scored as positive for necrosisHist. 
 
MYC fluorescence in situ hybridization 
For evaluation of a MYC rearrangement formalin-fixed paraffin-embedded tissue blocks of primary 
tumour samples were used. Interphase fluorescence in situ hybridization (FISH) was performed 
on 4-µm thick whole tissue sections, using Vysis break apart probes (Abbot technologies) and 
standard FISH protocols as previously described [24]. Researchers performing MYC FISH 
analyses were blinded for results from visual scoring, microscopic assessment of necrosis 
(necrosisHist) and clinical outcome. 
 
18F-FDG PET imaging 
All 18F-FDG PET scans were performed prior to therapy. Patients were allowed to continue all 
medication and fasted for at least 6 hours before whole-body (from skull vertex to mid-thigh level) 
three-dimensional PET images were acquired. This was done 60 minutes after intravenous 
administration of a standard dose of 3 MBq/kg (0.081 mCi/kg) bodyweight 18F-FDG on a 
Biograph mCT (Siemens Healthineers), according to the European Association of Nuclear 
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Medicine (EANM) procedure guidelines for tumour imaging with FDG PET/CT (version 2.0) [25]. 
Acquisition was performed in 7 bed positions of 2 minutes emission scan for patients 60-90 kg. 
Patient with body weight less than 60 kg and more than 90 kg body weight, were scanned with 1 
minute and 3 minutes per bed position, respectively. Low dose transmission CT was used for 
attenuation correction. Low dose CT and 18F-FDG PET scans were automatically fused by use of 
three-dimensional fusion software (Siemens Healthineers) with manual fine adjustments. Raw 
data were reconstructed through ultra-high definition (Siemens Healthineers). 
 
Computed tomography 
Diagnostic CTs were acquired via integrated 18F-FDG PET/CT scans according to the European 
Association of Nuclear Medicine (EANM) procedure guidelines for tumour imaging with FDG 
PET/CT (version 2.0) [25]. Bulky disease was defined as any nodal lymphoma lesion > 10cm in 
coronal, axial or sagittal planes. 
 
18F-FDG PET analysis 
All 18F-FDG PET scans were visually assessed for the presence of tumour necrosis 
(necrosisPET) by an experienced reader (TCK), who was blinded to clinical, laboratory, biopsy, 
and follow-up findings, as previously described [15]. Areas within any nodal or extranodal 18F-
FDG PET avid lymphomatous lesions that showed no 18F-FDG uptake were registered as having 
necrosisPET (Figure 2); no specific visual scale was used. 
Semiquantitative analysis was performed using an in-house tool for quantitative 18F-FDG PET/CT 
analysis, as previously described [26–28]. This program automatically preselects lesions using a 
SUVmax threshold of 4 and a metabolic volume threshold of 2.5 ml. Unwanted preselected FDG-
avid regions, such as bladder and brain, are removed by user interaction. Finally, remaining FDG-
avid segmentations are processed using a background corrected 50% of SUV peak region 
growing method, as described by Frings et al [26], to obtain the final tumour segmentations. In 
case obvious lymphoma lesions were not selected (n=3), they were manually added after 
automatic tumour segmentation. From the final segmentation the metabolic active tumour volume 
(MATV in ml), total lesion glycolysis (TLG = MATV × SUVmean) and SUVs are derived for each 
lesion independently as well as summed over all lesions. Lesion selection and semiquantitative 
analysis was performed by MH under direct supervision of an experienced nuclear medicine 
physician (WN) and a nuclear physicist (RB). SUVmax was defined as the highest SUV per voxel 
within one lymphomatous lesion. In this paper SUVmax is reported as the mean of SUVmax 
across all lesions of an individual patient. SUVmax single highest was defined as the highest 
SUVmax of all lesions within an individual patient.  
Statistical analysis 
Comparison between continuous, non-normally distributed variables was estimated by Wilcoxon 
rank-sum test. Differences between two nominal variables were evaluated using Pearson’s Chi 
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square or Fisher’s exact test (for expected groups sizes ≤ 5). For exploratory survival analysis the 
primary endpoints were OS, progression free survival (PFS) and diseases specific survival (DSS). 
OS was defined as time from diagnosis until death (from any cause). PFS was defined as the time 
from diagnosis until death or relapse or progression [12]. DSS was defined as the time from 
diagnosis until death from DLBCL. Surviving patients were censored at the last date of follow-up. 
Survival curves were estimated according to the Kaplan-Meier method. Cox regression was used 
for univariate and multivariate survival analysis and results were reported as hazard ratio (HR), 
95% confidence interval (CI) and P-value based on statistical Wald-test. A two-tailed P-value of 
less than 0.05 indicated statistical significance. All analyses were performed using R version 3.4.1 




Characteristics of the entire cohort (61 patients) are summarized in Table 1. A total of 21 patients 
(34%) had a DLBCL harbouring a MYC rearrangement. MYC rearrangement was observed in 11 
patients (21.6%) primarily seen in the UMCG (n=51) and 10 patients (100%) referred from 
affiliated hospitals (n=10). MYC groups did not differ with regard to baseline characteristics (Table 
1) except for serum LDH levels, which were higher in the MYC-positive group (P = 0.036) than 
cases without MYC rearrangement.  
MYC status, necrosis and semiquantitative 
18
F-FDG PET parameters 
NecrosisPET was observed in 15 patients (25%). The relationships between MYC status and 
necrosisPET, necrosis
Hist
 and semiquantitative 
18
F-FDG PET parameters are summarized in Table 
2. MYC
+ 
cases did not differ from cases without MYC rearrangement with regards to necrosisPET 
(P= 1.0) or necrosis
Hist 
(P = 0.52). When the semiquantitative parameters SUVmax, SUVmax single 
highest, MATV and TLG, were studied, no difference between MYC groups was observed. There 
was no relation between the presence of necrosisPET and necrosis
Hist
 (P = 0.1; Supplementary 
Figure 1). 
NecrosisPET and tumour volume 
In 14 of 15 necrosisPET cases necrosis was observed in the largest lesion. In comparison, the 
largest individual lesion of cases without necrosisPET had a significantly lower MATV (P = 
0.0006) and SUVmax (P = 0.02), irrespective of MYC status (Supplementary Figure 2). Bulky 
disease was observed in 24 patients (39%). Bulky disease was significantly correlated with 
necrosisPET (P = 0.005), but not with MYC status (P = 0.9) or necrosis
Hist 
(P = 0.8). Extranodal 
growth of lesions was not significantly correlated with the presence of necrosisPET
 




The median follow-up was 34 months. At 5-years OS was 67% (95% CI: 54–83%), PFS was 65% 
(95% CI: 53–81%) and DSS was 81% (95% CI: 70– 93%) for the entire cohort. Of the seven 
deaths unrelated to lymphoma, two were caused by metastatic adenocarcinoma, two were due to 
cardiac failure, one was due to acute on chronic renal failure and there were two cases of sudden 
deaths in patients in complete remission of DLBCL. 
Results of the univariate Cox regression analysis (HR, 95% CI and P-value) are shown in Table 3. 
Univariate analysis for OS identified MYC, NCCN-IPI and SUVmax single highest as associated 
factors. In univariate analysis for PFS only NCCN-IPI was associated with outcome. In univariate 
analysis for DSS MYC, NCCN-IPI, SUVmax single highest and necrosisPET were associated. Both 
SUVmax and SUVmax single highest showed negative beta-coefficients throughout the univariate 
survival analysis. 
For multivariate analysis the parameters MYC, NCCN-IPI, necrosisPET and SUVmax single highest 
were used due to their prognostic impact on lymphoma-related deaths in univariate analysis 
(Table 4). NecrosisPET did not con-tribute to the prognostic model for OS and PFS. However, for 
DSS, necrosisPET had a large adverse prognostic impact and proved to be independent (HR = 
13.9; 95% CI: 3.0–65; P = 0.001). Kaplan-Meier analysis for DSS showed no events during the 5 





Based on the current investigation, there is no association of MYC rearrangements with the 
presence of tumour necrosis assessed by 18F-FDG PET or the semiquantitative 18F-FDG PET 
parameters SUVmax, SUVmax single highest, MATV and TLG, thus rejecting the hypothesis that 
metabolic changes induced by MYC rearrangements might increase the incidence of necrosisPET 
or alter the profile of semiquantitative parameters in DLBCL. 
  
NecrosisPET was significantly associated with the MATV of the single largest tumour lesion. The 
SUVmax of the single largest necrosisPET lesion was significantly higher compared to the lesions 
without necrosisPET. Both of these observations support the notion of larger, more metabolically 
active tumours being more susceptible to necrosis, irrespective of MYC status. 
Our analyses demonstrate that necrosisPET had a significant impact on DSS, thereby 
substantiating previous findings about the prognostic value of this visual marker [15]. The 
presented data show that presence of MYC rearrangement, in itself a powerful predictive factor, is 
not related to necrosisPET. This allows for integration of MYC status and necrosisPET into a 
prognostic model for DLBCL. When combined with MYC, NCCN-IPI and SUVmax single highest 
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in multivariate analysis, necrosisPET had the highest significance in predicting death due to 
lymphoma and a higher prognostic impact than NCCN-IPI, the currently most accurate prognostic 
index for DLBCL [22]. Thus, our results support the potential additive value of necrosisPET as an 
important biomarker for risk stratification in the clinical setting [14, 15]. 
 
The lack of a relationship between MYC rearrangements and semiquantitative 18F-FDG PET 
metrics might have several causes. First, proliferation in DLBCL could be independent of MYC 
rearrangement. This would only partially explain the lack of relationship, since the median 
proliferation index (Ki-67 staining) of MYC+ DLBCL is universally high (>90%) in contrast to the 
much broader range observed in MYC− DLBCL [29]. 
 
Second, overexpression of MYC via other mechanisms such as epigenetic pathways might 
explain increased glucose uptake in MYC FISH negative DLBCL. This is supported by studies 
showing high MYC protein expression in 19–40% of DLBCL cases [30–32]. Cottereau et al. 
previously reported a lack of relation between MYC protein expression and 18F-FDG PET 
parameters in DLBCL [19]. However, FISH analysis, which is considered the gold standard 
examination for MYC rearrangements [33–35], was not performed. 
 
Third, high metabolic activity might be induced by alternative changes in metabolic drivers, such 
as mutations in PTEN (observed in approximately 15% of DLBCL) that lead to activation of the 
P13K/AKT/mTOR pathway [29, 36–38]. 
 
Intriguingly, univariate survival analysis indicated a protective effect for cases with SUVmax and 
SUVmax single highest measurements above the median. Studies on the prognostic impact of 
these variables are conflicting [20, 39–41]. Gallicchio et al. published results similar to ours, 
alluding to lymphomas with high metabolic activity being more responsive to chemotherapy [20]. 
In light of conflicting data on the prognostic value of semiquantitative 18F-FDG PET parameters 
[19–21, 42, 43], our results underline the need for larger, prospective studies with external 
validation cohorts [42]. 
 
This study has several limitations. First there is a referral bias with a high incidence of MYC+ 
cases (34%) in our dataset. The enrichment in our study can largely be explained by the fact that, 
as a reference centre, aggressive and MYC+ DLBCL cases (including suspected cases of Burkitt 
lymphoma which subsequently prove to be MYC+ DLBCL) are referred to our site. Second, the 
total number of cases with necrosisPET is small, which increases the risk of a sampling error. 
Nevertheless, the incidence of necrosisPET in our study is in line with previous studies [13–15]. 
Furthermore, patients were included irrespective of their comorbidities. Factors like differences in 
treatment regimen and non-cancer-related deaths might thus have a large impact on statistical 
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analysis. This is supported by the difference between DSS and OS. Despite its limitations, the 
prognostic potential of MYC status and NCCN-IPI was reproduced in this dataset making it a 
representative set of DLBCL cases. Larger prospective studies are warranted to validate the 




In this comprehensive analysis of MYC rearranged DLBCL we showed that a fundamental 
pathological change such as MYC rearrangement, which by itself has as significant impact on 
prognosis, has no influence on the presence of necrosisPET or semiquantitative 18F-FDG PET 
metrics. Explorative survival analysis suggests that the presence of necrosis determined by visual 
assessment of 18F-FDG PET scans is an independent predictor of disease specific survival in 






Table 1. Demographics and baseline disease characteristics of patients with diffuse large B-cell 
lymphoma according to MYC status 










No. % No. % No. % 
 
Gender 
       




   Female 25 41.0 16 40.0 9 42.9 
Age 
       
   Median (range) 63 (26 - 91) 64 (26 - 91) 61 (30 - 79) 0.64
b
 




   Age > 60y 37 60.7 26 65.0 11 52.4 
Stage 
       




   III-IV 39 63.9 25 62.5 14 66.7 
NCCN-IPI score 
       




   4-8 31 50.8 18 45.0 13 61.9 
Serum LDH 
       
   Median (range) 282 (126 - 3037) 237 (126 - 1292) 381 (140 - 3037) 0.04
b
 




   Elevated 32 52.5 18 45.0 14 66.7 
Treatment 
       




   Intensive chemotherapy 3 4.9 1 2.5 2 9.5 
   Palliative 2 3.3 2 5.0 0 0 
 
a
 = Pearson's Chi-squared test with Yates' continuity correction  
 b
 = Wilcoxon rank sum test with continuity correction  
 c




Table 2. Necrosis and semiquantitative 
18
F-FDG PET parameters according to MYC status 








 (n=21) P-value 
 
No. % No. % No. % 
 
NecrosisPET 
       




   Present 15 24.6 10 25.0 5 23.8 
Necrosis
Hist
        




   Present 16 26.2 11 27.5 5 23.8 
   Not available 3 4.9 1 2.5 2 9.5  
SUVmax 
      
   Median (range) 13.0 (3.0 - 38.4) 13.1 (3.0 - 33.9) 10.4 (5.8 - 38.4) 0.43
b
 
SUVmax single highest 
     




   
 




    
   Median (range) 
1387.4  
(3 - 29462) 
1632.8  
(3 - 29462) 
1147.1  





 = Wilcoxon rank sum test  
c




Table 3. Univariate analysis of patient characteristics and semiquantitative 
18
F-FDG PET 


















         






  MYC + 2.9 1.1 - 7.4 0.025* 2.3 0.97 - 5.7 0.058 6.3 1.7 - 24 0.007** 
NCCN-IPI 
         










         






  Present 1.7 0.6 - 4.5 0.3 1.8 0.7 - 4.6 0.2 3.9 1.2 - 13 0.025* 
SUVmax          










         






  ≥ Median 0.3 0.09 - 0.9 0.026* 0.4 0.2 - 1.1 0.07 0.1 0.01 - 0.8 0.028* 
MATV 
         






  ≥ Median 1.1 0.4 - 2.7 0.9 1.3 0.5 - 3.1 0.59 2.8 0.7 - 10.6 0.14 
TLG 
         










Table 4. Multivariate analysis of patient characteristics overall survival, progression free survival 
and disease specific survival. 
 Hazard Ratio OS 95% CI P-value
#
 P-value Model 
MYC  
0.004 
   MYC-negative Reference   
   MYC-positive 3.1 1.1 – 8.7 0.029* 
NCCN-IPI  
   0-3 Reference   
   4-8 2.4 0.8 – 6.9 0.116 
NecrosisPET  
   Absent Reference   
   Present 2.6 0.9 – 7.7 0.079 
SUVmax single highest  
   < Median Reference   
   ≥ Median 0.3 0.1 – 0.9 0.027* 
 Hazard Ratio PFS    
MYC  
0.005 
   MYC-negative Reference   
   MYC-positive 2.4 0.9 – 6.3 0.07 
NCCN-IPI  
   0-3 Reference   
   4-8 3.2 1.1 – 9.0 0.028* 
NecrosisPET  
   Absent Reference   
   Present 2.6 1.0 – 7.0 0.06 
SUVmax single highest  
   < Median Reference   
   ≥ Median 0.4 0.2 – 1.1 0.08 
 Hazard Ratio DSS    
MYC  
0.0007 
   MYC-negative Reference   
   MYC-positive 14.6 2.6 – 82 0.002** 
NCCN-IPI  
   0-3 Reference   
   4-8 6.5 0.6 - 66 0.113 
NecrosisPET  
   Absent Reference   
   Present 13.3 2.8 – 63 0.001** 
SUVmax single highest  
   < Median Reference   












Figure 2.  Visual assessment of necrosis and semi-quantitative 
18
F-FDG PET review process. (A) 
65-year-old man with diffuse large B-cell lymphoma (DLBCL) and tumour masses in the left dorsal 
chest wall and left pelvis, as shown on the coronal maximum intensity projection (MIP) 
18
F-FDG 
PET image (arrows). Coronal fused 
18
F-FDG PET /CT (B), axial CT (C) and axial fused 
18
F-FDG 
PET/CT (D) show the tumour mass with photopenic areas (arrow heads), in keeping with tumour 
necrosis. Coronal and sagittal MIP 
18
F-FDG PET images (E and F) show tumour segmentation 
(marked in red colour) for the calculation of metabolically active tumour volume (MATV), total 




Figure 3. Kaplan-Meier curve showing disease specific survival according to combined analysis 
with MYC rearrangement status and necrosisPET (log-rank test, P = 0.00022). No events were 







Supplementary Figure 1. Venn diagram showing the overlap between necrosisPET and 
necrosis
Hist
 scoring indicating poor concordance. 
 
 
Supplementary Figure 2. Distribution of metabolically active tumour volume (MATV) and 
maximum standard uptake value (SUVmax) of single largest tumour lesions in relation to the 
absence or presence of necrosisPET. MYC-negative, non-confluent  MYC-positive, non-
confluent  MYC-negative, confluent  MYC-positive, confluent. MATV (P = 0.0006) and 
SUVmax (P = 0.02) were significantly higher in patients with necrosisPET. MATV and SUVmax 
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A 19‐year‐old woman with no previous medical history was diagnosed with a stage IV primary 
mediastinal large B‐cell lymphoma with a bulky mass and an International Prognostic Index score 
of 3 (figure 1A). After 6 cycles of R‐CHOP14 (rituximab, cyclophosphamide, doxorubicin, 





F‐FDG‐PET) and computed tomography (CT) scan was performed (Siemens 
biograph mCT with 64 slices, 135 MBq 
18
F‐FDG with at least 6 h fasting prior to intravenous 
injection). The scan showed a partial remission with persisting 
18
F‐FDG PET‐positive mediastinal 
lymphadenopathy. She received 30 Gy radiation and a boost up to 40 Gy to the 
18
F‐FDG PET‐
positive lesions. Response evaluation after treatment showed intense 
18
F‐FDG uptake in the 
spinal cord at the level of the eleventh and twelfth thoracic vertebrae (Figure 1B). She had no 
neurological symptoms.  
The role of 
18
F‐FDG PET in staging and evaluation of remission in lymphomas is well established. 
The incidence of central nervous system (CNS) recurrence is reported to be 2–5%. In this case, 
the end‐of‐treatment 18F‐FDG PET showed abnormal spinal 18F‐FDG uptake and CNS 
progression of the lymphoma was considered. Magnetic resonance imaging of the spinal cord 
showed no lesions. The 
18
F‐FDG uptake in the spinal cord was therefore considered to be false 
positive. It appears that this physiological phenomenon is encountered in up to half of cancer 
patients and is seen more often in winter.[1] Increased 
18
F‐FDG uptake is primarily seen at the 
level of the cervical vertebrae, the eleventh and twelfth dorsal vertebrae, and the first lumbar 
vertebrae. The CNS is highly dependent on glucose and accounts for 50% of glucose metabolism. 
During fasting and stress conditions, such as during the 
18
F‐FDG PET‐CT procedure, there is a 
physiological increase in glucose uptake in the CNS to maintain a steady glucose state. This 
mechanism probably accounts for the increased 
18
F‐FDG uptake observed in the spinal cord of 
our patient.  
This case illustrates the potential pitfalls of normal physiological 
18
F‐FDG uptake in the spinal 
cord, which is frequently encountered in cancer patients. Awareness of this pitfall can avoid 









F-FDG-PET scan before treatment showing a large mediastinal mass  (B) 
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Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at 
diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most 
commonly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and R-
CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1–8) and 6 (range 
0–8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21) 
patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and 
overall survival (OS) were 45% (95%CI 34–56%) and 49% (95%CI 38–60%), respectively. Over 
90% of patients had an unfavorable international prognostic index score, reflected by treatment-
related mortality of 19% (4/21) and relapse-related mortality of 28% (6/21). The outcome of these 
patients was, however, unexpectedly good when compared to secondary CNS relapses. 
Prospective studies are needed to define the optimal treatment for patients with sysCNS, but its 





The risk of central nervous system (CNS) dissemination of aggressive B-cell lymphoma (B-NHL) 
is 5% [1]. High international prognostic index (IPI) score, kidney or adrenal gland involvement and 
diffuse large B-cell lymphoma (DLBCL) with dual expression of MYC and BCL2 by 
immunohistochemistry convey a high risk of CNS relapse [2,3]. In the majority, CNS involvement 
occurs during progression of the disease. Rarely, CNS dissemination is already present at initial 
diagnosis. Unlike the general favorable outcome of patients with primary CNS lymphoma 
(PCNSL) when treated with high dose methotrexate (HD-MTX), cytarabine and thiothepa [4–7], 
CNS relapse of aggressive B-NHL conveys a dismal prognosis [8,9]. Salvage regimens with 
relapsed PCNSL incorporating thiothepa and high dose chemotherapy followed by autologous 
stem cell transplantation (ASCT) showed an improved overall survival (OS) for these patients if 
initially responsive and subsequently eligible for intensive treatment [10,11]. 
It is unknown if the prognosis of concomitant systemic and parenchymal CNS B-NHL at diagnosis 
(sysCNS B-NHL) is different from secondary CNS lymphoma in the relapse setting. Given its 
rarity, data on treatment for sysCNS B-NHL are sparse and there is no established standard of 
care. Recent data from two studies suggest a beneficial effect of intensive chemotherapy followed 
by ASCT [12,13]. In both studies, ASCT was only offered to patients in complete remission (CR) 
(31%–50%). Furthermore, in one of the studies, anthracyclines – highly effective in systemic B-
NHL – were only a minor part of the induction regimen [13]. Outcome of non-transplant strategies 
in sysCNS B-NHL was only explored in small series [14,15]. 
We observed an excellent response in a patient with sysCNS initially treated as if primary CNS 
with the European Organisation for Research and Treatment of Cancer (EORTC) regimen MBVP 
(methotrexate, etoposide, carmustine and prednisolone) [5]. In this patient, not only the CNS 
component responded well, but also systemic involvement responded at the same time. 
Consequently, we continued after MBVP with rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisolone (R-CHOP), and applied this regimen to the next series of patients. 
Simultaneously, another University Medical Center in the Netherlands combined R-CHOP 
alternating with HD-MTX, based upon the same observations. 
Therefore, we retrospectively investigated the outcome of patients with sysCNS B-NHL treated in 
both centers with a combination of drugs effective for CNS and systemic involvement. None of 





Study design and patient identification 
Clinical data on patients with sysCNS B-NHL were retrieved from the electronical databases of 
two referral medical centres in the Netherlands. All patients had newly diagnosed, histologically 
proven aggressive B-cell lymphoma. In case of transformed lymphoma, patients had not received 
prior therapy. CNS involvement was determined either by biopsy, magnetic resonance imaging 
(MRI) and/or CSF examination. Patients had been treated between 2000 and 2015. Patients 
should have received at least one cycle of HD-MTX. Both regimens start with a cycle of HD-MTX. 
The pathological assessment was performed by experienced hematopathologists. Since patients 
were treated according to best practice no medical ethical committee approval was required. 
Initial assessment  
Staging consisted of computed tomography scan of neck, chest, abdomen and pelvis, bone 
marrow biopsy, cerebrospinal fluid (CSF) examination with four-color flow cytometry (FCM), MRI 
brain, and further investigations if clinically indicated. A fluorodeoxyglucose (
18
F-FDG) positron 
emission tomography scan was available for all patients treated at one of the medical centres. 
Systemic B-NHL was diagnosed by lymph node or tissue biopsies in all cases. CNS involvement 
was diagnosed either by brain biopsy or CSF flow cytometry in 58% (12/21) of patients. In 42% 
(9/21) neurological symptoms and parenchymal abnormalities on the MRI scan were considered 
sufficient for the diagnosis of CNS involvement. In 10% (2/21) CNS involvement presented as 
neurolymphomatosis. In all patients the international prognostic index (IPI) was documented. 
Treatment 
Patients were treated according to one of two regimens. At the University Medical Center 
Groningen a sequential regimen was adopted. Four cycles of MTX at a dose of 3 g/m
2
 were given 
as part of the MBVP regimen, which also includes carmustine (100 mg/m
2
 at day 4), teniposide 
(100 mg/m
2
 at day 2 and 3) and prednisolone (60 mg/m
2
 at day 1–5) [5]. Interim response 
evaluation was performed after completion of HD-MTX. Patients with a partial CNS remission 
received whole brain radiotherapy (WBRT) at this point. Patients subsequently continued for 6 
cycles of R-CHOP after which end-of-treatment evaluation took place. R-CHOP was given as a 
combination of rituximab (375 mg/m
2
 at day 1), cyclophosphamide (750 mg/m
2
 at day 1), 
doxorubicin (50 mg/m
2
 at day 1), vincristine (1.4 mg/m
2
 at day 1 up to a maximal dose of 2 mg) 
and prednisolone (100 mg at day 1–5). At the Erasmus Medical Centre Rotterdam an alternating 
regimen was adopted, which consisted of 6 alternating cycles of HD-MTX at a dose of 3 g/m
2
 and 
R-CHOP. Interim evaluation was performed after 3 cycles and end-of-treatment evaluation after 
completion of therapy. Patients with a partial remission (PR) of the CNS involvement received 
WBRT. In both regimens patients with leptomeningeal involvement received intrathecally 
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methotrexate and/or cytarabine until complete clearance of the CSF as assessed by FCM. 
Furthermore, 4 patients in the alternating regimen received i.t. therapy without a positive CSF 
because of local practice. 
Response assessment 
Response was evaluated according to the 1999 consensus criteria for systemic NHL and the 
consensus criteria for PCNSL [16,17]. Tumor response was classified as CR, PR, stable disease 
(SD), or progressive disease (PD). Only patients in complete remission at CNS and systemic sites 
at the end of treatment were reported as a CR. Treatment related mortality (TRM) was defined as 
death during or ≤3 months after treatment. Follow-up was completed until February 2016. 
Statistical analysis 
Duration of follow-up was calculated for all patients alive. The primary endpoints were OS and 
progression free survival (PFS). OS was defined as time from diagnosis until death (from any 
cause); PFS as the time from diagnosis until relapse, progression or death (from any cause). 
Survival curves were estimated according to the Kaplan–Meier method. Between-group 
differences in OS and TTP were evaluated using the log-rank test. All categorical variables were 
expressed as counts and percentages. Where applicable, differences between groups were 
evaluated by chi-square for binary variables and independent T-tests for continuous variables. A 
two-tailed p-value of less than 0.05 indicated statistical significance. All analyses were performed 




Between 2000 and 2015 21 sysCNS B-NHL patients were treated. Demographic data from the 
patients in the two treatment regimens are presented in Table 1. Diffuse large B-cell lymphoma 
composed the major histological B-NHL entity (66%). The median age was 54 years (range 19–71 
years) with a slight female preponderance. Two-third of patients had a WHO performance score 
≥2 and 91% of patients had an intermediate or high IPI-score. A large number of patients had 
lymphoma infiltration of organs known to convey a high risk of CNS relapse, like testicles (44% of 
patients at risk), bone (38%), kidney (19%) and breast (17% of patients at risk). Besides 





Thirteen patients (62%) completed therapy with only minor deviations. Two patients received less 
than 6 R-CHOP cycles. One patient had both a reduction in the number of MTX and R-CHOP 
cycles. Data on treatment intensity between the two treatment regimens are presented in Table 2. 
Detailed information on individual treatment and response assessment is shown in Supplementary 
Figure 1. The median number of HD-MTX cycles was 4 (range 1–8). Thirteen patients (62%) 
received concomitant intrathecal MTX. The median number of R-CHOP cycles was 6 (range 0–8). 
WBRT was given to 7 patients (33%), all because of persistent abnormalities on brain MRI. One 
patient received local radiotherapy on an extracranial site because of PR at the end of treatment. 
Besides the additional VP16 and BCNU in patients treated with MBVP, there was no significant 
difference between the two regimens 
Follow-up, response and survival 
The median duration of follow-up of patients was 44 months (range 5–104). The overall response 
rate (ORR) at the end of treatment was 62%: CR 57% (n = 12) and PR 5% (n = 1). PD was noted 
in 19% (n = 4), whereas early TRM due to infectious complications was observed in 19% (n = 4). 
All infectious complications occurred during neutropenia. Two patients died as a consequence of 
an aspiration pneumonia due to neurogenic dysphagia. One patient developed a complicated 
clostridium difficile infection after prolonged treatment with ciprofloxacin. One patient died of a 
complicated meningitis (Klebsiella pneumoniae), which was not related to a previous lumbar 
puncture. One patient died 6 months after treatment as a result of cognitive deterioration. 
Three-year PFS and OS for the entire cohort were 45% (95%CI 34–56%) and 49% (95%CI 38–
60%), respectively (Figure 1 A,B). No significant differences in PFS and OS were found between 
both regimens (HR OS 1.25, 95%CI 0.38–4.2; p 0.72). Although statistical analysis showed no 
significant differences in outcome between the various variables due to the small number of 
patients, all patients (n = 3) with IPI-score 0–1 were alive at follow-up, whereas all patients (n = 4) 
with IPI-score 4–5 died within 2 years after diagnosis. 
The combined incidence of refractory and relapsed sysCNS was 28% (6 of 21 patients). The 
relapse rate in patients achieving a CR was only 8% (1 of 12 patients), which is reflected by the 
plateau after 12 months in the PFS and OS curves (Figure 1(A,B)). Patients in CR/PR had a 3-
year PFS and OS of 74% and 83%, respectively (Supplementary Figure 2 A,B). The patient who 
relapsed did so within a year in the CNS. She subsequently received WBRT but died soon 
afterwards. The one patient in PR progressed after 8 months with both systemic and CNS 
involvement. He received no further therapy and died shortly thereafter. The four patients with PD 
all died within 6 months. The site of progression was systemic-only in two patients, CNS-only in 






By combining the results from two medical referral centres in the Netherlands, we performed the 
second largest retrospective study in patients with sysCNS B-NHL. Findings from this study 
indicate that non-transplant regimens of HD-MTX and R-CHOP can be an effective treatment for 
sysCNS B-NHL. With a 3-year OS of 49% the outcome in our cohort is comparable to the more 
intensive regimen including ASCT, which is available to only a selected group of patients (5-year 
OS 41%) [13]. In one of the three studies with non-transplant regimens 4 out of 6 (67%) patients 
achieved a CR when treated with HD-MTX and R-CHOP. In a second study with HD-MTX, 
rituximab, cytarabine and idarubicin (R-IDARAM) 4 out of 10 (40%) patients achieved a CR. 
Median OS of both studies was 25.1 months and more than 30 months, respectively [14,18]. In a 
pilot study with dose-adjusted EPOCH (etoposide, cyclophosphamide, doxorubicin, vincristine, 
prednisone) plus rituximab 8 out of 8 patients achieved a CR [15]. Four patients underwent a 
consolidative autologous stem cell transplantation. With a median follow up of 11 months all 
patients were alive. 
 
In most of our patients systemic involvement included one or more organs known to convey a high 
risk of CNS involvement in systemic B-NHL [1]. These findings suggest an early dissemination of 
a systemic B-NHL, rather than a systemic manifestation of a PCNSL. This might be important, 
since PCSNL has several pathological features that are only infrequently present in systemic 
DLBCL, such as a high incidence of mutations in CD79B and MYD88, loss of human leukocyte 
adhesion (HLA) molecules and frequent expression of the programed death ligand 1 [19–21]. 
Despite its similarity with systemic B-NHL, the OS of sysCNS B-NHL treated with HD-MTX and R-
CHOP was better than expected and comparable to that of PCNSL and certainly not as bad as 
secondary relapsed CNS B-NHL treated with HD-MTX and cytarabine (Supplementary Table 1) 
[4–6,8].  
 
The TRM in our cohort of 19% was high, and reflects the very unfavorable risk profile of our 
patients with 67% having a WHO performance of 3–4 and 14% being older than 65-years. Given 
the small numbers it cannot be answered whether the concomitant systemic involvement or 





Despite the limited number of relapses, two observations were interesting: firstly, all but one 
patient who relapsed did so less than 6 months after the end of treatment. All other patients who 
failed did so during the early phase of treatment; secondly, in refractory and relapsing patients the 
majority had systemic progression. The incidence of refractory/early progressing patients in our 
cohort (24%) was similar to that of more intensive regimens (35%) [13]. This means that 
progressive patients have a dismal outcome and are unlikely to be salvaged. It is interesting to 
speculate whether drugs such as bendamustine, ibrutinib, checkpoint inhibitors and lenalidomide 
would be effective in this setting, since these drugs generally have a favorable toxicity profile, 
known activity in relapsed systemic B-NHL and CNS penetration [22–26]. 
 
Notably, patients who obtain a CR have an excellent outcome and probably will not benefit from 
additional high dose therapy, especially those patients with a low IPI at start. This challenges the 
role of consolidation as suggested by the French lymphoma group LYSA, that showed a positive 
impact of high-dose therapy followed by autologous stem cell transplantation on 3-year OS and 
PFS [12]. However, in our series 7 of 21 patients (33%) received consolidative radiotherapy. The 
indirect answer if ASCT can replace WBRT will have to come from the analysis of the IELSG32 
trial, where patients with a chemosensitive PCNSL were randomized in a second randomization to 
WBRT or ASCT [7]. But even then we have to be cautious to extrapolate these findings to 
sysCNS, since PCSNL has a different biology. 
Our study obviously has limitations. Firstly, its retrospective nature has inherent known and 
unknown biases. We have no information on the outcome of those patients with synCNS 
lymphoma who were considered too frail for referral to our university centers. This means that our 
data might be based upon a selection of those patients fit for high dosed methotrexate. 
Furthermore, although the rationale behind the treatment was the same, e.g. the combination of 
primary CNS treatment followed by systemic immunochemotherapy, there was a considerable 
heterogeneity in the treatment received. Some patients were treated with a sequential MBVP/R-
CHOP and others with an alternating HD-MTX/R-CHOP regimen. Although we observed no 
significant difference between the regimens in OS, we cannot assess the separate effect of 
teniposide and carmustine. In addition, 7 of 21 patients were unable to complete treatment as 
planned (Supplementary Figure 1). Except for gender and associated testicular or breast 
localization we observed no significant differences in clinical characteristics or outcome. Given its 
rarity, sysCNS B-NHL comparative studies can only be performed in a large, international 
multicentre setting. Lastly, high dose cytarabine and thiothepa were not part of the treatment 
regimens, although in PCNSL the addition improved outcome in a randomized phase II study [7]. 
Whether the addition of cytarabine or thiothepa in sysCNS B-NHL is feasible remains to be 




In this second largest cohort of patients with sysCNS lymphoma at presentation described to date, 
the outcome of patients treated with HD-MTX and R-CHOP was excellent for those patients who 
obtained a complete remission. This challenges the fact that these patients are excluded from 
most trials, and usually are considered as having a dismal prognosis. Prospective studies are 






Table 1. Clinical characteristics at diagnosis of the 21 patients with concomitant systemic and 
parenchymal central nervous system B-cell non-Hodgkin. 
Characteristics Sequential MBVP 
/  R-CHOP 
Alternating MTX / R-
CHOP 
Patients (n) 10 11 
Median age 54 (41-60) 59 (19-71) 
Gender (M/F) 2/8 7/4 
B-cell lymphoma   
  Diffuse large B-cell lymphoma (%) 5 (50) 9 (82) 
  Iatrogenic immunodeficiency lymphoma (%) 2 (20) 1 (9) 
  Transformed marginal zone lymphoma (%) 2 (20) 0 (0) 
  Intravascular B-cell lymphoma (%) 1 (10) 1 (9) 
Extra CNS involvement   
   Testicular (%)
a
 0 (0) 4/7 (57) 
   Breast (%)
a
 2/8 (25) 0 (0) 
   Bone / bone marrow (%) 6 (60) 2 (18) 
   Kidney / lung (%) 4 (40) 0 (0) 
   Cerebrospinal fluid involvement (%) 4 (40) 4 (45) 
Elevated LDH (%) 6 (60) 6 (54) 
WHO performance    
   1-2 (%) 2 (20) 5 (45) 
   3-4 (%) 8 (80) 6 (55) 
IPI-score   
      1 (%) 1 (10) 1 (9) 
   2-3 (%) 7 (70) 7 (64) 
   4-5 (%) 2 (20) 3 (27) 
a





Table 2: Treatment intensity in the 21 patients with concomitant systemic and CNS B-NHL at 
diagnosis. 
Characteristics 
Sequential MTX / 
R-CHOP 
Alternating MTX /  
R-CHOP 
Patients (n) 10 11 
Median MTX cycles (n) 4 (2-6) 5 (1-8) 
Median cumulative MTX dosing (gr) 12 (6-18) 15 (3-24) 
Median i.t. MTX cycles (n)
 a
 6 (4-10) 9 (4-13) 
Median CHOP cycles (n) 6 (0-6) 6 (1-8) 
Rituximab (%) 10 (100) 10 (90) 
Additional chemotherapy Teniposide Carmustine n.a. 
Radiotherapy in partial remission (%) 3 (30) 4 (36) 
a






Figure 1. (A) Overall survival and (B) progression free survival of 21 patients with concomitant 






Supplementary table 1: Outcome of chemotherapeutic regimens in secondary relapsed CNS 























28 53 1-yr 22 1-yr 21 
Korfel 
(2013) 




50 57 2-yr 68* 2-yr 58* 
Maciocia 
(2015) 




40 70 2-yr 90 2-yr 70 
Ferreri 
(2015) 























No Yes 0/21 
HD-MTX 
anthracycline 
57 62 3-yr 49 3-yr 45 
For treatment regimens where an autologous stem cell transplantation (ASCT) was offered to patients in PR/CR the outcome data 
are shown separately (*). Abbreviations: CNS relapse, relapsed central nervous system of systemic B-NHL; sysCNS, concomitant 
systemic and parenchymal CNS B-cell lymphoma at diagnosis; HD-MTX, high hose methotrexate; ASCT, autologous stem cell 






Supplementary figure 1:  Detailed graphical representation of detailed treatment information, 
response evaluation, outcome and follow-up for 21 patients with concomitant systemic and 
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Primary mediastinal large B-cell lymphoma (PMBL) represents 2–4% of all B-cell non-Hodgkin 
lymphoma [1]. It shares clinical and molecular features with classical Hodgkin lymphoma [2]. 
Amplification or gain of 9p24.1 is observed in more than half of PMBL cases, resulting in 
overexpression of the immune checkpoints programmed cell-death ligand 1 and 2 (PD-L1 and 
PD-L2) and the cytokine receptor signaling kinase Janus kinase 2 (JAK2) [3, 4]. Besides 
increased growth signaling through the JAK-STAT pathway, JAK2 overexpression enhances PD-
L1 transcription and expression [3]. Although recent studies indicate a favorable outcome of 
PMBL patients treated with dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, 
and prednisone plus rituximab in first line [5], outcome of relapsed large B-cell lymphoma remains 
poor. 
 
Material and methods 
 
Immunohistochemistry 
Tissue sections of 3 μm were cut from formalin fixed and paraffin embedded tissue samples. 
Immunohistochemical staining was performed according to standard procedures. Briefly, sections 
were dewaxed with xylene and endogenous peroxidase was blocked. Antigen retrieval was 
performed in 10 mM Tris (tris-hydroxymethylaminomethane) / 1 mM EDTA (ethylene diamine 
tetracetic acid) at pH 9.0. Staining was visualized with rabbit monoclonal antibodies PD-L1 
(E1L3N) (anti-PD-L1, Cell Signaling Technology, the Netherlands) and phospho-STAT3 
(Tyr705)(D3A7) (anti-pSTAT3, Cell Signaling Technology, the Netherlands) and with the mouse 
monoclonal antibody PD-1 (MRQ-22) (anti-PD1, Ventana, Swiss). Primary antibodies were 
detected by secondary and tertiary conjugate antibodies. Scoring was performed by 2 
experienced hematopathologists.  
Fluorescence in situ hybridization 
Fluorescence in situ hybridization was performed with a CD274 / CEN9 dual color probe 
(ZytoLight SPEC CD274, PDCD1LG2 / CEN 9 Dual Color Probe, Zytovision, Germany) according 
to the manufacturer’s instructions. 
Ethics approval and consent to participate 
The patient provided informed consent for all her sequential therapies. Written informed consent 





Herein, we describe a 39-year-old Caucasian female with a refractory PMBL who was treated with 
a novel combination of PD-1 and JAK2 inhibition. PMBL had progressed after R-CHOP. 
Subsequent treatments consisted of dexamethasone, cytarabine, and cisplatinum (DHAP), 
brentuximab vedotin, and radiotherapy. Progression was histologically confirmed (Fig. 1a). 
Fluorescence in situ hybridization revealed 9p24.1 amplification (Fig. 1b) and polysomy (Fig. 1c). 
However, PD-L1 or pSTAT3 (as a measure of increased JAK2 activity) expression could not be 
observed (Fig. 1d, e). PD-1 staining of T-cells (Fig. 1f) was limited. The patient had a 
lifethreatening vena cava superior syndrome (VCSS). In the absence of a clinical trial, with the 
patient’s consent, she was treated with off-label ruxolitinib at a dose of 10 mg bid. Off-label 
pembrolizumab was initiated 2 weeks later at 2 mg per kilogram in 3-week cycles (Fig. 2a). Four 
weeks after start of ruxolitinib the VCSS had resolved. Staging and response evaluation were 
performed with combined fluorodeoxyglucose positron emission tomography and computerized 
tomography scans according to the Lugano classification [6]. A complete metabolic remission was 
documented 10 weeks after start of ruxolitinib (Fig. 2b). The patient continued treatment until an 
allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning with 
fludarabine (30 mg/m2/day for 3 days) plus 2 Gy total body irradiation from an HLA identical 
matched unrelated donor. Besides anemia grade 1, no adverse events were observed over the 





Optimal treatment of relapsed PMBL has not been defined. Despite CD30 expression in 80% of 
PMBL cases, the anti-CD30 antibody drug conjugate brentuximab vedotin showed an ORR of only 
13%.[7] In a small pilot study, the JAK 1/2 inhibitor ruxolitinib showed limited activity as a single 
agent.[8] With an overall response rate of 41% the efficacy of the anti-PD-1 antibody 
pembrolizumab in relapsed PMBL is encouraging.[9] However, complete remissions are observed 
infrequently and first responses are observed months after treatment initiation.[9] In contrast, the 
combined treatment with ruxolitinib and pembrolizumab in our patient resulted in a prompt clinical 
and metabolic remission. Accordingly, the addition of ruxolitinib to PD-1 blockade has been 
proposed to inhibit JAK-STAT proliferation and decrease PD-L1 expression on tumour cells.[3] 
Given the favourable toxicity profile, ruxolitinib can be applied in heavily pre-treated patients and 
is attractive for combination therapy.[10] Future studies are warranted to investigate the efficacy of 






Figure 1. Immunohistochemical staining and fluorescence in situ hybridization of formalin-fixed 
paraffin-embedded refractory primary mediastinal B-cell lymphoma tissue for PDL-1, pSTAT3, 
and PD-1. (A) Hematoxylin and eosin staining of the paraffin-embedded mediastinal needle 
biopsy at progression (40×). (B,C) Fluorescence in situ hybridization with a CD274 (green)/CEN9 
(red) dual color probe showed amplification (solid arrows) and polysomy (dashed arrow) both in 
10% of tumor cells. (D,E) Immunostaining with anti-PD-L1 and anti-pSTAT3 of paraffin-
embedded tumor biopsy revealed no staining of tumor cells (40×). (F) Immunostaining with anti-





Figure 2. Treatment and response assessment of patient with a refractory primary mediastinal 
B-cell lymphoma treated with PD-1 and JAK1/2 inhibition. (A) Treatment schedule and response 
assessments show a rapid clinical and complete metabolic response. The duration of response 
was sufficient to perform an allogeneic hematopoietic cell transplantation (HCT), with an ongoing 
remission 20 months after HCT. (B) Combined fluorodeoxyglucose (
18
FDG) positron emission 
(PET) computed tomography (CT) scans before treatment showed a metabolic active tumor in 
the anterior superior mediastinum with encasement of the vena cava superior and 
brachiocephalic vein. (C) 
18
FDG PET-CT scan 10 weeks after initiation of the combined 
pembrolizumab and ruxolitinib treatment showed a metabolic complete remission (Deauville 3) 
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Summary and general discussion 
 
Aggressive B-cell lymphomas are a heterogeneous group of mature B-cell neoplasms. 
Morphologically diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma with MYC 
and BCL2 and/or BCL6 rearrangement (HGBCL-DH) and primary mediastinal B-cell lymphoma 
(PMBCL) share similarities, but phenotypically and genetically there are big differences. Part of 
the aggressive B-cell lymphomas arise as transformed lymphoma from indolent lymphoma, with 
follicular lymphoma being the most prominent one. The aim of this thesis was to investigate what 
drives the aggressive lymphomas, to study the characteristics of relapses and to explore novel 
diagnostic and therapeutic options. 
Pathogenic drivers 
 
We performed proteome profiling analyses of DLBCL cell lines and compared these with 
immortalized lymphoblastoid cell lines (LCL). The results were confirmed in primary NHL tissues 
(Chapter 2). DLBCL cell lines had 14 recurrently downregulated proteins, 8 upregulated proteins 
and 10 with variable expression. Annotations of the proteins covered six hallmarks of cancer: 
motility (n = 6), metabolism (n = 6), chromatin modification and transcription (n = 5), anti-oxidant 
(n = 4), immune response (n = 4), and signal transduction and membrane transport (n = 3).[1] The 
anti-oxidative protein PRDX was more increased in cases with aggressive transformed follicular 
lymphoma (tFL) and DLBCL as compared to the indolent FL cases. This could have helped to 
overcome the effect of reactive oxygen species that stress tumor cells. Somewhat surprisingly we 
found PPIA, the target for the immunosuppressive drug cyclosporine, to be elevated. We showed 
that growth of these cell lines could be blocked by cyclosporine A. Cyclosporine has never been 
used as therapy in lymphomas, outside angioimmunoblastic T cell lymphoma, in which it was 
rather effective.[2] The clinical application of cyclosporine, however, might be outbalanced by the 
immune suppressive effects of cyclosporine and its association with post-transplant 
lymphoproliferative disorders (PTLD).[3] 
 
We showed that nearly 40% of tFL cases had a MYC rearrangement (Chapter 3). Our data 
support the findings of MYC being a strong driver of transformation of FL.[4,5] Although the 
number of MYC rearranged cases was limited, our data seem to indicate that Ig-MYC+ 
rearrangements result in stronger upregulation of MYC than non-Ig rearrangements.[6] In 2018 
Chong et al. showed that the breakpoint of Ig-MYC+ cases clustered in intron 1, whereas the non-
Ig MYC+ cases were characterized by breakpoints downstream of the MYC gene with a variety of 
translocation partners, including BCL6, ZCCH7 and RFTN.[7] By immunohistochemistry we found 
higher MYC expression in FL grade 3B than in FL grade 3A and FL1/2, and even higher 
expression in tFL. Immunohistochemistry showed MYC staining in >90% of tumor cells in Ig-
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MYC+ cases and a more variable staining in non-Ig MYC+ cases, with only 1 MYC rearranged 
case with MYC IHC <40%. Hence, a MYC expression of < 40% has a good negative predictive 
value for excluding MYC rearrangements. However, nearly half of the tFL cases without a MYC 
rearrangement also had high expression of MYC, suggesting alternative mechanisms of MYC 
activation, which limits the positive predictive value of MYC-IHC for the selection of MYC 
rearranged cases. Recent studies seem to indicate that irrespective of the cause of MYC 
overexpression, dual expression of MYC and BCL2 by itself might be a negative prognostic factor 
for survival.[8,9] In addition, Ennishi  et al. published in 2018 a study on a double hit gene 
expression signature, which has a strong correlation with the dual IHC expression. These data 




One of the hallmarks of both DLBCL and PMBCL is immune evasion. In this thesis we showed 
that there is a frequent defect in the cell surface expression or functioning of HLA class I and class 
II of aggressive B-cell lymphomas. In addition, we observed a novel functional defect of antigen 
presentation that is characterized by retention of the invariant chain in HLA class II, due to loss of 
HLA-DM (Chapter 4) (Figure 1). Interestingly we also found CALR, the chaperone molecule for 
HLA class I, to be differentially expressed in DLBCL as compared to normal LCL (Chapter 2). 
What underlies the HLA losses in DLBCL is only partially understood. In PMBCL rearrangements 
of CIITA causing downregulation of the HLA molecules are frequent [11],  whereas in primary 
CNS lymphoma (PCNSL) and testicular DLBCL loss of HLA molecules is mainly caused by the 
loss of the HLA locus.[12] Loss of β2M partially explains the loss of HLA class I (Chapter 2). 
Recently, loss of HLA class I, but not HLA class II, was related to MYC gene expression.[10] HLA 
class II loss might be caused by epigenetic mechanisms related to differentiation of post-germinal 
B cells to plasma cells (Chapter 5). Looking at DLBCL cases that relapsed after R-CHOP, we 
observed an enrichment of mutations of genes involved in antigen presentation, including the HLA 
molecules and immunoglobulin light chains, which further emphasizes the importance of immune 




Figure 1: Schematic representation of potential defects in antigen presentation in DLBCL, HL, 
PMBCL and PCNSL. Defects in HLA class I, HLA class II and HLA-DM with the underlying 
mechansims are shown. Abbreviations: B2M, beta 2 microglobuline; HLA, human leukocyte 
antigen; HC, heavy chain; ER, endoplasmic reticulum; MIIC, MHC class II loading compartment; 
CIITA, class II MHC complex transactivator; CLIP, Class II-associated invariant chain peptide. 
 
Previous in vitro studies showed that many of these losses lead to diminished tumor infiltrating 
lymphocytes and adverse prognosis.[13,14]  In 2018 Roemer et al. published their study on the 
prognostic impact of HLA and PD-L1 in Hodgkin lymphoma patients treated with the checkpoint 
inhibitor nivolumab.[15] Complete responses were correlated with HLA class II expression. Loss 
of HLA class II, but not of HLA class I, was an adverse prognostic factor for progression-free 
survival in patients treated > 12 months after autologous stemcell transplantation. Interestingly, in 
other malignancies, restoration of HLA class I and class II elicited anti-tumor responses. In 
metastatic Merkel cell carcinoma, treatment with interferon gamma or the hypomethylating agent 
azacitidine could restore the loss of HLA class I.[16] In samples from relapsed AML patients, 
treatment with interferon gamma  rapidly induced re-expression of HLA class II.[17] Whether HLA 
restoration is possible and if this has functional consequences in B-cell lymphomas has to be 
established. Moreover, this might be complicated as HLA does not stand alone in a very 
complicated immunological synapse. Among perturbations of this immunological synapse  
frequent loss or alteration of cell adhesion molecules (CD11a, CD18, CD54, and CD58), co-
stimulatory molecules (CD80 and CD86)  or checkpoint inhibitors (PDL-1, PDL-2, CTLA-4, and 
soluble HLA-G) in DLBCL should also be mentioned (Figure 2).[18-27] 
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Figure 2: Molecules in the immunological synapse known to be altered in diffuse large B-cell 
lymphoma. Abbreviations: BCR, B-cell receptor; TCR, T cell receptor; HLA, human leukocyte 
antigen; PDL-1, program death ligand 1; CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; 
sHLA-G, soluble HLA-G; CIITA, class II, major histocompatibility complex, transactivator. 
 
Characteristics of relapse 
 
In contrast to data on primary tumor samples, the knowledge on the characterics and biology of 
relapsed tumors is limited. In this thesis we explored relapses from patients who were considered 
to have a favorable prognosis at presentation, and relapses from advanced stage disease.  
Patients with stage I (E) DLBCL generally have an excellent outcome. Remarkably, data on the 
treatment and subsequent outcome of relapsing patients with limited stage DLBCL are scarce. 
Recently, the German study group presented their data on reducing the number of cycles of R-
CHOP to 4 in patients with limited stage DLBCL and an IPI-score of 0.[28] We and others have 
shown that de-escalation of therapy might not be optimal for all patients with stage I DLBCL 
(Chapter 6).[29] We observed that outcome of patients with relapse after stage I disease is 
generally poor, in part because the severity of the relapse is underestimated, and in part due to 
unfavorable clinical and biological factors that occur at relapse. Amongst these, central nervous 
system (CNS) relapse and the occurrence of MYC translocations seem important. The question is 
whether relapses could have been prevented by offering additional therapy but based on current 
evidence this is not likely. Firstly, Miller et al. already showed that eight CHOP cycles were as 
good as three cycles plus involved field radiotherapy, thereby not preventing less peripheral 
relapses.[30] Secondly, additional cycles of R-CHOP are unlikely to benefit patients with HGBCL-
DH.[31] Finally, rituximab has limited activity in CNS lymphomas.[32] 
























evolution in relapsed DLBCL is limited to small series. [33-36] To add to this data, we performed 
an explorative sequencing study in primary-relapse pairs (Chapter 7). We encountered the 
problem that obtaining good material from paired tumor samples is challenging, due to the 
omission of re-biopsies in patients with progressive disease, the tendency to perform fine needle 
biopsies, and degradation of DNA in formalin fixed paraffin embedded material, thereby making it 
unsuitable for the use of whole exome sequencing. In four out of six paired tumor samples we 
observed limited clonal changes, whereas in the other two patients there was a much larger shift 
in mutational load. This is in line with observations of early and late divergent models, which have 
different mutational dynamics.[33,34,36] In the early divergent model the relapse tumor evolves 
from a more distant progenitor and hence has more clonal drift. The late divergent model follows a 
more linear course. Which model occurs most frequent and how this will impact the development 
of targeted therapy – the target being the product of a new clonal change - are unexplored 
territories in DLBCL. As a proof of concept, Scherer et al. have shown that circulating tumor DNA 
in DLBCL can be used for tracking genes that potentially get mutated over time.[36]  Tracking of 
specific genes, however, implies that the mechanism of tumor evasion can be foreseen. While this 
might be the case for some drugs, the mechanisms of resistance are often not known. The most 
frequent base pair substitution (C:G > T:A) in mutations exclusively present in the relapse 
samples can arise as a consequence of canonical AID activity, but it is also the most frequently 
observed base pair change caused by cyclophosphamide. We identified genes possibly related to 
therapy resistance, including tyrosine kinases, (transmembrane) glycoproteins, and genes 
involved in the JAK-STAT pathway. Among the potentially resistance-related genes were PIM1 
and SOCS1, which were present in 5 of 6 patients. These genes have been reported to convey a 
risk for treatment failure and might be targets for therapy.[37,38] So far, the results of the pan-PIM 
inhibitors AZD1208 and LGH447 as monotherapy showed only very limited responses in AML, 
multiple myeloma and solid malignancies.[39,40] However, preclinical data suggests that PIM 




Tumor cells need to adapt to sustain their metabolic demands. While 
18
F-FDG is now a well-
established tool in the staging and evaluation of lymphoma patients [43], we were interested 
whether HGBCL-DH  would have a stronger metabolic PET signature, with MYC driving 
metabolism. However, we did not observe a difference for semi-quantitative PET characteristics in 
HGBCL-DH and DLBCL (Chapter 8). We did, however, observe an interesting phenomenon. It 
appeared that necrosis was present in 25% of cases and that this was an independent negative 
prognostic factor irrespective of rearranged MYC status. As always, one has to be careful in 
interpreting scan results. 
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Treatment has largely remained unchanged during the last 20 years. In light of the studies in the 
‘90s current attempts with more intensive chemotherapy seem unlikely to be beneficial. One 
important thing that should not be overlooked, is the risk of CNS relapse. Methotrexate (MTX) 
might be beneficial for patients at increased risk of CNS relapse. Although data from the phase 3 
trial of systemic versus intrathecal MTX have to be awaited (NCT02777736), we have shown in 
Chapter 10 that even in patients with concomitant systemic and CNS localization at diagnosis, the 
combination of R-CHOP and high dose MTX is an effective regimen. In contrast, patients with a 
CNS relapse after R-CHOP generally have a very poor outcome, even after initial stage I disease 
(Chapter 6).[44,45] Although the use of very high dose chemotherapy followed by autologous 
stem cell transplantation (ASCT) is advocated in this setting by Ferreri et al, the data supporting 
this strategy are limited.[46] We and recently others have shown a 2-year overall survival of 40-
70% with or without ASCT.[47,48] Even without the use of ASCT, toxicity is high compared to that 
seen in DLBCL without CNS involvement or in primary CNS lymphoma with a treatment-related 
mortality of 10-15%.[47,48] 
In PMBCL the use of the more intensive regimen - DA-EPOCH-R - was first published in 2013.[49] 
The very favorable outcome with long-term survival in excess of 90% of this rather toxic DA-
EPOCH-R has, however, not been confirmed thus far. The current advantage of DA-EPOCH-R 
over R-CHOP is the omission of radiotherapy in patients achieving a complete remission. Data of 
the phase 3 comparative International extranodal lymphoma study group (IELSG) study assessing 
the role of mediastinal radiotherapy after rituximab- containing chemotherapy regimens have to be 
awaited.[50] Irrespective of the results, novel less toxic therapies are needed. Brentuximab 
vedotin, targeting CD30, might be such a candidate. Despite the high efficacy in Hodgkin 
lymphoma and CD30 positive T-cell lymphoma [51-53], as well as encouraging results in relapsed 
B-NHL with variable CD30 expression [54], brentuximab vedotin was ineffective in PMBCL, which 
has CD30 expression in 80% of cases.[55] Amplification or gain of 9p24.1 is observed in more 
than half of PMBL cases, resulting in overexpression of the immune checkpoints programmed 
cell-death ligand 1 and 2 (PD-L1 and PD-L2), and the cytokine receptor signaling kinase Janus 
kinase 2 (JAK2).[56] Monotherapy with checkpoint inhibitors showed high overall response rates 
in both HL and PMBCL, but complete remission rate was low.[57,58] Based upon in vitro 
synergistic activities, we describe the successful treatment of a patient with a refractory PMBCL 
with the novel combination of the JAK2 inhibitor ruxolitinib, which on its own has limited activity, 
and the anti-PD1 checkpoint inhibitor pembrolizumab (Chapter 11). The potential therapeutic 
effect of this combined treatment could be counterbalanced by the negative effect of JAK1/2 
inhibition on T-cell activity.[59]  However, this might be limited as patients receiving ruxolitinib after 
allogeneic hematopoietic stem cell transplantation maintain effective graft versus leukemia 
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responses.[60] Given the favorable toxicity profile, ruxolitinib can be applied in heavily pre-treated 
patients, thus making it an attractive candidate for combination therapy for patients with 




Perspectives – from bench to bedside 
 
The contents of this thesis are linked to several ongoing studies. These studies are driven by 3 
key questions: 1) how can we define biological subgroups, 2) how and when can specific 
biological subgroups be targeted, and 3) how can we improve treatment strategies. 
Biological subgroups 
 
The optimal biological classification for DLBCL has not been established, but presence of a MYC 
rearrangement with a BCL2 and/or BCL6 rearrangement is well accepted to be a subgroup with 
an unfavorable outcome and is now part of routine diagnostics (Figure 3). Although the cell of 
origin (COO) within DLBCL is well established, the clinical trials with R-CHOP plus a targeted drug 
within a specific COO group have failed. This does not necessarily mean that the COO groups are 
not important. It could be that either the drugs used in combination with R-CHOP are insufficient 
or that the COO group should be refined. Based on consensus clustering, immune- and stromal 
background signatures, and MYC rearrangement status, it is likely that there are additional 
subgroups within the ABC and GCB-type DLBCL. [10,61-64]  How to implement the mutational 
data in clinical practice is still unclear. Although over 2000 DLBCL cases have been analyzed and 
some genes are more frequently mutated in the ABC or in the GCB subtype, the optimal 
clustering into biological subgroups is still a matter of debate.[37,38,65,66] Conformational 
studies, like the biological analysis of the HOVON 84 (a phase 3 study on the intensification of 
rituximab in DLBCL), will be necessary to solve this debate. [67] One important hurdle to complete 
the genomic classification, would be to capture the spatial evolution of a heterogeneous disease 
like DLBCL, as mutational analysis is usually performed on single tumor biopsies and hence 
subject to sampling error. This problem may be solved by analyzing circulating tumor DNA, that is 
released by apoptotic tumor cells derived from lymphoma cells throughout the body, thereby 






Figure 3. Schematic overview of the current diagnostic procedures and therapy in aggressive B-
cell lymphoma (upper line). Diagnostic procedures that will likely impact the diagnostic process 





When consensus is reached on the molecular subgroups, we will need to identify patients who will 
benefit from escalating therapy. This avoids overtreatment of low risk patients who are likely to be 
cured with R-CHOP, not only limiting additional toxicity as was observed with the combination of 
ibrutinib and R-CHOP [71], but also keeping the costs of healthcare in the Netherlands, with an 
annual budget of 100 billion euro, within bounds.[72]  
 
In Hodgkin lymphoma, the use of interim 
18
F-FDG PET scans has been very useful in the setting 
of escalation and de-escalation trials.[73,74] Although the negative prognostic value of interim-
PET in DLBCL is generally good, the positive predictive value is rather low, thereby limiting the 
use of interim PET in treatment decisions.[75]  
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Recent studies have shown the potential of circulating tumor DNA (ctDNA) as a tool of interim and 
end-of-treatment analysis. Not achieving an early molecular response, defined as a 2 to 3 log fold 
reduction of ctDNA load within 2 courses of R-CHOP, is strongly  related to progressive disease 
or relapse.[36,68-70] ctDNA based analysis of minimal residual disease (MRD) can be used for 
de-escalation studies, escalation studies early in the course of treatment or consolidation 
strategies after induction therapy.[76] Thus far, there is no consensus on which technique and 
gene panels have to be used. For each technique, ctDNA analysis will put high demands on the 
infrastructure and will be technologically demanding. If successfully implemented, the combined 
interim PET and interim ctDNA analysis could be a potential tool to guide therapy (Figure 3).[69] 
We have set up a national multicenter study to examine the combined use of 
18
F-FDG-PET/CT 
and ctDNA-based minimal residual disease monitoring for the response assessment in post-
transplant lymphoproliferative disorder (NTR 7402 / NL 7203) (Figure 4). With the successful 
implementation of MYC FISH screening in the Netherlands [77], we now need to organize the 
infrastructure for ctDNA analysis. 
 
Figure 4. Scheme of ctDNA based MRD monitoring in PTLD (NTR7402). ctDNA based analysis 
will be performed in parallel with standard of care 
18
F-FDG-PET scans and treatment. 
 
Evidently, identifying patients at high risk of treatment failure early during therapy is still no 
guarantee to success, as was shown in the PETAL study.[78] What we need is the development 
of effective drugs for salvage. The most obvious candidates of new salvage drugs are small 
molecules targeting the NF-kB, PI3K-m-TOR, JAK-STAT and NOTCH signaling pathways, B-cell 
lineage markers, epigenetic modifiers or immune therapy.[79,80] Targeting the signaling pathways 
in first line with single agents (ibrutinib, bortezomib, everolimus) has not been successful. 
[71,81,82]. In the HOVON 130 addition of lenalidomide to R-CHOP showed promising results for 
HGBCL-DH.[69]. Given the acquisition of mutations or activation of alternative pathways, it is 
unlikely that targeting just one pathway will be sufficient given the complexity of DLBCL. Even with 
response rates of 40% of ibrutinib in relapsed ABC-type DLBCL, the short duration of response 
and the absence of a plateau made it improbable that it would increase the plateau of the survival 
curves in first line. Fortunately, sometimes new drugs do have a good outcome in the relapse 































example is the successful addition of brentuximab vedotin to CHP in relapsed anaplastic large T-
cell lymphoma, where brentuximab vedotin resulted in a clear plateau in survival after 12 
months.[53,83] In the HOVON 136 brentuximab vedotin is investigated in combination with DHAP 
for patients with relapsed CD30+ DLBCL, a regimen that was highly efficacious in patients with 
chemo-resistant Hodgkin lymphoma.[84] Another promising antibody drug conjugate (ADC) is 
polatuzumab vedotin targeting CD79. Patients with a relapsed DLBCL had a significantly longer 
progression free survival when treated with polatuzumab plus bendamustine compared to 
bendamustine alone (hazard ratio 0.34).[85]  At 12-months the overall survival was 50%, which 
rivals the results of CAR-T therapy. An advantage of polatuzumab vedotin is that CD79 is 
universally expressed on all malignant and normal B-cells, but this does not necessarily mean that 
all DLBCL subgroups will benefit. In AML the efficacy of the ADC gemtuzumab ozogamicin was at 
least partially diminished due to upregulation of drug efflux pumps.[86] Furthermore, loss or 
downregulation of cell surface antigens might induce resistance, as has been observed in drugs 
targeting CD19, CD22 and CD52.[87-89]  
 
While most studies aim at improving efficacy of R-CHOP, nearly 50% of patients who relapse, do 
so after achieving a complete remission. In patients with an IPI-score of ≥ 3 the 2-year change of 
relapse is 21%.[90] Patient relapsing within a year after R-CHOP treatment have a similar poor 
prognosis as patients with progressive disease. In relapsed DLBCL, checkpoint inhibitors show 
modest efficacy.[91,92] However, treatment at overt relapse might not be the right moment, as 
these tumors are highly proliferative. Since steroids dampen the effect of checkpoint inhibitors 
[93], combination of checkpoint inhibitors with R-CHOP (NCT02596971) seems less attractive.[94] 
Therefore, we think that the best moment to treat these patients is in a state of minimal residual 
disease. To this end we designed and started the HOVON 151 trial (NCT02596971), in which 
patients with an IPI score of ≥ 3 are treated with the anti-PDL1 antibody atezolizumab for a 12-
month consolidation period (Figure 5). These patients will be monitored for dynamics of MRD at 
various stages of treatment and observation [68], tumor characteristics, alterations of the immune 
repertoire [95], microbiome [96,97]  and in case of relapse clonal evolution.[36,70] In a similar 
way, patients with a HGBCL-DH will receive the anti-PD1 antibody nivolumab after induction 




Figure 5: Scheme of the HOVON 151 study (NCT02596971). Patients with high risk DLBCL (IPI-
score > 2) have >20% change of relapse even after achieving a metabolic complete remission. 
Eligeble patients (n = 114) will be treated with atezolizumab for the duration of 1 year. 
 
Improving treatment strategies 
 
As discussed previously, several drugs have failed to improve first line treatment. Apart from the 
financial consequences, these studies potentially put patients at risk of additional toxicities. 
Therefore, drug development needs to be improved. One can do so by executing innovative 
biological driven studies, e.g. with a Bayesian design in which patient allocation across various 
(biological) study arms is modeled based on results acquired during the trial.[98] However, these 
are complex and challenging studies that require a good infrastructure, multiple pharmaceutical 
partners and robust biological and statistical support.  
Another important issue is that a translational program (from bench to bedside) needs to be an 
integrated part of clinical studies. As previously mentioned, this not only requires additional 
funding, but also proper specimen collection and biobanking. To that end the collection of ctDNA 
can improve the way we study clonal evolution and potential mechanisms of resistance.  
Obviously, this does not replace the need for collection of proper tumor tissue.   
Finally, we consider molecular imaging using immune-PET could be a valuable tool in drug 
development. Molecular imaging is the noninvasive assessment of radioisotope labeled 
monoclonal antibodies and ADCs. Unlike conventional pharmaco-kinetics, immune-PET provides 
detailed in vivo information on biodistribution, tumor uptake and optimal dosing of a drug. A wide 
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variety of antibodies and ADCs have been studied in different cancers including breast, colon, 
prostate, ovarian and neuroendocrine tumors, and also in lymphoma.[99] Clinical applications of 
immune-PET include improved staging prior to therapy [100,101], monitoring of tumor uptake over 
time in individual patients [102], assessment of drugs interactions [103], dose finding [104,105], 
and prediction of response to therapy.[106] Zirconium-89 (
89
Zr) is the radioisotope that lends itself 
best for visualizing antibodies and has been used in clinical trials with over 15 different 
monoclonal antibodies.[99] 
As part of the HOVON 136 trial we will perform a molecular imaging study using 
89
Zr brentuximab. 
While CD30 expression by IHC is generally required for participation in trials, there is no clear 
correlation between expression of CD30 and efficacy of the ADC.[52,107] Possible explanations 
might be tumor heterogeneity, uptake and subsequent release of the ant-tubulin MMAE in the 
tumor micro-environment or a threshold below the sensitivity of immunohistochemistry for 
detecting CD30.[54] Therefore, in the HOVON 136 
89
Zr brentuximab biodistribution will be related 
to CD30 protein and gene expression, to identify which patients benefit from brentuximab vedotin. 
Application of molecular imaging in the negative trial of brentuximab vedotin in PMBCL could 
potentially have helped to understand the mechanism of failure of therapy.[55] 
As part of the HOVON 151 trial, we will perform a molecular imaging study using sequential 
89
Zr 
atezolizumab PET scans (NCT03850028)(Figure 6). While it has been observed that the 
percentage of PDL1 positive DLBCL seems relatively low compared to other cancers (ranging 
from 13 to 31%), PDL1 amplifications can be observed in 39% and 25% of non-GCB and GCB 
DLBCL, using ctDNA analysis.[108-110] Despite higher overall response rates in PDL1 positive 
malignancies compared to PDL1 negative tumors, responses are seen in PDL1 negative 
patients.[111,112] PDL1 status from resected specimens shows poor correlation to the PDL1 
status from matched biopsies.[113] Variable expression of PDL1 can be observed in multiple 
tumor biopsies collected over time and/or from different anatomical sites in individual patients and 
can be influenced by treatment.[114,115] Therefore, PDL1 expression assessed by one single 
biopsy probably is not representative, hence there is a need for a better predictive marker. To this 
end we will perform sequential 
89
Zr-atezolizumab PET scans, that will provide information on the 
dynamics of atezolizumab biodistribution over time. In solid malignancies 
89
Zr-atezolizumab PET 
scans correlated better with tumor responses than PDL-1 immunohistochemistry or gene 




Figure 6: Flowchart of the HOVON 151 imaging side study with 
89
Zr-atezolizumab 
(NCT03850028). Biodistribution will be assessed before and after R-CHOP and in the event of 
suspected relapse. Data will be related to PDL1 expression (IHC and GEP), minimal residual 
disease and possible toxicity. 
89
Zr-PET scans at relapse might give valuable information on the 
mechanism of resistance. 
 
In summary, R-CHOP has been the standard of care for patients with aggressive B-cell lymphoma 
in the last 2 decades. During the last several years there is a tendency to apply more intensive 
chemotherapy regimens for PMBCL and HGBCL-DH, but the effectiveness of this approach is not 
yet supported by randomized trials. The mere fact that HGBCL-DH has a poor outcome, doesn’t 
automatically mean that more chemotherapy is the solution. Although much has been learned 
about the biology and genomic alterations in aggressive B-cell lymphoma, the clinical impact of 
the cell of origin, mutational classifications and affected pathways currently hold no clinical 
implications. Conformational studies based on tumor and liquid biopsies are needed to more 
robustly define molecular subgroups that have a meaningful prognostic impact. In combination 
with interim 
18
F-FDG PET scans, analysis of circulating tumor DNA has the potential to guide 
treatment decisions. In order to move on we need to find the Achilles’ heel of DLBCL either by 
improving induction or by eradicating minimal residual disease through consolidation strategies. 
Treatment strategies might be improved by smarter study design and solid translational research, 
including molecular imaging, which allows the study of the biodistribution of monoclonal antibodies 
and antibody drug conjugates in vivo. This might help to select patients who benefit most, could 
give information on toxicity, and indicate mechanism of resistance. These diagnostic and 
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Agressieve B-cel lymfomen 
 
Jaarlijks wordt er bij zo’n 4500 mensen in Nederland de diagnose lymfklierkanker (lymfoom) 
gesteld. Lymfklierkanker hoort daarmee tot de 10 meest voorkomende vormen van kanker. 
Lymfklierkanker is echter niet één ziekte, maar kent vele typen. Het Hodgkin lymfoom (HL) is een 
B-cel lymfoom dat al in 1833 als aparte ziekte is beschreven. Nadien zijn de andere vormen van 
lymfklierkanker als non-Hodgkin lymfomen (NHL) geclassificeerd. Door voortschrijdende 
biologische inzichten zijn er sindsdien meer typen NHL te onderscheiden en is de indeling van de 
lymfomen in de loop der jaren geregeld aangepast. In de meest recente World Health 
Organisation (WHO) classificatie uit 2017 worden er meer dan 30 verschillende vormen van B-
NHL onderscheiden. De B-NHL kunnen ingedeeld worden in laaggradige (indolente) en 
hooggradige (agressieve) lymfomen. De laaggradige lymfomen zijn over het algemeen goed te 
behandelen met immuno-chemotherapie, maar hebben sterk de neiging terug te komen 
(recidiveren). Bij een deel van de patiënten met een laaggradig lymfoom treedt een verandering 
op, waardoor het een hooggradig lymfoom wordt (transformatie). In tegenstelling tot de indolente 
lymfomen is de opzet van de behandeling bij patiënten met een agressief lymfomen om hen te 
genezen. Helaas is de keerzijde dat recidieven veelal niet goed te behandelen zijn en frequent 
fataal aflopen. Er worden momenteel 4 agressieve B-NHL onderscheiden: het diffuus grootcellig 
B-cel lymfoom (DLBCL, 37%), het primair mediastinaal B-cel lymfoom (PMBCL, 3%), het 
hooggradig B-cel lymfoom met een MYC breuk en een BCL2 en/of BCL6 breuk, ook wel dubbel of 
triple hit lymfomen genoemd  (HGBCL-DH, 2.5%) en het in Nederland zeldzame Burkitt lymfoom 
(BL, 0.8%). Binnen het DLBCL worden er nog enkele specifieke subtypen onderscheiden, zoals 
het primair grootcellig B-cel lymfoom van de hersenen, maar in de meerderheid van de gevallen is 
het (vooralsnog) niet nader te classificeren. Ondanks dat de agressieve B-NHL 
gemeenschappelijke overeenkomsten hebben, zijn er kenmerkende verschillen in de 
ontstaanswijze, de klinische presentatie, prognose en behandeling. De laatste 10 jaar zijn er 
nieuwe technieken gekomen voor diagnostiek, classificatie en respons beoordeling. Biologische 
inzichten hebben geleid tot de ontwikkeling en registratie van verschillende nieuwe medicijnen bij 
de laaggradige B-NHL. Echter, bij de behandeling van patiënten met een agressief B-cel lymfoom 
hebben deze inzichten nog niet geleid tot een verbetering.  
Het doel van dit proefschrift is om te onderzoeken welke additionele factoren bijdragen aan het 
ontstaan van agressieve lymfomen en wat de eigenschappen zijn van DLBCL die recidiveren. In 
dit proefschrift wordt onderzocht of er een relatie is tussen biologische karakteristieken en 




Etiologie van agressieve lymfomen 
 
De afgelopen decennia is er veel vooruitgang geboekt in het onderzoek naar de ontstaanswijze 
(etiologie) van de B-cel lymfomen. Zo is duidelijk geworden dat de verschillende B-NHL terug te 
voeren zijn tot de cel-van-oorsprong (COO). Onder normale omstandigheden heeft een B-cel (B-
lymfocyt) verschillende stadia die doorlopen wordt vanaf het herkennen van een lichaamsvreemd 
eiwit (antigeen) tot het produceren van afweerstoffen (antistoffen). Tijdens de selectie en uitrijping 
van een B-cel kan een defect ontstaan, waardoor dit proces wordt verstoord. De defecte B-cel zal 
geprogrammeerd dood gaan (apoptose) of door het immuunsysteem worden herkend en 
uitgeschakeld. Echter, indien de defecte B-cel additionele veranderingen ondergaat in het DNA 
(mutaties) of er veranderingen in de eiwitten (epigenetisch) ontstaan, kan deze ontaarden in een 
tumorcel. B-cellen hebben in tegenstelling tot andere tumoren een unieke eigenschap. Voor de 
normale functie van de B-cellen is het belangrijk om zoveel mogelijk verschillende antistoffen te 
kunnen maken. Hiertoe moet het stuk DNA wat codeert voor de antistoffen, het zware 
immunoglobuline locus (IgH), door de B-cel veranderd kunnen worden. B-cellen brengen hiervoor 
speciale eiwitten (RAG en AID) hoog tot expressie. Helaas veroorzaken deze eiwitten soms ook 
breuken en mutaties op plaatsen in het DNA buiten het IgH locus. Daarmee kan in beginsel ook 
een B-NHL ontstaan. B-NHL’s zijn dus het gevolg van fouten in de ontwikkeling tijdens 
verschillende ontwikkelingsstadia van de normale B-cel. 
Op basis van deze inzichten is duidelijk geworden welke eiwitten en signaaltransductie systemen 
(pathways) belangrijk zijn. Zo wordt er binnen het DLBCL op basis van gen-expressie profielen 
(GEP) onderscheid gemaakt tussen het germinal center type (GCB) en het geactiveerde B-cel 
type (ABC). Daarnaast is duidelijk geworden welke zeer uiteenlopende chromosoom 
veranderingen (rearrangements) en veranderingen in het DNA (mutaties) voorkomen. Een van de 
meest in het oog springende chromosoomverandering betreft het MYC gen, gelegen op 
chromosoom 8. Een verandering hierin kan worden vastgesteld bij 10-15% van de DLBCL 
patiënten. Dit is belangrijk, omdat patiënten met een HGBCL-DH helaas een slechte prognose 
hebben. 
Om inzicht te krijgen welke eiwitten veranderd tot uiting komen hebben we de eiwitexpressie 
tussen DLBCL cellijnen en EBV geïnfecteerde B-cellen vergeleken (Hoofdstuk 2). Voor eiwitten 
met een verschil in expressie in de cellijnen werd vervolgens onderzoek verricht op tumorweefsel 
van DLBCL patiënten. In de cellijnen waren er 14 eiwitten met verminderde expressie, 8 eiwitten 
met toegenomen expressie en 10 met variabele expressie. Deze 32 eiwitten zijn betrokken bij cel 
bewegelijkheid, metabolisme, veranderingen van het chromatine, anti-oxidanten, immuunrespons 
en signaaloverdracht. De expressie van het anti-oxidatieve eiwit PRDX was hoger in DLBCL dan 
in folliculair lymfoom (een indolent lymfoom). PRDX kan de DLBCL cellen helpen om beter om te 
gaan met de hogere oxidatieve stress die deze cellen ervaren. Enigszins verrassend was ook de 
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expressie van PPIA, het aangrijpings punt van het immuun onderdrukkend medicijn ciclosporine 
toegenomen. In DLBCL cellijnen was ciclosporine in staat om de celgroei te remmen. 
Een deel van de hooggradige lymfomen evolueert uit een folliculair lymfoom (FL). We laten zien 
dat in bijna 40% van de getransformeerde folliculaire lymfomen (tFL) een breuk aanwezig is in het 
MYC-gen (Hoofdstuk 3). Onze data ondersteunen de observatie dat MYC een sterke factor is 
voor transformatie van laaggradige lymfomen. In combinatie met observaties van anderen, lijken 
onze data erop te wijzen dat de fusie van het MYC gen met het IgH locus uniform leidt tot sterke 
expressie van het MYC eiwit, terwijl andere fusie partners leiden tot meer variabele MYC eiwit 
expressie. MYC eiwit expressie was significant hoger in de tFL dan in de gepaarde FL biopten. 
MYC eiwit expressie < 40% had in onze handen een uitstekende negatief voorspellende waarde. 
Dat wil zeggen dat het onwaarschijnlijk is dat casussen met een MYC eiwit expressie van < 40% 
een MYC breuk hebben. 
Ongeacht het type agressief B-cel lymfoom worden deze alle gemerkt door veranderingen in 
eiwitten die normaal nodig zijn voor de herkenning door het afweersysteem (immune escape). In 
dit proefschrift laten we zien dat er frequent een defect is in de expressie van de humaan leukocyt 
antigenen (HLA) klasse I en klasse II eiwitten op het celoppervlak van tumorcellen (Hoofdstuk 4). 
We beschrijven een nieuw defect, namelijk verlies van HLA-DM. Hierdoor raakt het laden van 
antigenen in het HLA-II molecule verstoort en komt er een HLA-II molecule op het celoppervlak 
met altijd hetzelfde stukje eiwit (invariant chain). HLA verlies kan niet alleen een rol spelen bij het 
ontstaan van een B-NHL, maar heeft ook implicaties voor therapie. Inmiddels is duidelijk 
geworden dat bij patiënten met een Hodgkin lymfoom effectiviteit van immuuntherapie (checkpoint 
inhibitors) samenhangt met de aan- of afwezigheid van HLA-II. Hoewel een gestoorde antigeen 
expressie dus frequent voorkomt, verschilt het mechanisme per B-NHL type. Dit kan van belang 
zijn voor therapie die aangrijpt op HLA expressie. Recent is een relatie gelegd tussen HLA-I 
verlies en overexpressie van het MYC gen. We laten zien dat in DLBCL verlies van HLA-II 
frequenter wordt waargenomen in het ABC-type dan in het GCB-type (Hoofdstuk 5). Het idee is 
dat verlies van HLA-II een epigenetisch fenomeen is van B-cellen in de transitie naar plasma 
cellen. Immers, op normale plasma cellen komt geen HLA-II voor. Of manipulatie van HLA 
expressie mogelijk is en of dit functionele (d.w.z. therapeutische) consequenties heeft, dient 




Evolutie en therapieresistentie 
 
De combinatie chemotherapie voor DLBCL met cyclofosfamide, doxorubicine, vincristine en 
prednisolon (CHOP) dateert uit 1976. Sinds 2000 is daar rituximab, een afweerstof gericht tegen 
het CD20 eiwit, aan toegevoegd. CD20 komt universeel voor op rijpe B-cellen. De afgelopen jaren 
zijn er verschillende medicijnen geregistreerd en beschikbaar gekomen voor patiënten met een 
laaggradig lymfoom. Helaas hebben deze medicijnen bij de behandeling van DLBCL de belofte 
van verbeterde overleving niet waar kunnen maken. Een van de uitdagingen is om de 
prognostische modellen te verbeteren, beter de heterogeniteit van DLBCL in kaart te brengen en 
de dynamiek (clonale evolutie) na R-CHOP maar ook gerichte therapie beter te doorgronden.  
Van patiënten met een stadium I DLBCL wordt over het algemeen aangenomen dat ze een 
uitstekende prognose hebben. Recent heeft de Duitse lymfoom studiegroep data gepresenteerd 
over de-escalatie van R-CHOP binnen deze groep van patiënten. Wij laten in dit proefschrift zien, 
dat dit niet noodzakelijkwijs voor alle patiënten de optimale keuze is (Hoofdstuk 6). Wij 
onderzochten 126 patienten met een stadium I DLBCL en bestudeerden de groep (n=19) die een 
recidief kregen. Patiënten met een recidief hadden een slechte overleving. Dit had deels te maken 
met de ongunstige klinische en biologische factoren van deze patiënten, waaronder 
veranderingen in het MYC-gen en recidieven in de hersenen, factoren waar R-CHOP weinig 
invloed op heeft. De huidige klinische risico scores zijn niet in staat deze patiënten te identificeren. 
Alhoewel het mutatie landschap van meer dan 2000 DLBCL samples inmiddels met nieuwe 
technieken (next generation sequencing) in kaart is gebracht, is er maar zeer beperkte informatie 
over de clonale evolutie van DLBCL. In dit proefschrift beschrijven we de bevindingen van onze 
pilotstudie naar veranderingen in het mutatieprofiel van gepaarde tumor samples (diagnose en 
recidief) (Hoofdstuk 7). Een van de uitdagingen waar we tegen aanliepen was het verkrijgen van 
tumormateriaal van voldoende kwaliteit om het hele coderende deel van het DNA (whole exome) 
in kaart te brengen. Dit lukte in 6 patiënten. In 4 van de 6 patiënten observeerden we een 
beperkte toename van mutaties. Dit lijkt ook in andere series het meest frequent voor te komen en 
past bij een lineaire evolutie vanuit een late kloon. Daarentegen, in de andere 2 patiënten waren 
de verschillen in mutaties groter. Dit kan passen binnen het model van clonale evolutie uit een 
vroege kloon met een divergent beloop. Bij onderzoek naar nieuwe therapieën is het goed om 
rekenschap te nemen van deze verschillen. Als een proof-of-concept is er één DLBCL patiënt 
beschreven die behandeld werd met een remmer van de bruton tyrosine kinase (BTK) en waarbij 
de klonen met de mutaties in BTK in de loop van de tijd de overhand kregen. Hierbij dient 
rekening gehouden te worden met het effect van AID, maar ook met mutaties die kunnen ontstaan 
door de therapie. In onze pilotstudie hadden 5 van de 6 patiënten een mutatie in PIM1 en SOCS1, 
waarvan ook anderen hebben beschreven dat ze gerelateerd zijn aan therapie resistentie. Tot 
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dusverre zijn er nog geen studies gepubliceerd over het effect van PIM-blokkers bij lymfomen, 
maar preklinische data lijkt te suggereren dat deze groep van remmers kankercellen gevoeliger 
kan maken voor chemotherapie. 
 
Diagnostiek en behandeling  
 
Ondanks dat de prognose voor patiënten met een laag risico DLBCL goed is, zijn de uitkomsten 
van patiënten met een hoog risico ziekte onbevredigend. De meest gebruikte risicoscore is de 
International Prognostic Index (IPI), waarbij de 2-jaars overleving varieert van 91% voor patiënten 
met een laag risico tot 59% voor patiënten met een hoog risico ziekte. Naast de IPI score kunnen 
patiënten die een verhoogd risico hebben op therapiefalen worden onderscheiden op basis van 
lokalisatie, 
18
F-FDG PET scans tijdens behandeling, de cel-van-oorsprong, de aanwezigheid van 
breuken in het MYC-gen, overexpressie van eiwitten MYC en BCL2, mutaties in het DNA en 
veranderingen in de hoeveelheid circulerend tumor DNA (ctDNA) in het bloed. Echter, 
implementatie van deze ‘nieuwe’ factoren in de klinische risico-inschatting of behandelstrategie 
van patiënten heeft nog onvoldoende plaatsgevonden. 
Hoewel het gebruik van PET-scans voor de stadiëring en responsbeoordeling van patiënten met 
een agressief B-NHL inmiddels standaard is, lijkt het voor prognose en interventies minder goed 
te functioneren. Dit kan ten dele komen doordat de brug tussen biologische eigenschappen van 
de tumor en PET-scans onvoldoende geïntegreerd onderzocht is. MYC geeft een hoge proliferatie 
en is daarmee een sterke aanjager van het metabolisme (Hoofdstuk 3). Daarom verrichtten wij 
een retrospectieve observationele studie naar de relatie tussen semi-kwantitatieve PET 
karakteristieken en necrose in DLBCL en HGBCL-DH  (Hoofdstuk 8). We vonden geen verschil 
in de semi-kwantitatieve eigenschappen tussen de twee agressieve B-NHL. Wel constateerden 
we in 25% van de gevallen necrose, welke een negatief prognostische factor was voor ziektevrije 
overleving. Uiteraard moet men oppassen voor vals positieve resultaten bij de interpretatie van 
PET-scans (Hoofdstuk 9). 
Behandeling van DLBCL is de laatste 20-jaar niet wezenlijk veranderd. Een belangrijk aspect is 
het risico op recidieven in de hersenen (Hoofdstuk 6). Hoge dosis methotrexaat (MTX) zou van 
toegevoegde waarde kunnen zijn in de profylactische behandelingen van hoog CNS risico 
patiënten, maar is nog niet bewezen effectiever dan toedieningen van MTX via een ruggenprik. In 
dit proefschrift laten we zien dat de combinatie van R-CHOP en hoge dosis MTX een effectieve 
therapie is voor patiënten met een agressief B-NHL met lokalisaties buiten en in het brein 
(Hoofdstuk 10). Hoewel intensieve chemotherapie gevolgd door een autologe 
stamceltransplantatie (ASCT) wordt gesuggereerd, is R-CHOP met MTX al toxisch. Wij en 
anderen toonden aan dat zonder ASCT een 2-jaars overleving van 40-70% bereikt kan worden. 
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Tenslotte beschrijven we de succesvolle behandeling van een patiënte met een therapieresistent 
PMBCL (Hoofdstuk 11). Op basis van een vermenigvuldiging van een stuk van chromosoom 9 
komen de eiwitten program death ligand (PDL) en Janus Kinase 2 (JAK2) verhoogd tot expressie. 
In vitro is de combinatie van blokkers van beide eiwitten synergistisch. Monotherapie met 
pembrolizumab toonde bij een aanzienlijk deel van de patiënten afname van de tumorgrootte, 
maar het aantal patiënten met een complete remissie was gering. Patiënte werd succesvol 
behandeld met de nieuwe combinatie van pembrolizumab en ruxolitinib - een blokker van JAK2. 
Niet alleen bereikte patiënte een complete remissie, ook trad de respons binnen enkele weken op. 





In het perspectief van bovenstaande kan gesteld worden dat er in de afgelopen decennia veel 
geleerd is over de biologie van agressieve B-cel lymfomen, maar dat dit maar een beperkte 
impact heeft gehad op de diagnostiek en behandeling. Confirmatie studies zijn nodig om de 
optimale biologische subclassificaties vast te stellen en relaties te leggen met klinische 
uitkomsten. Gezien de beperkingen in kwaliteit van biopten en de neiging om steeds minder 
invasieve diagnostiek te doen, lijkt de opkomst van analyse van circulerend tumor DNA (ctDNA) 
een grote stap voorwaarts. De combinatie van interim PET-scans en meting van minimale rest 
ziekte (MRD) op basis van ctDNA heeft de potentie om de heterogeniteit in DLBCL beter in kaart 
te brengen, de behandeling te sturen en clonale evolutie in kaart te brengen. Om echt stappen te 
maken, dienen we echter de Achilles hiel van DLBCL te vinden. Nieuwe behandelingen kunnen 
de inductietherapie helpen te verbeteren of als consolidatie worden gegeven in het geval van 
resterende minimale rest ziekte. De ontwikkeling van behandelingen kan verbeterd worden door 
slimmere studieontwerpen en door gedegen translationeel onderzoek, waaronder de mogelijkheid 
van moleculaire beeldvorming, welke de biodistributie van monoclonale antilichamen in kaart kan 
brengen. Dit kan bijdragen aan het selectieproces van patiënten die het meeste baat hebben bij 
de toekomstige behandelingen. Deze diagnostische en therapeutische overwegingen vormen de 
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